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Zusammenfassung 
 
Seit gezeigt wurde, dass die genetischen Informationen in Form von DNA 
gespeichert wird, ist das Geheimnis der DNA-Struktur gelöst, der Mechanismus der 
Gen-Expression und die Rolle der RNA verstanden worden. Das Interesse für die 
Chemie und die Biologie der Nukleinsäuren ist somit kontinuierlich gewachsen. 
Besonders interessant ist die RNA, die eine Rolle als ein Vermittler der genetischen 
Informationen (mRNA) spielt, aber auch als Bote von Aminosäuren (tRNA). Sie ist 
im Ribosom (rRNA) anwesend, arbeitet als Templat in Telomerasen für DNA-
Synthese und hat außerdem wichtige Funktionen in der RNA-Spaltung, z.B. bei 
Ribozymen wie RNAse P inne. Betreffend bestimmter Spaltstellen in RNA hat auch 
das Phänomen der siRNA beträchtliche Aufmerksamkeit in diesem Prozess erregt. 
Der sogenannte RISC-Komplex wird programmiert, einzelsträngige RNA mit hoher 
Sequenz-Spezifität zu schneiden. Die für die RNA-Interferenz verantwortliche 
zelluläre Maschinerie ist auch an der Bilbung von MikroRNAs beteiligt. RNA-
Interferenz ist heute eines der nützlichsten Werkzeuge in functional genomics 
geworden. Die große Hoffnung ist, dass es auch vielleicht in der Therapie angewandt 
werden könnte. 
Das Thema meiner Doktorarbeit trägt den Titel „Synthesis of Site-Specific Artificial 
Ribonucleases“. Es beschäftigt sich mit der Entwicklung künstlicher 
bindungsspezifischer Ribonucleasen. Diese künstlichen Katalysatoren sind im 
Wesentlichen aus drei Gründen bedeutsam: 
Zum einen liegt eine mögliche Anwendung in der Affinity-Cleavage 
(Affinitätsspaltung), eine Technik, die Bindungsstellen von RNA-Liganden durch 
das kovalente Anbringen eines Reagenzes lokalisiert, das zwischen den 
Nukleinsäuren schneidet. 
Zum anderen entsteht die Möglichkeit, neue Werkzeuge für eine gezielte 
Manipulation großer RNA-Moleküle zu schaffen.  
Die Vorteile des Ansatzes sind, dass man damit beliebige Zielsequenzen anwählen 
kann. Das Problem dieser Strategie ist die Notwendigkeit, hohe Genauigkeit im 
Spaltungssschritt zu erreichen, wie zum Beispiel mit natürlichen Ribozymen. 
Wichtige Ergebnisse wurden auch während meiner Arbeit erhalten, mit einem Fall B                                                                                                       Zusammenfassung 
 
von genauer Spaltung zwischen zwei Basen. Der dritte Grund ist die potentielle 
Anwendung als katalytische antisense-Oligonucleotide in der Chemotherapie.   
Gegenwärtig existieren zwei Ansätze, unspezifische künstliche RNasen relativ 
kleiner Größe zu schaffen. Der erste basiert auf Metallkomplexen und führt im 
Allgemeinen zu höheren Raten. Die Idee ist, ein Metall als elektrophiles Zentrum zur 
Unterstützung der Transesterfikation zu nutzen. Unter diesen Katalysatoren enthalten 
die effizientesten Lanthanid-Ionen, Cu
2+ und Zn
2+. 
Der zweite Ansatz zielt darauf ab, metallfreie künstliche Ribonucleasen zu 
entwickeln. Die Vorteile dieser Strategie sind, den Katalysator von der Stabilität der 
Metallkomplexe, die in vivo problematisch sein könnten, unabhängig zu machen. In 
diesem Ansatz wird die natürliche Katalyse durch Enzyme simuliert. Zweckmäßige 
Gruppen mit beschränkter katalytischer Aktivität z.B. als Nucleophile, Säuren oder 
Basen, werden in einer Weise zusammengesetzt, um Kooperation zu ermöglichen. 
Potente Katalysatoren können so ohne die Notwendigkeit von Metallen als 
Cofaktoren erzeugt werden.  
 
 
 
 
 
 
 
 
Unsere Gruppe hat einen der potentesten metallfreien Katalysatoren, das Tris{2-
[(benzimidazol-2-yl)amino]ethyl}amin (Abb. 1), erfolgreich entwickelt. Dieses 
Molekül katalysiert die Umesterung der Phosphodiesterbindung von RNA. 
Allerdings wurde die mechanistische Charakterisierung z.B. durch die pH-Wert-
abhängige Tendenz zur Aggregation mit der Zunahme des pH-Wertes kompliziert. 
Um dieses Problem zu lösen und um regiospezifische Spaltung zu erreichen, wurden 
während meiner Arbeit vier verschiedene 5'- DNA-Konjugate hergestellt, die über 
Disulfid-Bindungen verknüpft waren (Abb. 2: 1000, 1001, 1002 1006). 
N
HN
HN
NH
N
H
N
N
HN
N
N
H
O
O
Tris{2-[(benzimidazol-2-yl)amino]ethyl}amine
CH3
 
 
Abb 1: RNA-Spaltungsagens in dieser Arbeit. Zusammenfassung                                                                                                        C 
 
O P
O
O-
O
S
H
N
N
N
H
O
HN
N H
N
NH
H
N
N
NH
N S
DNA
catalyst-linker-5'GATCGGCAGTCGGCTAG3'
catalyst-linker-5'CGAGATCGGCAGTCGGCTAG3'
catalyst-linker-5'TCGGCAGTCGGCTAG3'
catalyst-linker-5'CTCCTGACAAGGTAT3'
1000
1001
1002
1006
catalyst-linker-5'tcggcagtcg3' PNA-Oligo1011
 
Abb 2: 5’-Oligonucleotid-Konjugate. 
Die RNA-Spaltungstests dieser Konjugate bewiesen ohne jeden Zweifel die Aktivität 
von Aminobenzimidazol-Katalysatoren. Weiterhin wurde eine pH-Abhängigkeit der 
Aktivität festgestellt, welche 
ein Optimum bei einem pH-
Wert von 8 zeigte. Ein hohes 
Niveau regiospezifischer 
Spaltung wurde durch die 
Verwendung von Helfer- 
Oligonucleotiden erreicht. 
Ein analoges PNA-Konjugat 
wurde ebenfalls synthetisiert 
(Abb. 2: 1011), welches sich aber interessanterweise als inaktiv erwies. Die Gründe 
dieses Misserfolges müssen noch geklärt werden. Auch wenn Anwendungen in vivo 
immer noch schwerer erreichbar scheinen, könnten diese Konjugate in vitro als 
sequenzspezifische künstlichen RNasen eingesetzt werden. Einige Fragen über den 
Mechanismus des Katalysators sind noch offen, doch könnten weitere wichtige 
Hinweise von einem Kristall des Katalysator-Substrat-Komplexes kommen. Weitere 
Studien, die die Wirkungsweise 
dieser Aminobenzimidazol-
Katalysatoren aufklären, sind 
wichtig, um neue Spaltagentien zu 
entwerfen, die es erlauben, 
vielversprechende Ergebnisse für in 
vivo-Anwendungen zu erhalten.  
Diese 5'-Konjugate zeigten wie 
erwartet keinen turnover. 
Infolgedessen wurde eine neue 
Klasse von Konjugaten entworfen, 
die den Katalysator in der Mitte der 
DNA-Stränge tragen, um 
mehrfachen turnover zu erlauben 
(Abb. 3). Von diesem neuen 
Konjugat basierten zwei auf Serinol, 
NH
O
S
O O P P
-O -O
O
O
O
O
N
H
N
NH
N
HN
HN
N
H
N
N
H
N
H
N
O
S
1008
TCGGCTAG-3' 5'-GAGATCGG
NH
O
S
O O P P
-O -O
O
O
O
O
N
H
N
NH
N
HN
HN
N
H
N
N
H
N
H
N
O
S
TCGGCTAG-3' 5'-GAGATCGG
1007
P P
-O -O
O
O
O
O
N
H
N
NH
N
HN
HN
N
H
N
N
H
N H
N
O
S
HN N
O
OO
O O
NH
S
O
CGGCTAG-3' 5'-AGATCGGC
1004
 
Abb. 3: Oligonucleotid- Konjugate, die turnover 
zeigen. D                                                                                                       Zusammenfassung 
 
3'-TATGGAACAGTC- - CTTC-
5'-AUACCUUGUCAG    GAAGAGAGGCCGUUA-3'
                                  GA
3'-TATGGAACAG TCCTTC-
5'-AUACCUUGUCAGGAGAAGAGAGGCCGUUA-3'
210
1012
1012
210
Abb. 4: 5’-Oligonucleotid Konjugat, um turnover 
zu erreichen. 
1007, 1008 und eins auf einem modifizierten Nukleotid (1004). Das Konjugat 1007, 
basierend auf Serinol mit einem kurzen Linker erwies sich als das Aktivste. Diese 
Moleküle erreichten eine erfolgreiche regiospezifische Spaltung und außerdem 
mehrfachen turnover. Für 1007 wurde ein ungefährer kcat von 0.03 h
-1 erhalten. 
Betreffend dieses Projektes bleibt es immer noch, die Spezifität und die Effizienz zu 
erforschen, die von der bulge-Größe abhängen. Dieses Problem konnte ohne 
besonderen Aufwand einer speziellen Synthese von einem neuem Substrat gelöst 
werden, welches bulges der gewünschten Größe ausbilden kann.  
Auf einer Arbeit von Häner 
basierend wurde eine alternative 
Strategie, die turnover erlaubt, 
angewendet, und zwar durch die 
Synthese von 1012 (Abb. 4). Dieses 
neue DNA-Konjugat wurde 
hergestellt, um am 5' -Ende durch 
eine Amid-Bindung den Katalysator zu tragen. In Analogie zur Arbeit von Häner 
wurde erwartet, dass Konjugat 1012 einen bulge mit Substrat 210 bildet. Dieser 
bulge ist die primäre Spaltungsstelle in der Arbeit von Häner gewesen (Abb. 4). 
Leider scheint in unserem Fall die Formation des bulges nicht energetisch begünstigt 
zu sein, während eine alternative bulgeless doppelsträngige Struktur  mehr bevorzugt 
zu sein scheint. Deshalb kam die Spaltung ausschließlich im einzelsträngigem 
Bereich vor (ohne turnover). Hier wird deutlich, dass der Schlüssel zum Verständnis 
dieses Projektes das Wissen über die Stabilisierung der bulge-Formation ist. 
Nach diesen Konjugationsstudien 
mit der DNA erschien der Tris(2-
aminobenzimidazol)- Katalysator 
für Anwendungen wie 
Affinitätsspaltung geeignet. Um 
diese Anwendung zu prüfen 
wurden andere Derivate 
hergestellt, die geeignet waren für 
Konjugation über Amid-Bindungen und über Maleimid-Chemie (Abb. 5). 37 
benutzend wurden vier verschiedene Peptidkonjugate synthetisiert (Abb. 6). 2001 
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Abb. 5:  Tris(benzimidazole) geeignet für 
Konjugation. Zusammenfassung                                                                                                        E 
 
und 2003 basierten auf der kurzen Sequenz 49-57 von Tat, die für die Erkennung des 
TAR wesentlich ist. 2004 und 2005 wurden aus einem Peptid, welches von Jörg 
Bäumler aus der Gruppe von Dr. Manuel Grez aus dem Georg- Speyer- Haus in 
Frankfurt ausgewählt wurde, das Affinität zu mRNA von Bcr-Abl hat. Wieder auf 
TAR zielend wurde noch ein Konjugat mit Neamin hergestellt, was in 
Zusammenarbeit mit der Universität von Grenoble (Professor Jean-Luc-Décout) 
geschah. Die Prüfungen dieser 5 Konjugate, um die Affinitätsspaltung unseres 
Katalysators zu bestätigen, wiesen 
darauf hin, dass die 
Spaltungsaktivität immer erhalten 
wurde, aber in einem Fall die 
Spezifität für das Target fehlte. 
Dadurch wurde in diesem Projekt 
ein optimales System für die 
Konjugation über Maleinimid- und Peptidbindungen etabliert, aber um diese 
Methode schließlich in der Affinitätsspaltung zu prüfen, müssen einige weitere Tests 
mit zuverlässigeren spezifischen RNA-Liganden durchgeführt werden.  
 
In Zusammenarbeit mit Professor Paolo Scrimin und Flavio Manea wurde ein 
Goldnanopartikel, mit 2-Aminobenzimidazol funktionalisiert, hergestellt (Abb. 7). 
Dieses Projekt versuchte die Frage zu beantworten, ob mehrere Kopien von 2-
Aminobenzimidazol in der Phosphoryl-Transfer-Katalyse kooperieren könnten, wenn 
sie in einer geometrisch weniger definierten Ansammlung bestehen. Aus Gründen 
schlechter Löslichkeit trugen nur 30% der Liganden auf dem metallischen Kern 2-
Aminobenzimidazol. Der Spaltungstest konnte keine signifikante katalytische 
Aktivität zeigen. Um ein positives 
Ergebnis zu erreichen, scheint es 
notwendig, den Prozentsatz funktioneller 
Gruppen auf der metallischen Oberfläche 
zu erhöhen. Eine alternative Strategie, 
um diese funktionellen Gruppen zu 
koordinieren, könnte die Verwendung 
von Dendrimeren sein. 
2001  NH2-YRKKR RQRRR C-Linker- Catalyst
2003  NH2-AAARKKRRQRRRAAAC-Linker-Catalyst
2004  NH2-KHLHLHKGGGC -Linker-Catalyst (L)
2005  NH2-KHLHLHKGGGC -Linker-Catalyst (D)
Neamine-Linker- Catalyst  
Abb. 6: Peptid- Konjugate, Neamin Koniugat. 
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mit 2-Aminobenzimidazolen. F                                                                                                       Zusammenfassung 
 
 
Ein letztes Projekt dieser Arbeit war die Synthese einer palindromischen Sequenz 
von 2',5'-Guanosin/Isoguanosin um die Stabilität dieses Duplexes zu verifizieren, die 
erwartet wurde, wenn sich Watson-Crick-artige Purin-Purin Basenpaare bilden. 
Dieses Projekt sollte die Grundlage für neue Experimente von nicht-enzymatischem 
Oligomerisierungen von Ribonucleotiden sein. Infolgedessen wurde die Synthese 
eines Phosphoramidits von Isoguanosin begonnen. Die Beendigung dieses Projektes 
ist noch zu erwarten. Trotzdem wurde an einer Syntheseroute zu diesem Molekül 
durch die Verwendung neuer Schutzgruppen weiter gearbeitet, um die synthetischen 
Herausforderungen in Zukunft lösen zu können, wie Abb. 8 illustriert.  
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1. Introduction 
 
Since it was demonstrated that the genetic information is stored in DNA,
[1][2][3] the 
puzzle of DNA structure was solved,
[4] the mechanism of gene expression and the 
role of RNA was understood.
[5][6][7] The interest for the chemistry and the biology of 
the nucleic acids has continued to grow. Particularly interesting is RNA, which plays 
a role as a mediator of the genetic information (mRNA), but also as a carrier of the 
amino acids (tRNA). It is present in the ribosome (rRNA), works as template for 
DNA synthesis in telomerases, and can play important functions in RNA cleavage, 
e.g. in ribozymes such as RNAse P. Concerning site specific cleavage of RNA, also 
the phenomenon of siRNAs has attracted considerable attention.
[8] In this process the 
so called RISC complex is programmed to cut single–stranded RNA with high 
sequence specificity. The cellular machinery responsible for RNA interference is also 
involved in the formation of micro-RNAs. RNA interference today has become one 
of the most useful tools in functional genomics. The big hope is that it may also be 
applied in therapy. 
In this context my thesis was focused on the development of artificial site-specific 
ribonucleases. These artificial catalysts have received attention for three reasons.  
The first aspect coming closest to possible applications is in affinity cleavage,
[9] 
which is a technique to localize the binding sites of RNA ligands by attaching 
covalently a reagent that cuts the nucleic acids. The second reason is the possibility 
of creating new tools for the sequence selective manipulation of large RNA 
molecules. The advantages of this approach are that one could have such tools for 
any sequence. The problem of this strategy is the necessity to achieve high precision 
in the cutting step, like for instance with the natural ribozymes. Important results 
were achieved also during my work.
[10] With a case of exact cleavage between two 
bases. Further improvements are still possible, as it will be described later. The third 
reason, but not in order of importance, is the potential application as catalytic 
antisense oligonucleotides in chemotherapy.
[11] Briefly, when the 
oligodeoxyribonucleotides (ODN), or their phosphorothioate analogues enter the 
cells, a RNA/ODN duplex is formed. The RNA/DNA duplexes activate an 
intracellular enzyme, the RNase H,
[12] which degrades the RNA component releasing 2                                                                                                              1 Introduction 
 
the ODN antisense. However, the stability of DNA and their phosphorothioate 
derivative in cells against enzymatic degradation is not exceptional. Efforts to 
improve the derivatives gave satisfactory results with respect to affinity and stability 
against non-specific nucleases, like in the case of PNA.
[13] Unfortunately not all of 
these structurally modified nucleic acids are substrates for RNAse H.
[14][15] Therefore 
the attachment of a catalyst able to destroy the target could become important.  
Currently two approaches exist for creating unspecific artificial RNases of relatively 
small size. The first one is based on metal complexes and has generally resulted in 
higher rates.
[15] The idea is to use a metal as an electrophilic centre, for promoting the 
transesterification. Among these catalysts the most efficient ones are made with 
lanthanide ions, Cu
2+ and Zn
2+.  
The second approach aims at developing metal-free artificial ribonucleases. The 
advantages of this strategy are to render the catalyst independent from the stability of 
metal complexes that could be problematic in vivo. In this approach the natural 
catalysis of the enzymes is simulated. Functional groups with limited catalytic 
activity e.g. as nucleophiles, acids or bases, are put together in a way to enable 
cooperativity. Potent catalyst can thus be generated, without the requirement of 
metals as cofactors. 
Our group has successfully developed one of the most powerful metal-free catalysts, 
the tris{2-[(benzimidazol-2-yl)amino]ethyl}amine.
[16] This molecule acts catalysing 
the transesterification of the phosphodiester bond of RNA however, the mechanistic 
characterization e.g. the pH-dependent activity was complicated by the tendency to 
aggregate with the increase of the pH. To solve this problem and to achieve site 
specific cleavage, a series of 5’ DNA conjugates, different in length and sequence, 
were synthesized during my work.
[10] The resulting compounds behaved as true 
artificial ribonucleases, and allowed to complete mechanistic studies on tris{2-
[(benzimidazol-2-yl)amino]ethyl}amine. However, this kind of site-specific 
ribonucleases, as expected did not show turnover. To generate site-specific 
ribonucleases exhibiting turnover, a series of oligonucleotides inducing a bulge in the 
RNA substrate were synthesized. These conjugates carry the benzimidazole catalyst 
unit in an intrachain position of DNA. To complete the synthetic part, a PNA 
conjugate was also investigated. In long terms the artificial nucleases might offer 
new opportunities for chemotherapy in vivo. In short terms, however, a more realistic 1 Introduction                                                                                                             3 
   
application of such catalysts could be in affinity cleavage. Towards this purpose and 
for the conjugation with RNA ligands carrying thiols (e.g. peptides and proteins), a 
maleimide derivative of the tris{2-[(benzimidazol-2-yl)amino]ethyl}amine was 
synthesised. Conjugates of different peptidic RNA ligands ending with cysteine were 
obtained. For the conjugation with RNA ligands with free amino groups via amide 
bonds, another derivative with a GABA linker was made. A further project, relevant 
in the context of affinity cleavage, was the conjugation of trisbenzimidazole catalysts 
with neamine,
[17] which was achieved in collaboration with the group of Professor 
Jean-Luc Décout (Université Joseph Fourier in Grenoble). The objectives of this first 
part of my thesis are summarized in Fig. 1. 
 
 
 
 
 
 
Starting from the observation that in the trisbenzimidazole catalyst three subunits 
interact cooperatively, raised almost spontaneously the idea to benefit more broadly 
of this effect. The concept was to prepare gold nanoparticles functionalised with 2-
amino-benzimidazole residues that may act cooperatively. Once an unspecific RNase 
is obtained, gold nanoparticles have the ability to exchange thiols on their 
surface.
[18][19] Therefore, by a partial exchange with thiols carrying a specific ligand 
they could become specific nucleases (this project is done in collaboration with the 
group of Professor Paolo Scrimin at the university of Padova).  
 
A second project has been the synthesis of isoguanosine nucleotides for studies of the 
“non-enzymatic oligomerization of ribonucleotides”. The discovery that RNA by 
itself exhibits catalytic activity
[20][21][22] led to the hypothesis that life could have its 
origin from a prebiotic ‘‘RNA world’’. To support this hypothesis it is necessary to 
explain, how RNA could spontaneously polymerise and self-replicate. Orgel and co-
workers have tried to develop a system of ‘‘non-enzymatic oligomerization of 
ribonucleotides’’
[23][24] based on imidazole activated nucleotides. This system has 
been studied also in our group. However, a series of obstacles hampering 
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oligomerization became visible: the tendency of G-rich templates to form 
quadruplexes, the weakness of the A-U base pair, less efficient stacking of 
pyrimidines compared to purines, inhibition by enantiomeric monomers, inhibition 
by single 2',5' connections, inhibition by purine-pyrimidine alternation and by-
products due to hydrolysis or erroneous chain extension that cause irreversible 
"poisoning". An alternative mechanism for non-enzymatic oligomerization  could 
start from ribonucleotides 2’,3’-cyclic phosphates as activated monomers. It was 
experimentally observed that the template controlled polymerisation of 
ribonucleotides 2’,3’-cyclic-phosphates leads mainly to chains with the 2’-
5’connection.
[25] This connection, although less stable,
[26] could be desirable, because 
it allows a reversible process of elongation and cleavage by formation of 
ribonucleotides 2’,3’-cyclic-phosphates. A possible correction of errors during chain 
elongation could thus be achieved under thermodynamic control. The problem is that 
with the normal bases and the normal Watson-Crick base pairings, because of the 
vicinity of the negatively charged phosphates the duplex of 2’-5’ connected RNA are 
unstable.
[27] Furthermore, it remains to explain the origin of the natural RNA, which 
has a connection 3’-5’. How is it possible to find a solution that solves all these 
problems? A hypothesis could be that before the development of an RNA world there 
might have been another kind of nucleic acid that somehow transmitted by selection 
and evolution its information to the RNA. 
One approach to form stable duplexes of 2’-5’ RNA and to solve the rest of the 
obstacles for the non-enzymatic polymerisation could be to consider RNA analogues 
composed of purine-purine base pairs. Expanding the base pairs should diminish 
charge-charge repulsion thus leading to stable duplexes. To support this hypothesis a 
duplex consisting only of purines should be prepared and tested for stability. In this 
context my project was to synthesise the isoguanosine phosphoramidite to assemble a 
palindromic sequence of guanosine and isoguanosine and to test the duplex stability. 
Considering that the tris{2-[(benzimidazol-2-yl)amino]ethyl}amine is a catalyst for 
cleavage which produces 2’,3’-cyclic phosphates ribonucleotides, by the principle of 
microscopic reversibility, it must also work in the inverse process becoming a 
candidate catalyst for polymerisation of nucleosides 2’,3’-cyclic phosphates, and for 
ligation.2 Catalysis and Catalysts for RNA Cleavage                                                            5 
   
2  Catalysis and Catalysts for RNA 
Cleavage  
 
2.1 Phosphodiester  Bond 
 
In general the cleavage–transesterification of a phosphodiester bond can be 
schematised as it is shown in Fig. 2.1, with a SN2 type mechanism, where the 
nucleophile and the leaving group are in apical positions.
[28] We speak about 
transesterification when an alcohol or an alkoxide is the nucleophile, while we speak 
about hydrolysis when a molecule of water or hydroxide is the nucleophile. 
 
 
 
 
 
 
 
Under physiological conditions the cleavage of RNA involves the formation of a 
marginally stable trigonal-bipyramidal dianionic phosphorane.
[28c] If it is more 
correct to speak about an intermediated or transition state is still object of dispute.  
Early studies gave evidence that RNA has an higher instability compared to 
DNA.
[28a] The reason of this difference is commonly attributed to the presence of an 
intramolecular nucleophile, the OH in 2’ position. To realize how resistant a 
phosphodiester bond can be, we can consider that the half life of the diphenyl 
phosphate. It is 180 years under neutral conditions at 100 °C and in absence of 
catalysis.
[29] To have an idea of what can be the effect of the 2’-OH, other studies 
have estimated the effective molarity of the 2'-OH group of RNA as 3 × l0
7 M for the 
hydroxide-catalysed reaction of a phenyl ester.
[30] 
Although the presence of the OH in 2’ position increase tremendously the rate of the 
cleavage, the half-life of a model for RNA like cytidylylcytidine is still quite long 
OH
P
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Figure 2.1: Trigonal-bipyramidal dianionic phosphorane. 6                                                             2 Catalysis and Catalysts for RNA Cleavage 
 
(1000 to 10000 days at 60 °C and pH 7).
[31] Hence the interest for possible catalysts 
of RNA cleavage is understandable.  
 
2.2  Cleavage of RNA 
 
In the mechanism of RNA-cleavage (Fig. 2.2), there is an attack of the 2’-oxyanion 
on the phosphorus (V), formation of the dianionic trigonal-bipyramidal phosphorane 
“intermediate”, and departure of the 5’ oxyanion. Contemporarily the reactive 2’,3’-
cyclic monophoshate is formed, which generates by hydrolysis a mixture of 2’ and 3’ 
nucleoside monophosphates.
[28a] 
 
 
 
 
2.3  Catalysis of RNA Cleavage  
 
In accord with what has been said so far, how should a catalyst act to accelerate this 
reaction? In a recent publication Lönnberg
[32] says that viable candidates for cleaving 
agents are molecules or ions that: 
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(i)  Enhance deprotonation of the 2’-OH.  
(ii)  Reduce the electron density at the phosphorus atom upon formation 
of the phosphorane “intermediate”, but allow it to be increased upon 
cleavage of the P–O5-bond. 
(iii)  Reduce the electron density at the departing 5-oxygen atom upon 
cleavage of the P–O5 bond. 
There is still another factor to be considered, in accord with the rules of 
Westheimer
[33] nucleophiles are expected to enter and leave the phosphorane only 
through apical positions. To let the cleavage to occur, the 2’OH and the leaving 5’O 
must be in line (Fig. 2.3a). Collinearity is required because the phosphorane is too 
short-unstable to allow an interchange of apical and equatorial positions by pseudo 
rotation (Fig. 2.3b). What said is particular important in helical structures as of RNA 
duplexes where the geometry prevents a collinear arrangement of the 2’-OH and the 
5’O, thus stabilizing the phosphodiester bonds. This is also the reason why the target 
for artificial RNases should not be a RNA duplex or a region rich in purines that by 
stacking tends to assume a helical form.
[32][34] On the other hand some sequence 
combinations of nucleotides seem to be particular reactive.
[34b] 
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2.4  Enzymatic Catalysis  
 
The problem of the catalysis was first solved by nature through enzymes. The variety 
of natural enzymes that catalyse phosphoryl transfer reactions is really enormous. 
There are not only nucleases or ribonucleases, but also phosphatases, DNA 
topoisomerases. DNA polymerases have a mechanism of correction therefore, they 
can also work as nucleases. We have then reverse transcriptases, integrases, without 
consider the ribozymes. Not all these enzymes are well characterized, but their use in 
biotechnology is increasing tremendously. Of all these enzymes, RNase A and the 
staphylococcal nuclease are particularly well known and studied. Therefore, they can 
be taken as classical examples to elucidate how nature arrived to optimise these 
reactions fundamental for life. A short description of these two enzymes will be done 
in the next two subchapters. 
 
 
2.4.1 Ribonuclease  A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bovine pancreatic ribonuclease A (Fig. 2.4) is one of the most studied enzymes, 
probably because even in the past it was easily available from the ruminants’ 
pancreas. It was crystallized already in 1939
[35], and in 1941
[36] it was possible to 
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Figure 2.4: Active site of ribonuclease A.
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have a resolution of 2 Å in X-ray structural analysis. What is really fascinating and 
probably also the reason why this enzyme has inspired the design of several artificial 
ribonucleases is its “Ping-Pong” mechanism.
[37][38] In this enzyme metal cofactors are 
not directly involved, but we have two imidazoles of two histidines that work in 
concert. His-12 deprotonates the 2’-OH, which becomes a better nucleophile to 
attack the phosphorus (V). On the other site the His-119 donates a proton to 5’O, 
neutralising the negative charge of the leaving group, which departure in this way is 
accelerated. Then other elements like Lys-41, are involved in the stabilization of the 
phosphorane. The role attributed to this amino acid is to reduce by electrostatic 
interaction the excess of negative charge that accumulates on the non-bridging 
phosphoryl oxygens in the “transition state”.
[39][40] It has also been proposed that the 
stabilization could occur by a short strong hydrogen bond, involving the partial 
transfer of a proton.
[41] No real detailed studies exist on the role in the catalysis of the 
main-chain nitrogen of Phe-120, but the closeness to the active site suggests an 
involvement by donating a proton in an hydrogen bond to a non-bridging oxygen.
[38] 
 
 
2.4.2 Staphylococcal  Nuclease 
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Figure 2.5: Active site of Staphylococcal nuclease.
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The second widely studied enzyme and source of inspiration for the design of 
artificial nucleases is staphylococcal nuclease. In a publication of 1979 Cotton et al. 
proposed a mechanism of action for this enzyme (Fig. 2.5).
[42] In the active site Ca
2+ 
is involved with its inner-sphere in the activation of a molecule of H2O, which is 
close enough to the Glu-43 to donate a hydrogen bond to this residue. In this way 
H2O is sufficiently nucleophilic to attack the phosphorus (V). Therefore, the 
carboxylate of Glu-43 acts as general base. Regarding the role of Arg-35 and Arg-87, 
both are involved in the catalysis by stabilising the dianionic phosphorane as strong 
donors of a bifunctional hydrogen bond, but their role seems to be different.
[43] In 
fact by mutation of Arg-87 with a Gly, the catalysis is profoundly reduced, but not 
the affinity. This suggests that Arg-87 interacts with the trigonal-bipyramidal 
phosphorane rather than with the tetrahedral ground state of the substrate. In the 
other hand the mutation of Arg-35 corresponds to a large reduction in activity and 
affinity, suggesting also a role in the recognition of the tetrahedral phosphodiester 
group of the substrate. 
 
 
2.5 Artificial  Ribonucleases 
 
The development of articial ribonucleases has followed mainly two directions, one 
based on metal complex, and the other based on metal free catalysts. With this 
preface a short presentation of the metal based catalyst will begin here, followed by a 
more deep description of the metal free catalysts. 
 
 
2.5.1  Metal Based Catalysis 
 
The modes in which metal ions can catalyse the RNA cleavage are basically 3, and 
they are summarized in Fig. 2.6.
[44][45][46][47] In the first mode the metal can promote 
the nucleophilic attack of the 2’-OH by interacting with it and deprotonating it. This 
interaction can occur directly (Fig. 2.6a) or by an hydroxide ion ligand of the outer 
sphere (Fig 2.6b). In the second mode the metal can interact with the negative charge 
of the phosphate (Fig. 2.6c), making the phosphodiester more electrophilic and more 2 Catalysis and Catalysts for RNA Cleavage                                                            11 
   
prone towards nucleophilic attack. 
After the attack the formation of the 
dianionic phosphorane can be 
stabilized by the positive charge of the 
cationic metals (Fig. 2.6d). In the 
third mode the metal can assist the 
departure of the leaving group 
protonating the oxygen by a water 
molecule of his outer sphere, or 
directly by interaction of the metal ion 
with the partial negative charge on the 
leaving oxygen. Therefore, metals 
combine intrinsic properties to 
catalyse the RNA cleavage.
[48][49] To 
illustrate these catalytic properties we 
can take a recent publication, where 
with the simple incorporation of a modified nucleotide in the middle of a DNA 
sequence, a conformational change in the complementary RNA strand was induced, 
and 10 mM MgCl2 (pH 8) was sufficient to cleave specifically this site (Fig. 2.7).
[50] 
 
 
 
 
 
 
 
 
 
 
2.5.2 Metal-Based  Catalysts 
 
Already in 1938 it was observed that certain metals like lanthanide ions were able to 
catalyse the cleavage of phosphoric acid esters.
[51] Knowing the properties of these 
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Figure 2.6: Modes by which the metal iones 
can catalyse the RNA cleavage.
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Figure 2.7:  Modified nucleotide  induced a conformational change, with a 
concentration of 10 mM of MgCl2 (pH 8) a site specific cleavage was achieved.
[50] 
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metals, one strategy towards artificial nucleases was to attach related metal 
complexes to DNA oligonucleotides in order to get site specific cleavage by 
formation of antisense conjugates. With this strategy the best results were achieved 
by complexes of lanthanide ions, Cu
2+ and Zn
2+
.
[32][15] 
The most promising complexes of lanthanides are macrocyclic complexes,
[52] which 
were conjugated with different modalities to antisense oligonucleotides (Fig. 
2.8).
[53][54][55] 
 
 
 
 
 
 
 
 
 
 
The catalysts based on Cu
2+ ions are usually complexes of terpyridines and 
dimethylphenanthroline (Fig. 2.9), then conjugated to have specificity.
[32][15] The first 
conjugate was obtained by Bashkin et al. using terpyridine as agent to complex 
Cu
2+.
[56] Improvements to optimize the cleavage continued by the conjugation of 
these complexing agent in different positions.
[32][15] 
 
 
 
 
 
 
 
Another ion metal often used in metal based ribonucleases is Zn
2+. The catalysts that 
form complexes with this metal in different constructs, are usually a combination of 
the following chelating agents: dimethylphenantroline, 1,4,7-triazacyclononane, 
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Figure 2.8: Macrocycles complexing lanthanides as catalysts for RNA 
cleavage. 
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1,5,9-triazacyclododecane and 1,4,7,10-tetraazacyclododecane (Fig. 
2.10).
[15][32][44][45][47][57] 
 
 
2.5.3 Metal  Free  Artificial RNases 
 
In the development of artificial RNases the second strategy is based on metal free 
catalysts, agents able to cleave independently of metallic cofactors, however, without 
excluding a possible participation of physiological metals in vivo. The aim of such 
strategies is clear, to make the catalyst independent from complexes, whose stability 
can be challenged in vivo by other natural metal-binding sites. Even for uses in vitro, 
the structures of RNA could form metal-binding sites that could compete for the 
metal of the cleaving agent. 
In some cases these catalysts have been inspirited by RNase A, where an important 
role is played by two residues of histidine. Also staphylococcal nuclease has been 
source of inspiration. Here an important role is played by two residues of arginine. 
Another category of these catalysts are the polyamines. 
In these catalysts are combined elements that represent single chemical functions, 
like acid-basic properties or the ability to form pairs by hydrogen bonds. Such 
elements by themselves are not powerful catalysts. However, when combined in 
more complicated molecules to work cooperatively, they are able to generate large 
catalytic effects. An analysis of the elements that can catalyse RNA cleavage will 
follow in the next subchapters. 
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2.5.3.1 Imidazole  Based  Catalysis 
 
 
 
 
 
 
 
 
The imidazole in form of histidine with its pKa close to 7 has important functions in 
several enzymatic reactions, because it can exist at neutral pH as imidazolium or as 
imidizole. Under physiological conditions the imidazole residues are the strongest 
bases that can exist at least partially deprotonated, while the imidazolium is the 
strongest acid that can exist at least partially protonated. These properties allow the 
imidazolium to act as general acid, and the imidazole as general base, or like in 
RNase A as combined acid and base catalysis.
[58][59][60]  
 
 
 
 
 
 
 
 
 
 
The options of imidazole to catalyse the transesterification of RNA are shown in Fig. 
2.12, where we have three modes.
[28a][28c][60] The first modality a) is by general base 
catalysis, the free base in proximity to the 2’-OH can support the deprotonation and 
therefore, the subsequent nucleophilic attack. The second modality b) is by general 
acid catalysis. We can have a protonation of the phosphodiester anionic oxygen (pKa 
≈ 1)
[28a] prior to nucleophilic attack, making the phosphodiester more electrophilic. 
This event can also occur simultaneously with the formation of the dianionic 
N N N N H H H
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Figure 2.11: Imidazolium imidizole equilibrium. 
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phosphorane, thus stabilizing this intermediate/transitionstate. The oxygen of the 
dianionic phosphorane by theoretical calculations can assume a pKa in the range of 
6.5-11.
[28c] The last modality c) is also by acid catalysis, the imidazolium in 
proximity to the leaving 5’O can protonate it, and make the departure of the leaving 
group easier. 
On the base of these three 
modalities and numerous 
studies, two mechanisms for 
imidazole catalysis and in 
RNase A are proposed (Fig. 
2.13).
[28a][28c][60] In the classical 
mechanism (Fig. 2.13a) an 
imidazole acts as base 
deprotonating the 2’-OH and in 
a second step or simultaneously 
an imidazolium group protonates 
the leaving 5’O.  While in the 
second mechanism called 
“Triester Mechanism” (Fig. 
2.13b), an imidazole 
deprotonates the 2’-OH. The 
other imidazolium first protonates the phosphorane and then removes the proton to 
place it on the leaving group. With this mechanism of ‘‘push-pull’’ the second 
imidazolium in first step lowers the barrier for the nucleophilic attack and then by 
transferring the proton to the leaving group reduces the barrier for its departure. Note 
that the protonated phosphorane, in contrast to its dianion, is thought to be a stable 
intermediate. 
 
2.5.3.2  Guanidium Based Catalysis 
 
The guanidinium group is the residue of the arginines present in the active site of 
SNase (staphylococcal nuclease) as well in other enzymes. It is particularly versatile 
because it can make 5 hydrogen bonds, due to its high pKa (in arginine 12.48)
[61] it 
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Figure 2.13: Mechanism for imidazole catalysis and 
RNase A: A) Classical mechanism. B) Triester 
mechanism.
[28c] 16                                                             2 Catalysis and Catalysts for RNA Cleavage 
 
can carry a positive charge, and is planar. The general modalities of guanidinium-
phosphate interactions are described in (Fig. 2.14).
[62] 
 
Two other patterns of interaction between guanidinium and phosphate are described 
in Fig. 2.15. In Fig. 2.15a two guanidiniums form strong hydrogen bonds with a 
monohydrogenphosphate.
[63] While in Fig. 2.15b one guanidinium is able to 
coordinate two phosphates forming four hydrogens bonds. This last pattern is also 
called ‘‘Arginine fork’’.
[64] 
 
These modes of interactions are more interesting for the recognition of phosphates by 
guanidinium, nevertheless our goal is catalysis. Anslyn
[62] has postulated that for the 
guanidinium group at least three roles can be played in the nuclease-mediated 
hydrolysis: 
 
1.  The ditopic nature of the hydrogen-bonding pattern can bind and orient 
a phosphoester substrate. 
2.  The positive charge allows for electrostatic stabilization of anionic 
phosphorane-like transition states. 
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Figure 2.14: Interaction patterns between guanidinium and phosphate.
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Figure 2.15:  a)  Two guanidiniums form strong hydrogen bonds with a 
monohydrogenphosphate.
[63] b) A guanidinium coordinates two phosphates ‘‘Arginine fork’’.
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3.  Proton transfer to the leaving groups (whose pKa comes close to 14.8)
[65] 
may occur.
[66] Given our phosphorane pKa, guanidinium groups (with 
pKa near 13) should also act as general acids and therefore protonate the 
phosphoranes (Fig. 2.16). 
 
 
 
 
 
 
 
 
 
According to these roles a guanidinium group can act as acid and base to shuttle 
protons on and off the phosphorane intermediates formed along the hydrolysis 
pathway. 
 
2.5.3.3 Catalysis  Based on Oligomeric Amines 
 
The first studies about activity of oligoamines in RNA cleavage, were reported by 
Komiyama and co-workers.
[67] On the base of these studies it was shown that the 
simple ethylenediamine or its oligomerers diethylenetriamine, triethylenetetraamine 
at pH 8 and pH 7, give an acceleration of RNA hydrolysis, however this effect was 
negligible for ethylamine (Fig. 2.17a). Therefore it was deduced that this catalysis  
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Figure 2.16:  Guanidinium 
mediates RNA hydrolysis. 
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was due to a cooperativity of two amino groups. Accurate analysis of RNA cleavage 
for different amines at pH 7 showed the order of activity reported in Fig. 2.17b 
left.
[68] The explanation was that of the possible forms of these diamines; neutral, 
mono cationic, and fully protonated, only the first two are active. At pH 7 the 1,4-
diaminobutane and the 1,5-diaminopentane are almost completely protonated and 
thus show only a small activity. On the contrary the ethylenediamine and the 1,3-
diaminopropane preferentially form the monocation. This is caused by the 
electrostatic suppression of the second protonation. If at pH 7 the active diamines 
adopt the monocationic form, the mechanism may occur with two modalities (Fig. 
2.18). In the first hypothesis the free amino group acts as general base and the 
protonated one can be a general acid. In the second hypothesis the free amino group 
again acts as genereral base, while the protonated amino group assists by electrostatic 
stabilisation. To clarify which of these two hypothetic mechanisms are real, the 
activity of (2-aminoethyl)trimethylammonium ion [H2N(CH2)2N(CH3)3
+] were 
checked (Fig. 2.18). 
 
 
 
 
 
 
 
 
 
 
 
This ion has a positive charge as does the monocation of ethylenediamine, but at pH 
7 it has no acidic proton, and is 4.4 fold less active. The conclusion was that the 
ammonium cation acts as general acid. Another test was done in D2O to see the 
“Solvent Isotope Effect”. For the ApA hydrolysis by the monocation of 
ethylenediamine and by its neutral species: kc(in H2O)/kc(in D2O) = 2.0 and 1.4 
respectively.
[68] This was another argument for a proton transfer from the ammonium 
group. The conclusions of these studies were that for the monocation of 
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Figure 2.18: Mechanism for oligoamines in RNA 
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ethylenediamine the mechanism proceeds by acid–basic catalysis, with the amino 
group that acts as base taking away the proton of the 2’-OH and the protonated 
amino group donating a proton during phosphorane formation. The diamines with 
longer chains, are less active in catalysis, because at neutral pH exist predominantly 
in form of dications. The increased distance of the nitrogens renders the electrostatic 
suppression of the second protonation less effective. At more basic pH the neutral 
amines should then react mainly by general base catalysis. 
 
2.5.3.4  Metal Free Cleaving Agents  
 
In the last years various metal-free catalysts have been developed.
[28a] After the 
description of the elements that generally are used in the design of artificial metal 
free RNases, some examples of catalysts will be now taken in consideration.  
The compound in Fig. 2.19a was synthesized with the aim to take advantage of the 
properties of the oligomeric amines and trying to improve the cleavage by 
conjugation with an intercalator.
[69] The cleavage induced by this compound (1 mM) 
was 40 % of rRNA (0.1 unit A260) in 1 h at 37 °C and pH 7.4. 
 
 
 
 
 
 
 
 
 
 
The compound shown in Fig. 2.19b
[69] (1 mM) was reported to cleave 60 % of rRNA 
(0.1 unit A260) in 1h at 37 °C and pH 7.4. While for the compound in   
Fig: 2.19c
[70] showed to be able to cleave the 50 % of the substrate in 12 h at pH 7.5 
and 37 °C. With the aim to reproduce the active site of RNase A, different cleaving 
agents were produced. One of the first catalysts is shown in Fig. 2.20b,
[71] where is 
also proposed a possible mechanism. Such catalyst showed to cleave 30 % of the 
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RNA target in 4 days at pH 7.5 and 50°C. A catalyst inspired by staphylococcal 
nuclease and based on the guanidinium groups, is given in   
Fig. 2.20a.
[72] This molecule was able to cleave RNA in the presence of imidazole, 
which should work as base deprotonating the 2’-OH. 
 
 
 
2.6 The  Tris(2-aminobenzimidazole) 
 
In the last years tris{2-[(benzimidazol-2-yl)amino]ethyl}amine (29) (Fig. 2.22) was 
developed in our group as a catalyst for RNA cleavage.
[16] During my work this 
catalyst was used to obtain site specific RNA cleavage. 
 
This compound was the result of studies on the catalytic influence of guanidinium 
ions on the phosphodiester transesterification. An important observation was made 
by analysing the reaction of catechol cyclic phosphate and phenylethanol in DMF in 
presence of different guanidinium derivatives (Fig. 2.21).
[16][73] The connection of 
two guanidinium groups by a proper spacer (Fig. 2.22a) could show an interesting 
catalytic cooperativity. 
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Figure 2.20: Some metal free cleaving agent. 
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Figure 2.21: Reaction of catechol cyclic phosphate and phenylethanol.
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The substitution of the guanidinium groups by heterocycles (Fig. 2.22b) led to a 
further rate increase by a factor of 10. This effect was attributed to the increased 
acidity of the heterocyclic guanidinium analogue.
[74] In fact the increased acidity 
reinforces hydrogen bonds with the substrate and improves the transition state 
stabilization. In addition, it enables the cation to participate in general acid/base 
catalysis.
[66] However, in water this effect was not visible anymore. The explanation 
can be found in the electrophilicity and polarity of water that allows it to stabilize the 
phosphorane transition state by solvation. The guanidinium ions in aqueous solutions 
are mostly protonated and not sufficiently acidic to compete with water as general 
acid. Therefore, the remaining activity of the compounds in Fig. 2.22a and b was too 
weak to induce major rate effects in aqueous solution. As a consequence of these 
observations it was decided to decrease the pKa of the guanidinium group by 
incorporating them into aromatic heterocycles. 
 
HN NH H2N
NH
NH2
NH
HN NH
N
N
H
N
H
N
HN NH N
H
N N
HN NH
N N
NH
N
N
H NH
N
N
H
HN N
H
N
NH
N
N
H
HN
N
HN NH
N
N
H
N
H
N
N
HN
HN
NH
N
HN
NH
N
N
H
N R R = H
R = COOCH3
a) b) c)
d) e) f)
g) h)
i)
29
 
 Figure 2.22: Structure of the compounds that preceded 29. 22                                                             2 Catalysis and Catalysts for RNA Cleavage 
 
Table 2.1: RNA degradation for the compounds in 
Fig. 2.22. at 10 mM Catalyst, 50 mM Tris HCl, pH 7, 
0.01 % SDS, 37 °C, 20 h, RNA 120-140 nM. 
                      % degradation 
compound  pKa  RNA 1*  RNA 2* 
c 
d 
e 
f 
g 
h 
i 
6.2 
6.5 
6.9 
6.6 
7.1 
7.0 
n.d 
6 
2 
15 
15 
31 
n.d. 
n.d. 
4 
<1 
13 
13 
31 
86 
n.d 
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Figure 2.23:  RNA structures used to test the 
compounds in Fig. 2.22. 
 
Table 2.2: RNA cleavage for the compounds in 
Fig. 2.22. at 1 mM Catalyst, 50 mM Tris-HCl, pH 6, 
0.01 % SDS, 37 °C, 20 h, RNA 120-140 nM. 
                                     % degradation 
compound  pKa  RNA 124   RNA 2* 
c 
d 
e 
f 
g 
h 
i 
6.2 
6.5 
6.9 
6.6 
7.1 
7.0 
n.d 
 
 
4.8 
4.6 
4.5 
23.1 
92.9 
 
 
2.4 
3.0 
3.2 
15.3 
87.6 
To really prove a relation between 
the activity and the acidity, 
different guanidinium analogues 
were synthesized. The pKa values 
were determinated and are 
reported in Tab. 2.1. For the 
tris(benzimidazole) Fig. 2.22i it 
was not possible to measure 
reproducible values. The 
absorption versus concentration 
curves around pH 7 did not fulfil 
Lambert-Beer’s law, indicating 
some form of aggregation. In the 
first tests to evaluate these 
different guanidinium and 
amidinium derivatives, the 
monomeric 2-aminobenzimidazole 
derivative in Fig. 2.22e (10 mM) 
already cleaved 13–15 % of the 
RNA substrate (120-140 nM) at 37 
°C, 20 h and pH 7. For the 
bisbenzimidazole in Fig. 2.22h the 
cleavage could reach 31 % in the 
same conditions. The problem was 
that under such conditions 
excessive RNA precipitation was 
observed in several experiments. 
For the same reason, no data could be obtained for the tris(benzimidazole). To 
minimize such effects 0.01 % of n-dodecyl sulfate (SDS) was added to the cleavage 
buffer. To exclude precipitation effects new sets of experiments were run at pH 6 
(Tab. 2.2). From these experiments it was possible to see that the tris(benzimidazole) 
was the best catalyst, inducing cleavage yields of 87-92 % in 20 h, at 37 °C and pH 
6. The resulting half-lives are 120 min for the linear substrate 124 (Fig. 2.23) and 2 Catalysis and Catalysts for RNA Cleavage                                                            23 
   
200 min for the TAR analogue sequence 2* (Fig. 2.23). This corresponds to a formal 
first-order rate constant of 3.3 × 10
-6 s
1 for a mean phosphodiester linkage in 
substrate  124. After these first series of 
experiments the most promising compound 
was the tris(benzimidazole). Therefore, 
more detailed investigations were done 
studying the cleavage as a function of 
catalyst concentration. From these studies a 
non-linear dependency was found, with a 
sudden decrease of activity around 100 μM 
(Tab. 2.3). The phenomenon was again 
investigated with the suspect that the 
formation of aggregates could be the 
reason. To verify aggregation the 
Fluorescence Correlation Spectroscopy 
(FCS) was used. With this method the diffusion time is measured in relation to the 
size of a molecule. Bigger molecules will have a longer diffusion times. This 
parameter was measured using a dye labelled DNA sequence, incubated with 
different concentrations of the tris(2-aminobenzimidazole) and with different 
detergents. A clear correlation between aggregation and catalytic activity was found. 
With the formation of the aggregates the activity was much higher.  
Therefore, a non-aggregated form of catalyst 29 suitable for pH dependency 
correlation was desirable. A task of my thesis was to solve this problem of solubility. 
At the same time a method for site specific RNA cleavage had to be developed. To 
reach this objective, during my thesis different DNA conjugates were synthesised to 
generate a soluble and specific derivative of the tris(2-aminobenzimidazole). 
 
 
 
 
 
 
 
Table 2.3: RNA degradation for 29 at 
different concentrations. Conditions: 50 
mM Tris-HCl, pH 6, 0.01 % SDS, 37 °C, 
20 h, RNA 120-140 nM. 
                             % degradation 
Concentration 
29 [μM] 
RNA 1  RNA 2 
250 
200 
150 
120 
100 
80 
60 
40 
20 
10 
87.4 
85.6 
63.3 
60.3 
16.6 
6.2 
3.9 
5.2 
6.3 
4.1 
48.7 
44.8 
27.1 
26.7 
8.5 
6.4 
6.5 
5.2 
7.7 
1.1 24                                                             2 Catalysis and Catalysts for RNA Cleavage 
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2.7  Assays for RNA Cleavage 
 
2.7.1  Models for RNA Cleavage 
 
In recent years different assays have been developed to measure the reaction rates of 
RNA cleavage. Some of the most successful systems are reported here. One method 
is to use reactive models of RNA. 
Among the models of RNA the two 
mostly used are shown in Fig. 
2.24.
[31][75][76] The names are HpPNP 
and  UpNP when the base is uracile. 
These compounds are designed to 
mimic the dialkyl phosphate esters that 
form the backbone of RNA. The leaving 
group is 4-nitrophenolate, which is a 
better leaving group compared with an 
alkoxylate. Consequently, these 
compounds are more prone to base catalyzed cleavage. The advantage of these 
models is the possibility to monitor by UV absorbance the release of 4-
nitrophenolate, which gives an increase of absorbance at 400 nm. These models are 
then particularly useful for studying the mechanism of phosphate ester hydrolysis. 
Furthermore, the cleavage can be followed by HPLC and 
31P NMR. Caution should 
be taken, however, to predict reactivity of 
real RNA, which can largely differ from 
the rates observed with RNA models.  
Other substrates for mechanistic and 
kinetic studies of RNA cleavage are 
dinucleotide mono and diphosphates
[15] 
such as ApA, and ApUp (Fig 2.25). The 
reactivity of these dinucleotides comes 
closer to the properties of the polymeric 
RNA, and they have the advantage of a 
single cleavage site. The cleavage can be then monitored by HPLC, or by NMR 
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Figure 2.24: Activated models for RNA 
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Figure  2.26: Alfexpress
TM automatic sequencer for RNA cleavage assays. 
exploiting the different δ of C1’ protons in the starting dinucleotide and the cleavage 
products. As disadvantage they have not the polymeric and polyanionic character of 
the biological RNA. Significant differences have been observed between 
dinucleotides and the polymeric RNA, and even between ApA and ApAp.
[15] 
 
2.7.2  Fluorescently Labelled RNA Probes Analysed by Alfexpress
TM 
 
Although RNA models can be useful tools to probe the activity of artificial 
nucleases, the final test should be done with real RNA. Site specificity was among 
the objectives of this work. Therefore, the cleavage assays were performed with 
defined RNA sequences. The methods to analyse RNA cleavage are usually based on 
gel electrophoresis. Traditional procedures with standard electrophoresis chambers 
and radioactively labelled sequences have some inconveniencies, like the cost of the 
waste disposal, radiation protection, and the short half-life of the radioisotopes 
(usually 
32P, 
35S).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To avoid these inconveniencies a method based on fluorescently labelled RNA 
probes and automatic deoxyribonucleic (DNA) sequencers was developed in our 
group (Fig. 2.26).
[77][78] During the electrophoresis, Cy5-labeled RNA products are 
detected as they pass through a laser beam (633 nm) at the bottom of the gel. Cy5 is a 26                                                             2 Catalysis and Catalysts for RNA Cleavage 
 
carbocyanine dye with an absorption maximum at 643 nm and λem= 667 nm. It 
withstands a wide variety of solvents and incubation conditions. Laser excitation of 
the dye takes place simultaneously in the 40 lanes of the gel. Thus a great number of 
probes can be analysed in parallel. The emitted fluorescence is measured by a linear 
array of photodiodes with a detection limit similar to that of modern laser 
fluorescence scanners. Detector signals are recorded by the system’s computer and 
analysed by the AlleleLinks
TM software package. Compared to a simple 
electrophoresis chamber, the sequencer offers superior band resolution owing a long 
migration distance (26 cm), and the machine controls the temperature of the gel, 
normally 55 °C. A typical result of cleavage experiments analysed with the 
Alfexpress
TM automatic deoxyribonucleic (DNA) sequencer, is reported in Fig. 2.27, 
where an example of the electropherograms is shown. Lane B shows the result of a 
partial alkaline hydrolysis of RNA, used to prepare base ladders to analyse cleavage 
patterns and to identify cleavage sites. In lane A the result of one site-specific 
cleavage experiment is reported. In the right of both the lanes is present a big peake 
corresponding to the non-degraded substrate. The electropherograms are integrated 
using the AlleleLinks
TM software. The percentage of degraded RNA is then 
calculated from the ratio of integrals for product and product + substrate. 
 
 
The RNA substrates used in these experiments have in common the general structure 
shown in Fig. 2.38. The oligonucleotides are dye labelled with a fluorescent cyanine. 
This allows the detection of the RNA and of all degradation products with high 
sensitivity on the DNA sequencer. A short spacer of DNA (T10) was placed between 
the dye and the RNA sequence to prevent the formation of very short fragments that 
A
B
 
Figure 2.27: An electropherograms integrated using the AlleleLinks
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would complicate the electrophoretic separation. The DNA lacking the 2’-OH group 
is stable under the conditions of RNA cleavage. A T4 fragment is also attached to the 
3
’-end. A second type of RNA substrate, constructed in a similar way, contains a 
stem-loop element from HIV-1 TAR (Fig. 2.30). 
 
A problem that often arises during RNA cleavage experiments is the contamination 
by natural RNases, which can falsify the results. Our group has developed an 
incorruptible assay
[79] that makes use of enantiomeric RNA. In fact the natural 
enzymes are chiral entities, capable to cleave natural RNA with high 
enatioselectivity while the mirror image RNA is completely resistant to the natural 
RNases. Achiral catalysts however, are expected to cleave both enantiomeric 
substrates with the same pattern. For this reason enantiomeric RNA oligonucleotides 
were also studied (Fig. 2.30, substrate 158 and 190). 
 
Another construct with the schematic structure reported in Fig. 2.29 (Fig. 2.30 
substrate 202) was used to test the activity of antisense DNA conjugates. In this 
substrate a sequence of DNA in 3’ is complementary to the antisense DNA, while the 
catalyst is held close to the enantiomeric RNA sequence. Therefore, the binding is 
RNA SEQUENCE 5'- DNA-T10 DNA-T4 -3'
N N
OH OH
Dye
Cy5
 
Figure 2.28: Oligonucleotides dye labelled with a fluorescent cyanine as probe for RNA 
cleavage. 
ent-RNA SEQUENCE 5'- DNA sequence DNA-T4 -3' Cy5
 
Figure 2.29: Enantiomeric oligonucleotides dye labelled with a fluorescent cyanine as 
probe for RNA cleavage. 28                                                             2 Catalysis and Catalysts for RNA Cleavage 
 
guaranteed by the DNA sequence and the cleavage should occur in the enantiomeric 
RNA, excluding in this way the effect of possible contaminations. At the end of this 
chapter a survey of all substrates used in this thesis is given (Fig. 2.30). The 
numeration of Fig. 2.30 will be used later for describing the experiments of RNA 
cleavage. 
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3  Site-Specific Cleavage of RNA by 5’ 
Antisense Conjugates 
 
 
We have already seen in the precedent chapter how the tris(2-aminobenzimidazole) 
was identified as a powerful cleaver of ribonucleic acids. Unfortunately this 
molecule shows a tendency to aggregate in a pH-dependent way. This feature 
prevented deeper mechanistic studies such as pH-rate correlations and similar 
experiments. To solve this problem and to achieve a site-specific cleavage, a 
conjugation with DNA was planned. The investigations of the mechanism of the 
tris(2-aminobenzimidazole) was the first objective of these conjugates. Furthermore, 
this thesis also hopes to contribute to future practical applications. 
Useful synthetic ribonucleases should be characterized by two properties:  
1)  High site specificity 
For this purpose different antisense oligonucleotides were synthesized of which 
one presented a single cleavage site. In collaboration with Kathrin Beier it was 
furthermore tested if helper antisense oligonucleotides placed after the cleavage 
site might improve the site specificity.  
2)  Turnover  
This problem is generally solved by placing the catalyst in an intrachain position 
of the antisense oligonucleotide. With this approach the RNA fragments after 
cleavage are bound less strongly to the catalyst. Thus they can be released for a 
new catalytic cycle.  
A conjugate of this catalyst with a sequence of PNA was also synthesized. 
 
3.1 DNA  Conjugates 
 
In artificial ribonucleases the probe for sequence recognition is usually an 
oligonucleotide, which can be made of DNA or its modified analogues. Due to its 
relatively low cost and its standard automated synthesis, in these preliminary 
experiments of site specific cleavage the conjugation was done with DNA. Some 
general characteristics of DNA are summarized in Fig. 3.1. The typical Waston-30                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
Crick base pairings permit a specific recognition of a complementary DNA or RNA 
sequence. 
 
From a structural point of view, the possibility to form these fixed pairings allows to 
the single polynucleotides to form a duplex helix, which structures are mostly of 
three types: B for DNA, A for RNA and in certain conditions Z for DNA. The duplex 
RNA-DNA assumes indeed the A structure. 
In the last 20-30 years the automated synthesis of nucleic acids has become standard. 
This chemistry is based on the phosphoramidite method, because of the inherently 
high coupling efficiency and the stability of the starting material.
[81] The building 
blocks are the phosphoramidites of the 4 bases, which are commercially available as 
well as the other reagents. The cycle of oligonucleotide synthesis by 
phosphoramidite chemistry (Fig. 3.2) can be dissected in 5 steps: 1) Detritylation. 
The dimethoxy trityl group that protects the 5’-OH is removed by treatment with 
trichloroacetic acid (TCA). This liberates the 5’-OH for the coupling step. 2) 
Coupling. The tetrazole and the phosphoramidites are mixed as they enter the 
reaction chamber. These form a highly reactive species, which rapidly reacts with the 
 
Figure 3.1: Parameters of the duplex helix in B form.
[80] 3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates                                       31 
   
5’-OH. 3) Capping. Acetic anhydride and dimethyl amino pyridine are mixed and 
form a powerful acetylating species, which terminates any chain that did not react 
during the coupling step. 4) Oxidation. The labile phosphorous linkage formed in the 
coupling step is converted to the stable, pentavalent phosphorous linkage of 
biologically active DNA. 5) Deprotection. After chain assembly is completed, the 
phosphate protecting groups are removed, the chains are separated from the solid 
support, and the base protecting groups are removed. Alternatively the newly 
inserted nucleotide can enter another elongation cycle. 
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3.2  Conjugation at the 5’ Terminus 
 
 
 
 
 
 
 
 
The conjugation of 29 (Fig. 3.3) was attempted first with the standard procedure to 
synthesize DNA conjugates involving acylation of amino linkers by active esters in 
aqueous buffer. When it was applied to the charged benzimidazole 29 however, 
complete precipitation of the oligonucleotides occurred and therefore, the coupling 
was prevented. At this point it was decided to proceed with the conjugation by solid 
phase synthesis. Two possible methods for the conjugation were taken in 
consideration, by peptidic linkage and by disulfide linkage.
[82][83] The disulfide 
linkage was used in this work. The choice of the disulfide chemistry was also 
suggested by a recent work of Lönnberg where a 1,5,9-triazacyclododecane 
conjugated to 2’-O-methyl oligoribonucleotides by a disulfide linkage showed to be 
8 times faster than the amide bond conjugate although the length of the linker was 
almost equal.
[83] The disulfide bond was preferred for a first investigation also 
because it should be more flexible and more capable of possible conformational 
adjustments to reach the phosphodiester bond. 
 
3.2.1  Synthesis of the Building Blocks for the Conjugation 
 
The thio linker phosphoramidite 62 was synthesized in two steps following the 
scheme 3.1. 6-Bromo-1-hexanol was converted into 61 by substitution with 
triphenylmethyl mercaptan using a published procedure.
[82d-e] The corresponding 
phosphoramidite was obtained in the classical way by phosphitylating the hydroxyl 
group with 2-cyanoethoxy-N,N-diisopropylchloro-phosphoramidite in the presence 
of N,N-diisopropylethylamine. 
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Figure 3.3:  The catalyst used during this work as 
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According to the procedure published by our group, the compound 29 was 
synthesized as shown in the scheme 3.2.
[16]  
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Scheme 3.1: Synthesis of 62. 
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Scheme 3.2: Synthesis of 29.
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Using Boc-ON, tris (2-aminoethyl) amine (TREN) was doubly Boc protected. In 
parallel the carboxyl group of the diaminobenzoic acid dissolved in methanol was 
protected by methyl esterification using thionylchloride. The stepwise reaction of 5 
with thiocarbonyl diimidazole and the compound 2 gave the thiourea 6. The 
compound  6 was cyclized forming the monobenzimidazole 7 using HgO as 
condensing agent. The Boc protecting groups of 7 were removed by adding SOCl2 to 
a solution in MeOH giving the compound 23, which was converted in the thiourea 24 
adding o-nitrophenylisothiocyanate. The nitro groups of 24 were reduced by Pd 
catalysed hydrogenation and the final compound 29 was achieved using HgO for the 
ring closure of intermediate 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 2-thiopyridine activated compound 63 was obtained following the scheme 3.3. 
In accordance with the published procedure
[82b] Aldrithiol-2
TM was mixed with 2-
aminoethanethiol hydrochloride giving the desired compound 58. 
The compound 29 was then converted into 63 in two steps. The methyl ester was 
refluxed in 6 M aqueous HCl giving the carboxylic acid 30, which was coupled with 
58 using DIC and HOBT.  
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3.2.2  Conjugation at 5’ via Disulfide Linkage 
 
In the procedure used for the conjugation of compound 29 with DNA (Sch. 3.4), the 
thio linker 62 was introduced in position 5’ of a DNA strand by a synthesizer cycle. 
The trityl group was selectively removed by treating the modified oligonucleotide on 
solid phase with a 0.1 M solution of AgNO3. To reduce possible disulfide bonds 
followed a treatment with a 0.1 M solution of TCEP.
[84] Compound 63 that is the 2-
thiopyridine activated compound 29, was dissolved in DMF to form a 0.1 M 
solution, and was incubated for 12 h with the mercaptooligonucleotide on solid 
phase. 
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To remove possible impurities, the solid phase was then washed with DMF and 
CH3CN. Afterwards a treatment with ammonia 25 % for 24 h was done in order to 
cleave off the conjugate from the solid support and to remove the protecting groups. 
The crude conjugates were purified by denaturing PAGE, and characterized by 
MALDI mass spectrometry. In some cases it was possible to detect a mass peak with 
70 units above the calculated mass, which corresponds to an isobutyryl protecting 
group still attached to the oligonucleotide. For this reason in the future it is 
recommended to use fast deprotecting phosphoramidites, which make use of the 4-
isopropyl phenoxy acetyl protecting group instead of isobutyryl. In this way it should 
be possible to reduce the time of the deprotecting step to have a major guarantee to 
preserve the disulfide bond and at the same time be sure of a total deprotection of the 
nucleotide. Following this protocol the pure conjugates 1000, 1001, 1002 and 1006 
were finally isolated and fractions of 60-70 % of conjugated versus non-conjugated 
strands were typically obtained.  
 
3.3  Experiments towards Site Specific RNA 
Cleavage 
 
Dr. Ute Scheffer carried out the experiments of RNA cleavage. One of the objectives 
of these first conjugates was to analyse the activity of the tris(2-aminobenzimidazole) 
in a non-aggregated state. For this reason preliminary studies to exclude the existence 
of molecular aggregates were performed. The dye-labelled DNA 108  (25 nM), 
diluted with 175 nM unlabeled DNA 109 was studied by fluorescence correlation 
spectroscopy (for FCS see 2.6 and Sch. 3.1 for 108 and 109).
[10][16] The diffusion 
time around 150 μs at 24 °C is consistent with the size of 108. Upon addition of 
conjugates 1000, 1001, 1002 (1.5 μM), no change in diffusion times and no signs of 
aggregation could be observed. Substrate 124  (200 nM) was then mixed with 
complementary conjugates 1000, 1001, 1002, (1.5  μM), again without producing 
significant effects. The gain in molecular mass by hybridization was not expected to 
be sufficient to influence the diffusion time of 124. Further experiments with 
substrate 210 and conjugate 1006 confirmed the general view that higher aggregates 3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates                                       37 
   
of oligonucleotides beyond the stage of hybridisation did not occur in the 
experiments shown below. 
 
 
The results of the first cleavage tests are illustrated in Fig. 3.4. When the substrate 
124 was incubated with the catalysts 1000, 1001 and 1002 at pH 8, strong cleavage 
occurred. To locate the cleavage positions, lane d can be taken as a reference, which 
corresponds to alkaline hydrolysis of RNA substrate 124. The cleavage site was 
related to the position of the catalyst. In particular for 15mer 1000 the cleavage 
occurred mainly in position 13, 14 and 15. For 17mer 1001 the cleavage occurred 
mainly in position 17, while for the 20mer 1002 the main cleavage sites were in 
position 19 and 20. Under these conditions no turnover was observed. 
The influence of the pH was another important aspect determining the amount of 
aggregation of trisbenzimidazole 29. The complete water solubility of these 
conjugates on the other hand allowed to determine pH/rate correlations. In Tab. 3.1 
are summarized the results of the experiments of pH dependency, done in 50 mM 
Tris-HCl buffer ranging from pH 6 to 9. The pH dependent rates showed an increase 
of activity till pH 8. Keeping in mind that the pKa of the amino-benzimidazole is 
close to 7,
[16] at pH 8 the catalyst should be mostly deprotonated. Therefore, general 
base catalysis should be an important mechanistic aspect of benzimidazole mediated 
RNA hydrolysis. 
 
 
Figure 3.4: Cleavage of RNA 124 (150 nM) induced by conjugates 1000 – 1002 (1.5 µM). 
Conditions: 50 mM Tris-HCl pH 8.0, 37 °C, 20 h. Lane d: base ladder of substrate 124 (Na2CO3). 38                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
 
Subsequently saturation experiments were carried out with constant concentration of 
the substrate and an increasing concentration of the conjugates (Fig 3.5). Saturation 
could be observed above 200-300 nM. Consequently, running the experiments at a 
concentration of 1.5 μM, the substrate was completely saturated and the results 
should therefore not be affected by minor pH-dependent changes of duplex stability. 
In addition these experiments were done at constant ionic strength (100 mM 
NaCl).
[10] 
 
 
An important requirement for an artificial nuclease is the specificity for the substrate. 
In Fig. 3.6 an experiment of cross reactivity is shown. The substrates 124 and 210 
Table 3.1: Substrate degradation (%) as a function of pH. Cleavage of RNA 124 (150 nM) 
by conjugates 1000, 1001, 1002 (1500 nM), and cleavage of RNA 210 (150 nM) by conjugate 
1006 (1500 nM). Conditions: 50 mM Tris-HCl pH 8.0, 37 °C, 20 h. 
pH 1000 1001 1002 1006 
6.0  25.3 18.8 29.3 18.8 
7.0  46.9 41.1 54.4 41.1 
8.0  68.8 54.8 69.1 60.4 
9.0  - - 66.9  66.9 
 
 
Figure 3.5: Cleavage of RNA substrates 124 as function of conjugate concentration 150 
nM 124, 20-1500 nM of conjugates 1000, 1001 and 1002. Conditions: 50 mM Tris-HCl, pH 
8.0, 37 °C, 20 h.  3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates                                       39 
   
were incubated separately with the complementary and with the non-complementary 
conjugate. As we can see the cleavage was dependent on the hybridization of 
substrate and conjugate. 
 
 
Cleavage kinetics were studied in detail for the reaction of conjugate 1006, with the 
substrate  210 (pH 8, with 150 mM NaCl). Without catalyst, the substrate was 
practically stable for several days (Fig. 3.8 lane b). In contrast, conjugate 1006 
cleaved significantly within a few hours and the substrate was almost completely 
degraded after 56 hours (Fig. 3.7). A small percentage however, did not react even 
after 1 week (Fig. 3.7, lane o). This may result from structural damages in chemically 
synthesized RNA preventing hybridisation with conjugate 1006 (e.g., 2′,5′ linkages, 
residual protective groups, etc.). Interestingly, a more defined cleavage pattern arises 
after longer incubation times (Fig. 3.7). In fact upon standing, secondary cleavage 
events may cut off all conformationally mobile ribonucleotides protruding out of the 
duplex with conjugate 1006. 
 
 
 
 
 
 
Figure 3.6: Substrate specificity of conjugates 1000 and 1006. Lane a: Conjugate 
1000 and substrate 124. b: Conjugate 1000 and substrate 210. c: Conjugate 1006 and 
substrate 210. d: Conjugate 1006 and substrate 124. e and f: Base ladder of 124 and 210
(Na2CO3). 40                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
 
Fig. 3.9 shows the decay of RNA 210 as a function of time. The regression line 
demonstrates the high substrate stability in the control reaction (Fig. 3.8) with   
t1/2  ~  3500 h. For the cleavage induced by conjugate 1006, a proper fit of 
experimental and calculated data (Fig. 3.9 solid curve) was obtained by assuming a 
first order rate law with k1 = 0.056 h
-1 and t1/2 = 12.4 h.  
A general problem in studies of artificial ribonucleases are contaminations of natural 
ribonucleases that can give false positive results.
[79] To exclude these possible effects 
the chimeric substrate 202 (Fig. 2.29 - 2.30) was used. In this substrate a DNA 
sequence of 15 bases complementary to the sequence of the conjugate 1000, is 
followed by a sequence of enantiomeric RNA that is resistant to natural 
ribonucleases, but not to achiral catalysts. The cleavage with this substrate is 
illustrated in Fig. 3.10. As expected the cleavage occurred with the complementary 
conjugate 1000 selectively after nucleotide 16, the first ribonucleotide placed in close 
proximity to the benzimidazole moiety (Fig. 3.10 lane a). Note that the DNA part of 
Figure 3.7: Time dependent cleavage of
RNA 210 by conjugate 1006. Conditions:
150 nM substrate, 1.5 µM conjugate, 50 mM 
Tris-HCl pH 8.0, 100 mM NaCl, 37 ° C.
Figure 3.8: Controlls of time-dependent
cleavage of RNA. Conditions: 150 nM substrate, 50 
m MT r i s - H C l ,p H8 . 0 ,1 0 0m MN a C l ,3 7° C .a )
Control without incubation. b) Control after 56h.
Figure 3.9: Cleavage kinetics of 210 in the
presence and absence of conjugate 1006. Conditions: 
150 nM substrate, 0 or 1.5 µM conjugate, 50 mM
Tris- HCl, pH 8.0, 100 mM NaCl, 37 °C. The solid
curve is calculated by assuming first-order kinetics.3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates                                       41 
   
substrate  202 cannot be degraded. The preferred cleavage sites of the duplex 
1000•124 (nucleotides 13, 14, and 15), were thus inert in duplex 1000•202. As 
counterproof the substrate 202 proved resistant to degradation when incubated with 
the non-complementary conjugate 1006 (Fig. 3.10 lane b). 
 
 
 
 
 
 
 
 
 
 
 
3.3.1 Effect  of  Sulfate on Cleavage  
 
Further cleavage studies were made to explore the effects of SO4
2-, which should 
interact with guanidinium groups thus inhibiting the cleavage, by competition with 
the substrate phosphate.
[85] Moreover the guanidinium should change the pKa when 
in complex with the sulfate.
[86] To evaluate the effect of SO4
2- at different pH and to 
exclude possible effects due to the increased ionic strength, NaCl was used as inert 
salt. Consequently two sets of samples were prepared in Tris-HCl buffer at different 
pH, one with Na2SO4 and one with a concentration of NaCl such to have the same 
ionic strength μ (Fig. 3.11). 
 
 
Figure 3.10: Lane a: conjugate 1000 cleaves the enantio RNA insert of substrate 
202. Lane b: no cleavage occurs with the non-complementary conjugate 1006. 
Conditions: 150 nM substrate, 1.5 μM conjugate, 50 mM Tris-HCl, pH 8.0, 37 °C, 20 
h. Lane c: base ladder of substrate 202 (Na2CO3). 
 
 
μ = ionic strength 
c = concentration of a ion i 
z = charge of the ion i 
 
Figure 3.11: Ionic strength μ.
Table 3.2: Conditions: 150 nM substrate, 1.5 
μM conjugate, 50 mM Tris-HCl, pH 6, 7, 8, 9, 
100 mM for NaCl, and 67 mM for Na2SO4, 37 
°C, 20 h.. 
pH % Cleavage 
 Na2SO4 NaCl 
6  11.1 11.1 
7  34.4 31.7 
8  52.3 42.0 
9  43.7 39.3 42                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
The results are reported in Tab. 3.2 and in Fig. 3.12, where a weak increase of 
cleavage was observed with Na2SO4. This was in contrast with the expected 
inhibition. Interestingly it seems to appear a bell shape with a maximun around pH 8. 
(Conditions: 150 nM substrate, 1.5 μM conjugate, 50 mM Tris-HCl, pH 6, 7, 8, 9, 
100 mM for NaCl, and 67 mM for Na2SO4, 37 °C, 20 h.). 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Effect  of  Imidazole on Cleavage 
 
Imidazole as described in the precedent chapter can play an important role in RNA 
cleavage.
[72] To test the effect of imdazole, 1000 at 4 different concentrations (10, 5, 
1, 0.5 μM) was incubated with RNA 124 (150 nM), in one series with Tris-HCl 
buffer (50 mM, 0.01 % SDS, pH 7) at 37 °C for 20 h, and in the other series with an 
imidazole buffer (50 mM, 0.2 M KCl, 1 mM 
EDTA, pH 7) at same temperature and for the 
same time. In Tab. 3.3 are reported the results 
of these experiments. Interestingly from these 
data resulted that when the concentration of 
1000 was 1 μM in imidazole buffer, the 
cleavage was of 48.3 % compared with 35.9 
% in TRIS buffer showing an increase of 34 
% as possible catalytic enhancement due to 
imidazole. 
Table 3.3: Cleavage in presence of 
imidazole. Conditions: see text. 
Cg1000 %  Cleavage 
 Imidazole  TRIS 
10  μM 48.1  41.1 
5    μM 46.6  41.5 
1    μM 48.3  35.9 
0.5 μM 45.3  36.5 
Figure 3.12: Cleavage in relation of pH and NaCl or Na2SO4. 3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates                                       43 
   
3.4  Highly Site Specific Cleavage  
 
Once the general concept of trisbenzimidazole DNA conjugates was proven 
successful, the focus of my work was shifted to find the conditions for increasing 
specificity and multiple turnover. This task was solved by conjugating 29 in the 
middle of a DNA sequence. The turnover problem is discussed in the next chapter. 
Furthermore, the attention was focused on the objective of cleavage precision. At this 
stage an collaboration with Kathrin Beier in my group was started.  
Using the conjugate 1006 synthesized during my work, Kathrin Beier improved the 
specificity of the construct, applying a method reported by Komiyama.
[87] The 
strategy is illustrated Fig. 3.13a. It consists in placing a helper oligonucleotide after 
the cleavage site. In RNA duplexes the attack of the 2’-OH at phosphorus is a 
stereoelectronically forbidden process. If just a single base of RNA is not involved in 
duplexes, the cleavage should be restricted to this position. In contrast simple 
conjugates may cleave in all the positions that are single stranded and accessible to 
the catalyst (Fig. 3.13b). The final result of this strategy therefore, should be a single 
base cleavage. 
 
The helper DNA oligomers 246, 245 and 244 used in this experiment are reported in 
Fig. 3.14. They let a space for the cleavage of 2, 1 and 0 bases respectively. This 
strategy proved particularly successful as reported in Fig. 3.15. We can see that 
Figure 3.13: Strategy to have high specificity by helper oligonucleotides. 44                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
incubating 210, with 1006 and 246, the cleavage occurred in two positions lane c, 
using then 245 instead the cleavage occurred in only one position, and using 244 the 
cleavage was almost suppressed. To better figure out the improvement Fig. 3.15 lane 
b and Fig. 3.7 lane b should be compared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5 PNA  Conjugation 
 
A buffer even if particularly complex can only mimic a cellular environment. The 
presence of proteins or enzymes could inhibit the activity of 29 and by recruitment of 
some cellular machinery even an improvement could be observed. With no 
possibility to be excluded, some preliminary cellular experiment could clarify how 
such catalyst could behave in vivo. DNA conjugates such as 1006 however, suffer 
 
Figure 3.15: Lane a: 1006, 244, 210. Lane b: 1006, 245, 210. Lane c: 1006, 
246, 210. 150 nM substrate, 1.5 μM conjugate, helper 1.5 μM. Conditions: 50 
mM Tris-HCl, pH 8, 100 mM NaCl. Lane d: base ladder of substrate 210 
(Na2CO3). 
Cy5-T10-ribo(5'AUACCUUGUCAGGAGAAGAGAGGCCGUUA)-T4
3'  210
Oligo1006
3'TATGGAACAGTCC TC5'
3'TTCT CT CCGGC AAT5'
3'TCT CT CCGGC AAT5'
3'CT CT CCGGC AAT5'
244
245
246
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from cellular instability. For this reason an analogous PNA conjugate was 
synthesized. The synthetic methodology is simple. Sequences of PNA still on solid 
phase are commercially available. Hence a sequence of PNA corresponding to the 
decamer shown in Fig. 3.16 was purchased, and coupled on solid phase to 30 using 
DIC and HOBT (see 9.3.25). The conjugate was then deprotected and cleaved off 
from the solid phase with the standard procedure for PNA.  
 
 
 
When 1011 (1500 and 150 nM) was incubated with 124 (150 nM) or as control with 
210 (150nM) in Tris-HCl buffer 50 mM, pH 8, 37 °C, for 20 h, unexpectedly no sign 
of cleavage was detectable (Fig 3.17). The cause of this inactivity could be due to a 
collapse of the cleaver in the hydrophobic structure of PNA or to an insufficient 
duplex stability between 1011 and 124 that could prevent an efficient cleavage, 
although this should be in contrast with the higher stability of RNA-PNA duplexes. 
This problem might be solved by future experiments: trying the cleavage in presence 
of ethanol to prevent a hydrophobic collapse, by conjugation to a longer sequence of 
PNA or by using some other nucleic acid analogues. 
 
 
 
Figure 3.17: RNA cleavage test for the PNA conjugate. Lane a: 1011 and 124, lane b: 1011 and 
210. Conditions: 150 nM substrate, 1500 nM conjugate, 50 mM Tris-HCl, pH 8, 37 °C, for 20 h.  
Cy5-T10-ribo(5'CUAGCCGACUGCCGAUCUCGCUGACUGAC)-T4
3'  124
gctgacggct
1011
 
 
Figure 3.16: The PNA conjugate. 46                                       3 Site-Specific Cleavage of RNA by 5’ DNA Conjugates  
 
3.6  Comparison with other Conjugates 
 
For a comparison of the conjugates obtained in this work with others, it is here 
reported a small list of the best conjugates with RNase activity (a deeper overview 
about these conjugates is present in a recent publication of Lönnberg).
[32] 
The best results until now were achieved with artificial nucleases based on 
lanthanide ions. The texaphyrin-Dy
3+ conjugate in Fig. 3.18b was reported to cleave 
its substrate with a half life of 2.1 h at pH 7.5 and 37 °C, showing also turnover.
[55] 
The Eu
3+ pyridine cyclophanes conjugate in Fig. 3.18a also showed to cleave the 
RNA with similar efficiency. In this case the half life of the substrate was 4 h at pH 
7.5 and 37 °C.
[54a] Continuing with conjugates bound to the 5’ or 3’ ends of an ODN 
sequence, the artificial ribonucleases based on Cu
2+ ions are less active. The Cu
2+ 
conjugate in Fig. 3.18d cleaved its substrate with a half life of 70 h at pH 7.4 and 45 
°C, while the conjugate at the 5’ Fig. 3.18c was inactive. Nevertheless, when these 
two conjugates were incubated together with the same cleavage-site the half life of 
the substrate was reduced to 5 h (Fig. 3.18e).
[32][88] 
 
A more interesting comparison could be done with conjugates based on metal free 
artificial ribonucleases. Two examples are reported in Fig. 3.19. The PNA conjugate 
in Fig. 3.19a induced a half life for its RNA substrate of 8 h at pH 7.0 and 40 °C.
[89]  
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When the conjugate in Fig. 3.19b was addressed to a particular instable site of t-
RNA
phe (C63-A64A) the half life of the substrate was reported to be 1.5 h in 50 mM 
imidazole at pH 7.0, and 37 °C.
[90] 
 
 
 
3.7 Conclusions   
 
With the 5’ conjugates 1000, 1001, 1002 and 1006 it was possible to prove the 
activity of the tris(2-aminobenzimidazoles) as real catalyst for RNA cleavage. The 
activity of aminobenzimidazoles seems to be among the best reported for metal-free 
constructs.  
An important improvement of specificity was obtained with helper oligonucleotides. 
Concerning the mechanistic aspects, it was possible to establish the pH dependency 
of cleavage rates, which shows an optimum at pH 8, suggesting a maximal activity 
for the deprotonated form. This is somewhat in contrast with the initial idea, 
considering to combine general base and general acid catalysis with electrostatic 
stabilization of the pentacoordinated transition state. However, it is premature to give 
a final interpretation of the mechanism. In fact the conjugation of the catalyst to the 
polymeric DNA, could shift the pKa. 
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4  Site-Specific Artificial RNases Exhibiting 
Turnover 
 
After the successful conjugation of 29 to the 5’-end of DNA sequences the RNase 
activity of this catalyst was proven without any doubt. Site-specific cleavage was 
also obtained, but an enzyme mimic should exhibit turnover as well. The new 
objective of this work became therefore, the development of a new class of 
conjugates showing specificity and turnover.  
The approach to this new objective is similar to the conjugates already presented. 
The synthetic RNase consists of two domains: the first domain can be a strand of 
DNA or its analogues and ensures substrate recognition. The second domain consists 
of our tris(2-aminobenzimidazole) moiety which provides the RNA-cleaving feature. 
 
A possible catalytic cycle of this class of RNases is described in Fig. 4.1: at first the 
conjugate binds to the RNA substrate with k1 and then cleaves the substrate with k2 
within the duplex region. The stability of RNA-DNA helices is strongly length 
dependent. Thus the generated RNA-fragments are released with k3 allowing a new 
catalytic cycle. This makes the major difference between the precedent conjugates 
and this new class. In contrast, when the cleavage by conjugates occurs at one 
extremity of the duplex, the helix stability is not reduced. Therefore, the conjugate 
k1 k-1
k2
k3
TARGET mRNA
 
Figure 4.1: Possible catalytic cycle of a ribozyme mimic. 50                                             4 Site-Specific Artificial  RNases Exhibiting Turnover 
 
stays tightly bound to the RNA strand without being released for a new catalytic 
cycle. Clearly the constants of these new constructs must be properly balanced to 
achieve a optimally operating catalyst.
[15] 
 
4.1  Resistance of RNA-Duplexes to Cleavage 
 
A fundamental aspect of this project is the enhanced resistance of RNA-duplexes to 
cleavage.
[91] In fact the topology of the helix prevents even enzymatic degradation.
[92] 
The reason of this resistance is illustrated in Fig. 4.2. Generally, for small catalyst the 
cleavage of RNA occurs via attack of the 2’-OH at phosphorus in a pentacoordinated 
transition state with the 5’oxygen in line with the 2’-OH (Fig. 4.2a). 
 
This trigonal-bipyramidal arrangement is only possible in flexible, single stranded 
parts of RNA. In a more rigid structure like in a helix after the initial attack of the 2’-
OH at phosphorus, the oxygen in 5’-position is in equatorial position and has to 
pseudorotate to the apical position before the cleavage can occur (Fig. 4.2b). 
Nevertheless, in an RNA-DNA duplex the phosphodiester backbone of the RNA can 
be forced to assume a favourable conformation for a catalysed transesterification 
reaction. For instance, this can be obtained by forming secondary structures like 
mismatches and bulges in the RNA strand. In these structures the conformation of 
O
HO
O
O
O
O O
O
P
O
O
H
P
O
O O
B
B
O
HO
O
O
O
O
O
O
P
O O H
P
O
O O
B
B
a) b)
 
Figure 4.2: Conformation of the phosphate in bulge and in duplex.
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the phosphate is favourable to the cleavage and can be induced even by Mg
2+ (2.5 
mM, pH 8).
[50][92] Therefore, a fundamental feature for these intra-chain conjugates is 
the induction of a bulge where the cleaving agent should be addressed. 
 
4.2  Key Design Features for Site Specific RNases 
with Turnover 
 
In creating these constructs some key design features should be taken in 
consideration. Fig. 4.3 summarizes the most important variants of these systems. 
The first characteristic is the presence of a bulge in the cleavage site. Häner et al.
[54b] 
reported that fully complementary conjugates cleave only 7 % of the substrate. In 
contrast 92 % are cleaved under the same conditions by addressing the catalyst into a 
bulge of the substrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar observations were also reported by Strömberg et al.
[93] Furthermore, this 
author reported a strong cleavage-rate dependency on the size of the bulge, observing 
optimal rates when the bulge has a size of 3-4 bases. 
Another structural aspect is the type of linker that carries the catalyst. When 
nucleotides are used to attach the catalyst, it can be located in different helix grooves 
depending on the position of the conjugation as illustrated in Fig. 4.4.
[15] 
RNA
DNA
Lengh 
and kind of linker
Number of bases for arm?
Structure symmetric or asymmetric?
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Again Häner reported for his system a cleavage of 61-92 % when the catalyst was 
delivered through the minor groove, in contrast to 21 % when the same catalyst was 
delivered through the major groove.
[54b] 
 
 
 
 
 
 
 
 
 
 
 
Concerning the length of the linker a longer and more flexible linker should assure 
more possibilities to reach phosphodiester moieties. On the other hand a short linker 
should allow a more precise cleavage.
[94] 
A last parameter to analyze is the size of the duplexes surrounding the bulge. Clearly 
longer helices permit a higher specificity. Nevertheless this means also retarding the 
release of cleavage products. Experiments with ribozymes suggest that the optimal 
helix length depends on the substrate. However, my work was based on a model of 
Joyce and Santoro, who developed a RNA-cleaving DNA enzyme, which showed an 
optimum when the arms were between 7+7 or 8+8 nucleobases.
[94][95]  
 
4.3  Design of the Conjugates  
 
During my work not all of the possible combinations of these parameters have been 
tested. It was rather decided an initial conjugation, to which could follow future 
improvements. The chosen sequence for these conjugates is complementary to the 
sequence of 124: Two first conjugates 1007-1008 (Fig. 4.5) were made with a 
structure 8+8 bases inducing a bulge of 3 bases. The problem of the optimisation of 
the binding constant has been solved modulating the ionic strength.  
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The linkers used are based on serinol, the reduced form of serine. As shown in   
Fig. 4.6, serinol can be accounted as a minimal nucleotide replacement. This kind of 
linker without any complementary base should introduce a local flexibility into the 
duplex, thereby rendering the phosphodiester bond of the opposing base more prone 
to cleavage.
[96][15] An amino 
group is then suitable for the 
anchorage of the catalyst and the 
length of the linker is easily 
adjustable. This very flexible 
serinol might be a good choice 
for an initial exploration of 
conjugation in intra-chain 
position, because it does not force the catalyst into a certain position. A disadvantage 
of this approach could be the formation of two stereoisomers, but since in the serinol 
backbone free rotation can occur it should not be a problem.
[96b] 
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Figure 4.5: Structure of 1007 and 1008. 
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The conjugate 1004 (Fig. 4.7) was prepared using the modified desoxy uridine 
furnished by Nelly Piton of the group of Professor Engels. In this case the conjugate 
structure was 8+7 bases inducing a bulge of 3 bases. 
 
4.4 Synthetic  Strategy 
 
 
With the aim to test the effect of the linker length, two phosphoramidites based on 
serinol, one with 3-mercaptopropionic acid and one with 8-mercaptootanoic acid 
have been synthesised (Sch. 4.1). The synthesis started with 8-bromooctanoic acid or 
3-bromopropionic acid, which by nucleophilic substitution with the triphenylmethyl 
mercaptan was converted into 66 or 69. The subsequent coupling with serinol, using 
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3'  124
C
U
P P
-O -O
O
O
O
O
N
H
N
NH
N
HN
HN
N
H
N
N
H
N H
N
O
S
HN N
O
OO
O O
NH
S
O
CGGCTAG-3' 5'-AGATCGGC
CG-oli-1004
A
 
Figure 4.7: Structure of 1004. 
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DIC and HOBT, led to 67 or 73. A following partial DMT protection using DMTCl 
in Pyridine gave rac-68 or rac-74. (At this point a mixture of two enantiomers was 
generated) The remaining OH group was then converted into the phosphoramidites 
71 or 75 as mixture of the diastereoisomers, using 2-cyanoethoxy 
diisopropylchlorophosphoramidite. 
 
A different nucleotide phosphoramidite was prepared in collaboration with Nelly 
Piton who furnished the starting desoxy uridine derivative, which was converted into 
70 by coupling with 69. With the following phosphitylation using 2-cyanoethoxy 
diisopropylchlorophosphoramidite the phosphoramidite 72 was produced. 
 
The phosphoramidites 71, 72, and 75 were used in solid phase nucleic acid synthesis. 
With this methodology the linkers could be introduced at any position along the 
sequence. After finishing the solid–phase synthesis the trityl group was still on the 
mercaptan. Therefore, it was removed on solid phase by treatment with AgNO3. 
Subsequently followed a treatment with TECP to reduce the possible disulfides. 
After which the oligonucleotides with the free mercaptans were coupled with 63. The 
corresponding conjugates were deprotected and cleaved off the solid phase using 
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aqueous NH3 (25 %). With this procedure were synthesised the conjugates 1004, 
1007 and 1008. 
 
 
 
 
 
4.5  Test of Cleavage 
 
Dr. Ute Scheffer performed the experiments of RNA cleavage. Having completed the 
synthesis of the conjugates, a first screening was done to select the best candidate for 
kinetic studies. In Fig. 4.8 the electropherograms of a first experiment are shown. 
The conjugate 1004, 1007 and 1008 at two different concentrations 150 and 1500 
nM, were incubated with the corresponding substrate 124 (150 nM) in 50 mM Tris-
HCl at pH 8.0, 37 °C for 20 h. These preliminary results proved that 1007 with the 
short linker was the best catalyst and 1004 was the worst. It was consequently 
decided to continue only with 1007 and 1008, because 1004 did not show a 
significant cleavage. 
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In general this first experiment was disappointing when compared with the cleavage 
of the 5’ conjugates. As already illustrated in Fig. 4.1 for obtaining an optimal 
cleavage all the constants involved in this system must be well balanced. The 
RNAase activity can be modulated with the pH, but pH 8 represents already the 
optimum. Therefore, the binding constant could be still modulated. This was done by 
changing the ionic strength. Increasing the ionic strength is known to stabilize 
oligonucleotide duplexes. 
 
A first test of saturation was run to assure that the system was working under 
saturation conditions. In Tab. 4.1 are reported the rates of RNA-cleavage keeping the 
concentration of 124 constant (150 nM) and varying the concentration of 1007 and 
1008 from 1500 to 37.5 nM. 
Table 4.1: Results of saturation experiments. Conditions: 150 nM substrate, 50 mM Tris-HCl, 
pH 8.0, 37 °C, 20 h. 
  290_041   291_041   290_041   291_041  
  total main  site  total main  site  total main  site  total main  site 
Conc., 
nM 
% degr 
CG1007 
% degr 
CG1007 
% degr 
CG1007 
% degr 
CG1007 
% degr. 
CG1008 
% degr. 
CG1008 
% degr. 
CG1008 
% degr. 
CG1008 
0  n.d.  n.d. 0,1 0,1 n.d. n.d. 0,1 0,1
1500 33,9 25,8 18,8 14,6 8,9 4,6 12,1  8,0
1200 29,9 23,0 23,4 18,1 18,6 11,8  3,3  1,3
900 - -  24,3 18,7 23,4 14,7  11,2  7,0
600 25,4 19,5 27,0 20,6 20,9 13,2  9,4  5,6
300 31,6 24,3 19,9 15,3 15,6 9,8 14,5  9,2
150 22,9 17,5 12,1 9,1 17,4 10,8 12,5  7,9
75  15,3  11,4 6,7 5,0 11,2 7,2 7,4 4,6
37,5  11,2 8,1 2,8 2,0 7,9 5,0 3,6 2,2
 
Figure 4.8: Preliminary test of clevage of 1008, 1007 and 1004 at pH 8. 58                                             4 Site-Specific Artificial  RNases Exhibiting Turnover 
 
The experiment was repeated twice (290_041 and 291_041) in 50 mM Tris-HCl, pH 
8.0, 37 °C, 20 h. The analysis of the data showed complete saturation of the substrate 
with conjugates concentration between 150 and 300 nM and further increase of the 
concentration did not lead to an increase of cleavage. To prove the real site-specific 
cleavage, an experiment of cross reactivity was also made. 1008 and 1007 (1500 nM) 
were incubated with 124 (150 nM) in lane b and c and with 210 (150 nM) lane d and 
e respectively (50 mM Tris-HCl at pH 8.0, 37 °C for 20 h). The specificity was 
therefore proved, because the cleavage occurred only in presence of the 
complementary RNA substrate (Fig. 4.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Further experiments were conducted to test the influence of Mg
2+ on cleavage. The 
incubations were done at different ionic strength, with MgCl2 or without MgCl2. The 
results are reported in Tab. 4.2. 
Table 4.2: RNA cleavage of 124 (150 nM) with 1007 (1500 nM) and 1008 (1500 nM) in presence 
of NaCl and MgCl2. Conditions: 50 mM Tris-HCl pH 8.0, 37 °C, 20 h. 
   total  total  total  main site  main site  main site 
mM NaCl  mM MgCl2  % degr 
control 
% degr 
CG1007 
% degr. 
CG1008 
% degr 
control 
% degr 
CG1007 
% degr. 
CG1008 
0 0  1,26  27,35 15,20 0 25,09  14,14 
0 10 9,73  14,80 18,42 0,83 9,66 10,00 
0  5 10,98 25,74 19,61 0,76 20,26  11,75 
0 1  6,04  29,83 12,23 0,47 26,56 6,41 
100 0  0,00    12,46 0,00 43,30  11,81 
100 10 6,14  9,52 0,42 16,77  8,53 
100 5  3,48  11,89 0,30 28,72  11,24 
100 1  2,93  15,19 0,25 28,02  14,17 
 
Figure 4.9: Cross reactivity experiments, 1007 and 1008
with 124 lane b and c, 1007 and 1008 with 210 lane d and e. 4 Site-Specific Artificial RNases Exhibiting Turnover                                             59 
   
From these results it appears clear that the MgCl2 has more an effect of inhibition 
then to enhance the cleavage, but at high ionic strength (100 mM NaCl) without 
MgCl2 the cleavage increased. Following these results the next subject of the tests 
became the study of cleavage rates in dependency on different concentrations of 
NaCl. In fact, the ionic strength can influence the binding constant helping to find a 
proper balance of the system constants. 
 
In Tab. 4.3 is reported the percentage of 
cleavage of two experiments at the 
following conditions: 50 mM Tris-HCl 
at pH 8.0, 37 °C for 20 h and at 
different ionic strengths. The results 
shown indicate an improvement of 
cleavage increasing the ionic strength. 
The physiological concentration of 
NaCl corresponds at 100 mM 
consequently this ionic strength was 
used for the next experiments. The final 
observation of this table is that 1007 is 
the best construct. Cleaving under the 
reported conditions 43-46 % of the 
substrate. Therefore, this conjugate 
became the candidate for running 
turnover-experiments. 
To have turnover a catalyst must be able 
to carry out more catalytic cycles when 
incubated with an excess of substrate. 
Table 4.3: RNA cleavage of 124 (150 nM) with 1007 (1500 nM) and 1008 (1500 nM) in presence 
of NaCl at different concentrations. Conditions: 50 mM Tris-HCl pH 8.0, 37 °C, 20 h.  
  290_041   291_041   290_041   291_041  
NaCl  total main  site  total main  site total  main  site total  main  site 
Conc., 
mM 
% degr 
CG1007 
% degr 
CG1007 
% degr 
CG1007 
% degr 
CG1007 
% degr. 
CG1008 
% degr. 
CG1008 
% degr. 
CG1008 
% degr. 
CG1008 
0 n.d. n.d. 0,1 0,1 n.d. n.d.  0,1  0,1
1000 36,8 23,7 46,0 29,0 19,5 11,0 14,8  8,2
800 35,4 23,5 41,6 27,0 22,3 12,8 15,1  8,7
400 45,5 32,1 43,2 30,2 15,6 9,4 15,3  9,2
200 32,9 24,33 8 ,02 7 ,82 4 ,91 5 ,4 14,6 9,1
Table 4.4: Turnover experiment 1 with 50 
nM 1007 against 300 nM 124. Conditions: 50 
mM Tris-HCl, 100 mM NaCl, at pH 8.0, 37 °C. 
294_041 control    CG1007  
  total  main site  total  main site 
Time, h  % degr   % degr   % degr   % degr  
0 n.a.  n.a.  n.d. n.d.
24 0,2  0,1  12,3 9,1
48 0,3  0,1  26,4 19,5
72 0,5  0,2  45,7 34,2
96 0,5  0,2  56,2 41,4
168 0,8  0,3  75,9 55,3
192 0,8  0,3  74,0 56,2
216 0,9  0,3  80,4 57,7
264 1,0  0,4  84,7 58,4
337 1,0  0,4  82,0 58,2
 
Table 4.5: Turnover experiment 2 with 50 
nM 1007 against 300 nM 124. Conditions: 50 
mM Tris-HCl, 100 mM NaCl, at pH 8.0, 37 °C. 
 
295_041 control    CG1007   
  total  main site  total  main site 
Time, h  % degr   % degr   % degr   % degr  
0 n.d.  n.d.  n.a. n.a.
19 0,1  0,0  8,9 6,7
50 0,3  0,1  23,1 17,2
72 0,4  0,2  41,8 31,4
75 0,3  0,1  38,0 28,3
93 0,4  0,1  44,5 33,9
101 0,4  0,2  55,6 41,2
120 0,5  0,2  66,2 47,9
141 0,8  0,3  68,7 50,8
151 0,6  0,3  77,4 57,0
175 0,8  0,3  82,2 60,0
194 0,8  0,3  83,1 60,6
242 1,0  0,5  85,5 61,360                                             4 Site-Specific Artificial  RNases Exhibiting Turnover 
 
Therefore, 1007 (50 nM) was incubated with excess of 124 (300 nM in 50 mM Tris-
HCl buffer, NaCl 150 mM, pH 8.0, 37 °C). In Tab. 4.4, and 4.5 are reported the 
results of two turnover experiments, one for 337 h, and the other for 242 h. The 
experiment was stopped after 337 h because it is known that part of the substrate is 
not cleaved.
[10]  
Fig. 4.10 illustrates the electropherograms of the sequencer at different times. 
 
The ability to exhibit turnover for 1007 was therefore proved, because the excess of 
substrate was site specifically cleaved. The values of Tab. 4.4 and 4.5 are represented 
in a graphic percentage of substrate in dependency on time in Fig. 4.11. In the next 
section are analysed the kinetic data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Electropherograms of the sequencer show the increase of the cleavage and the 
reduction of the substrate. 
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4.6  Turnover Kinetic Analysis 
 
A minimal kinetic scheme for these types of artificial RNases is shown in Fig. 4.12. 
In this assumption also the reverse reactions k-3 and k-5 are taken in consideration. In 
fact if the products of the reaction are the 2’-3’-cyclic phosphates also the ligation 
can be catalysed by the same catalyst.
[94] 
 
A complete analysis of each event is complicated and goes beyond the scope of this 
work. However, the analysis can be simplified in accord with the theory of Henry, 
Michaelis, Menten and the following modifications of Briggs and Haldane.
[97] 
Therefore, it could be interesting to extract the values of Km and kcat. This would help 
to evaluate the efficiency of our system and to allow a possible comparison with 
other systems for site-specific cleavage.  
In accord with these theories, the kinetic experiments should be made in steady state 
conditions where the [ES] is constant with an excess of substrate, and in the initial 
part of the reaction where the slope of the plot of the products formation versus time 
is linear. Under these conditions the substrate is in great excess compared with the 
products. Consequently, the inhibition by the products and the reverse reaction are 
negligible. Taking these assumptions as a basis it should be possible to monitor the 
first part of the complicated scheme shown in Fig. 4.12 and to extract the values of 
Km and kcat.  
These problems have already been encountered by other authors.
[88b][94b][95][98] 
Classically this analysis is done by a modified Eadie-Hofstee linear plot of kobs vs. 
kobs/[S] where the slope is –Km, the y intercept is equal to Vmax and kcat=Vmax/[E]. 
The reaction rates (kobs) should be calculated from the linear slope of plots 
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concentration of the product vs. time over the first 5-10 % of the reaction, in a set of 
kinetics where the concentration of the substrate span a range ≥10-fold excess over 
[E]. An illustrative example is given in Fig. 4.13. 
 
 
 
 
 
 
 
 
 
 
 
 
An analysis like in Fig. 4.13 should be desirable. However, at the moment there are 
not enough data available. The experiments done are nevertheless sufficient for an 
approximate analysis. In fact assuming that when [S] is in 6-fold excess compared to 
[E], the catalyst should operate under conditions of saturation. Hence, the velocity 
over the first 10% of the reaction corresponds to Vmax and it becomes easy to 
calculate an approximate kcat. 
 ∆[P] = C0 × % Cleavage, V = ∆[P] / ∆[t] that in our case correspond to Vmax. 
Considering Tab. 4.4 and 4.5, a cleavage of 12.3 % occurs in 24 h and of 8.9 % in 19 
h. The Vmax is therefore 1.54 nM h
-1 and 1.41 nM h
-1. Now, if the concentration of 
the catalyst was 50 nM, kcat is 0.031-0.028 h
-1. 
 
 
 
 
 
 
 
kobs/[S]
kobs
Vmax
slope = -Km
 
Figure 4.13: A typical modified Eadie-Hofstee 
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4.7  Alternative Strategy to Have Turnover with 5’ 
Oligonucleotide Conjugates 
 
Until now we have illustrated the classical procedure to design conjugates with 
turnover capacity. An alternative strategy with indisputable synthetic advantages was 
proposed by Häner et al.
[54b][54c] According to this author, if a bulge is induced 
closely to the 5’-end of the conjugate, the catalyst should be able to reach the bulge 
and to cleave the RNA in the single stranded region as well as in the double strand 
(Fig 4.14B). The consequence is obvious, the two fragments of RNA will bind more 
weakly to the conjugate and they will be released for another cleavage cycle. 
Following this strategy, Häner reported two conjugates, which were able to cleave in 
the bulge.
[54b][54c] One of these antisense constructs, 12 base long and built from 
2’methoxyethoxy modified RNA, exhibited also turnover. Since the last 7 bases at 
the 3’ terminus of our RNA substrate 210 are identical with the corresponding bases 
in Häner’s substrate (Fig. 4.14a), it was thought to design a similar DNA conjugate 
applying the same strategy. This new project was started in collaboration with 
Kathrin Beier (Fig. 4.14). 
 
The conjugate 1012 was synthesized applying the classical automated synthesis on 
solid phase, following the synthetic strategy illustrated in Fig. 4.15. The 
3'-TATGGAACAGTC- - CTTC-
5'-AUACCUUGUCAG    GAAGAGAGGCCGUUA-3'
                                  GA
3'-TATGGAACAG TCCTTC-
5'-AUACCUUGUCAGGAGAAGAGAGGCCGUUA-3'
210
1012
1012
210
a) b)
Figure 4.14:  a)  Alternative hybridisations of 1012 with 210.  b) Illustration of possible 
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monomethoxytrityl protected C6 amino linker was coupled to the 5'-end of the DNA 
sequence and detritylated by the synthesizer. 30 was conjugated on solid phase 
manually using DIC and HOBT as condensing agents. Finally, the conjugate was 
cleaved off from the solid phase and deprotected by aqueous ammonia (25 %). 
 
 
As preliminary experiment 1012 (1500 nM) was incubated with 210 (150 nM) under 
the usual conditions (50 mM Tris-HCl, NaCl 150 mM, pH 8.0, 37 °C), but the 
cleavage occurred mostly at position 15, as illustrated in Fig. 4.14a and 4.16a. This 
led to the conclusion that in this construct the structure without a bulge is preferred 
over the one with a bulge. 
 
 
 
 
 
 
 
 
 
 
However, Häner used 2’methoxyethoxy modified RNA for the synthesis of his 
conjugate. This probably is of fundamental importance for the stabilization of the 
 
Figure 4.16: a) Preliminary cleavage test of 1012 (1500 nM) with 210 (150 nM). 
b) Alkaline hydrolysis. 
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bulge. The same author obtained similar results also with DNA,
[54b] but with a 
different sequence. Therefore, a sequence dependency in the stabilization of these 
constructs must exist. A new oligonucleotide was made by Kathrin Beier using the 
compound 30 for conjugation. These experiments are still in progress and they will 
be reported in her dissertation.  
 
 
4.8  Comparison with other Systems Exhibiting 
Turnover 
 
To evaluate the efficiency of the system created in my PhD thesis, a short 
comparison with other systems is done here (an overview on these conjugates is also 
presented in a recent publication of Lönnberg).
[32]  
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Starting with the metal dependent catalysts, the dysprosium texaphyrin conjugate in 
Fig. 4.17a showed to cleave 67 % of the 10 fold excess substrate in 50 mM HEPES, 
pH 7.5, 100 mM NaCl in 24 h at 37 °C, with kcat of 0.286 h
-1.
[55c]  
The macrocyclic lanthanide complex artificial RNase in Fig. 4.17b inducing a bulge 
in the substrate 4 bases before the 5’ end of the conjugate, showed turnover cleaving 
90.3 % of the 5 fold excess substrate, at pH 7.2, 37 °C in 64 h. The bis-Cu
2+-
terpyridine-2’-O-methyl oligoribonucleotide conjugate in Fig. 4.14c with n = 1 (n = 
0-3), showed a kcat of 0.647 h
-1 at pH 7.5, 37 °C, and 100 nM NaClO4.
[88b] Bashkin et 
al. reported that the Cu
2+-terpyridine conjugate in Fig. 4.17d was able to cleave 6.7 
equivalents of 10 equivalents of RNA, at pH 7.4, 45 °C in 40 h with 0.1 mM 
NaClO4.
[100] 
Concerning the metal free constructs the results are not so brilliant. For instance the 
triethylenetetramine conjugate in Fig. 4.18a cleaved 3 % of the RNA substrate in 16 
h (Conditions: 0.2 mM substrate, 20 mM conjugate, pH 7.5, 37 °C).
[101] The 
methanephosphonate ODNs conjugate bearing an diimidazole or imidazole/amino 
cleaving agent in an intra-chain position in Fig. 4.18b showed to cleave less then 10 
% of the RNA substrate at pH 7.2, 25 °C, in 5 days.
[96a]  
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To conclude this comparison the kcats of some natural enzymes and ribozymes are 
reported in Tab. 4.6.
[95] Here the large difference still existing between the natural 
and the artificial systems becomes clear. 
 
 
 
4.9 Conclusions   
 
During this project site specific artificial RNases exhibiting turnover were obtained. 
Three different conjugates carrying the catalyst in an intra-chain position were 
synthesized. The most successful could exhibit a kcat of 0.031 h
-1, probably the best 
site specific metal-free artificial ribonuclease showing turnover. Nevertheless, a 
quick comparison with natural ribozymes shows that this catalyst is still some 
thousand folds inferior. 
It still remains to investigate the specificity and efficiency depending on the   
bulge-size, but this problem could be solved without big synthetic efforts by buying 
new substrates that can form bulges of the desired size. 
Concerning the turnover project with 5’ conjugates the first result are not extremely 
brilliant. Further studies must be undertaken to really understand the reasons 
governing bulge stability in these constructs. 
 
 
Table 4.6: Catalytic activity of various RNA-cleaving 
enzymes.
[95] 
 
Enzyme   kcat h
-1 
Ribonuclease A 
 
UpA substrate  50.4 × 10
5
Poly(C) substrate  18.6 × 10
5
Hairpin ribozyme  12.6 × 10
2
Hammerhead ribozyme    8.4 × 10
2
10-23 DNA enzyme
[95]  20.4 × 10
268                                             4 Site-Specific Artificial  RNases Exhibiting Turnover 
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5 Tris(2-aminobenzimidazole)  in  Affinity 
Cleavage 
 
RNA can assume complicated structures that can be recognized specifically by 
binding proteins. Such interactions are important in numerous biological processes 
like splicing, polyadenylation, nuclear export, translation, mRNA localization and 
mRNA decay. To understand these processes several methodologies exist. During 
this work the possibility of applying the tris(2-aminobenzimidazole) in affinity 
cleavage was explored. At this purpose the tris(2-aminobenzimidazole) was 
conjugated to possible peptidic RNA ligands further in collaboration with the group 
of Professor Jean-Luc Décout (Université Joseph Fourier at Grenoble), a conjugate 
with neamine was achieved. 
 
5.1 RNA  Structure 
 
 
RNA chemically differs 
from DNA by the presence 
of uridine instead of 
thymidine and the 2’-OH. 
This extra hydroxyl group 
influences the reactivity 
against cleavage, but also 
the structure. The DNA 
helixes normally assume a 
B conformation and under 
particular conditions the Z 
form. RNA on the contrary 
assumes an A 
conformation (Fig. 5.1). 
The ribose in these 
different helices has also 
O
'5 Base
O
'5 Base
'3 O
OH
H
O 3'
C2'-endo 
B-Duplex
C3'-endo
A-Duplex
Figure 5.2: Conformation of deoxyribose and ribose in the 
B and A double helical form. 
 
Figure 5.1: Double-helical molecular structure of nucleic 
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different conformations as 
shown in Fig. 5.2, where 
for the B form the C 2’ is 
in  endo, while in the A 
form the C 3’ is in endo. 
The differences of the two 
helixes are summarized in 
Tab. 5.1. 
Another important 
difference between the two 
nucleic acids is that DNA usually forms regular double strand helices, while RNA is 
usually single stranded. This is an important difference because RNA single strand 
can remain without a particular structure (random coil) or when complementarities 
exist in the same sequence it can form short helices, letting other part of sequence 
unpaired. This leads to the formation of secondary structures, which are typical for 
RNA. A schematic view of such elements, bulges, loops, hairpin and pseudoknots is 
shown in Fig. 5.3.  
 
 
 
 
 
 
 
 
 
 
Furthermore, these secondary structures of RNA can fold into more complicated 
tertiary structures like in t-RNA. This allows RNA to adopt unique structures 
creating micro environments that can be specifically recognized by proteins, small 
molecules or generate catalytic functions. For these reasons this nucleic acid can 
have more complicated roles than being a simple carrier of genetic information,
[102] 
A)  Hairpin Loop
B)  Internal Loop
C)  Bulge Loop
D)  Multibranched Loop
E)  Stem
F)  Pseudoknot
A
B
C
D
E F
 
Figure 5.3: RNA secondary structures. 
Table 5.1: Parameters of the A and B helical form. 
Parameters  A Form  B Form 
Direction of helical rotation  Right  Right 
Residues per turn of helix  11  10 
Rotation of helix per residue (in 
degrees)  33  36 
Base tilt relative to helix axis (in 
degrees)  20  6 
Major groove  narrow and 
deep 
wide and 
deep 
Minor groove  wide and 
shallow 
narrow and 
deep 
Orientation of N-glycosidic Bond  Anti  Anti 5 Applications of the Tris(2-aminobenzimidazole) in Affinity Cleavage                  71 
   
from here it develops the great interest for the interactions between RNA and its 
binding proteins or ligands. 
 
5.2  Identification of RNA-Binding Proteins 
 
The first step of studying RNA protein interactions is the identification and isolation 
of the proteins that could interact with a RNA target. To achieve this objective three 
methodologies exist: 1) North-western screening of a cDNA expression library, 2) 
Affinity chromatography, 3) Phage display. 
 
5.2.1 North-Western  Screening 
 
In the North-western screening an expression library of cDNA is cloned into 
bacteriophage expression vector, displaying several different proteins (Fig. 5.4A). 
These proteins are then adsorbed by platting on a membrane of nitrocellulose that is 
a replica of the Petri dish. This membrane is then incubated with the labelled RNA 
target (Fig. 5.4B), after a rinsing step to reduce the false positive, it is possible to 
identify the clone expressing RNA binding proteins (Fig. 5.4C).
[103]  
 
5.2.2 Affinity  chromatography 
 
A second methodology is affinity chromatography.
[104] Several variants of this 
technique are known, but the general principle can be explained in Fig. 5.5. The 
RNA target is fixed on a solid support, generally sepharose. A mixture of proteins is 
Target RNA
Labeling
AB C
cDNA expression library Adsorbed  recombinant 
proteins
to nitrocellulose membranes
Identification
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eluted through the column, where the RNA binding proteins remain fixed. Using a 
different buffer, the fixed proteins then can be collected. A variant of this method 
makes use of columns with streptavidin fixed on the matrix. A biotinylated RNA 
target is used. In this way the protein-RNA interaction can occur in solution, and the 
RNA-protein complex is fixed in a second moment by the biotin streptavidin 
interaction. In both the cases the protein is isolated, sequenced and a clone 
expressing its gene can be identified. 
 
5.2.3 Phage  Display 
 
Another system for identifying proteins with affinity for a certain target is phage 
display.
[105] A modified version of this methodology can be used for in vitro 
selection of BP (binding protein) for a RNA target.
[106] The system is summarized in 
Fig. 5.6 in the following steps: 1) Preparation of a combinatorial library of 
mutagenized cDNA encoding the RNA-binding domain, these fragments are then 
inserted in a phagemid vector in a way that the protein of interest is fused to the gene 
III coat protein of the phage. In this way the phage displays on its external face the 
protein of interest. This library is then transformed into an E. coli host. 2) Infecting 
the host with a helper phage, a pool of modified phages with coat proteins fused to 
RNA-BP variants is generated. 3) The phages are then released from the bacterium 
host into the external environment, so that they can be collected. In the next step the 
phages are incubated with the target RNA fixed on beads. Therefore, the phages 
expressing the RNA-BP’s remain fixed to the target. 4) The bound viral particles are 
RNA Target
Labeling
Solid Support
RNA Target
Labeling
Solid Support
RNA-Binding 
Protein
A B
Figure 5.5: A) RNA Target is fixed to a solid support. B) RNA-binding protein 
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washed, disconnected from the target and collected. These selected phages can be 
used for another cycle of infection, allowing amplification of the best clones and a 
better selection. At the end it is possible to have the best clones in useful amount to 
identify the new RNA binding protein. 
 
This technology was used by Jörg Bäumler
[106c] of the group of Dr. Manuel Grez at 
Georg Speyer Haus of Frankfurt, to select a peptide with affinity for mRNA of the 
Bcr-Abl fusion oncoprotein. (This peptide has been used also in this thesis. See 
5.4.3). 
 
5.3  Studying Ligand-Target Interactions by 
Affinity Cleavage 
 
Once a binding protein for a RNA target is found, the problem arises of finding the 
specific binding site in a large RNA, and of studying the ligand-target interaction. 
For this purpose different systems exist, like X ray diffraction when it is possible to 
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Figure 5.6: In vitro selection of RNA-BP variants that bind tightly to a RNA target.
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isolate the crystal of the RNA-ligand complex or NMR when a high frequency 
spectrometer is available. In the absence of X ray or NMR data, there are different 
convenient systems like FRET assays,
[107] and foot-printing.
[108] Another system that 
allows to characterize the topology of RNA-protein complexes is affinity 
cleavage.
[109] This method was introduced first by Dervan et al.
[9a][9b] and was applied 
for investigating DNA-peptide interactions.
[109][9c]  
 
The concept of this technique is illustrated in Fig. 5.7. 1) Isolation of an RNA-
binding protein. 2) The protein is conjugated to an unspecific cleaving agent forming 
a new specific nuclease. 3) The conjugate is incubated with the RNA substrate. 
Hence, we will have site-specific cleavage. 4) It is possible to identify the binding 
site, or to obtain even more precise information. For instance, changing the position 
of the amino acid for the conjugation it could reveal key topological features of the 
ligand-RNA complex.  
The cleaving agents employed in this technique are usually metal complexes, able to 
cleave by oxidative mechanisms DNA and RNA equally well. Fig. 5.8 summarizes 
the cleaving agents most often used for this technique.
[110] A well known agent is the 
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copper 1,10-o-phenanthroline (OP). This is a redox active complex, which is able to 
generate oxygen radicals that cleave the DNA or RNA backbone. Another family of 
catalysts are the derivatives of the Fe-EDTA complexes. The cleavage reaction is 
usually initiated by addition of a reducing agent such as DTT or sodium ascorbate in 
the presence of O2. The scission of the nucleic acid backbone occurs by oxidation, 
through the formation of activated oxygen species, presumably hydroxyl radicals. 
The most successful of these EDTA derivatives is called BABE (S-1-[p-
(bromoacetamido)benzyl]-EDTA).  
 
However, these catalysts for affinity cleavage present the disadvantage to produce 
diffusible radicals and to generate pattern of cleavage, which are not always precise. 
Moreover, the EDTA derivatives cleave also peptidic bonds and therefore, can 
autocatalyticaly degrade their own binding protein. Once the activity of the tris(2-
aminobenzimidazole) as RNase is confirmed a possible application of such 
molecules could be affinity cleavage. To explore such applications a set of 4 RNA 
binding peptides, and a small ligand for RNA were conjugated to the tris(2-
aminobenzimidazole) and tested on the corresponding RNA substrates. 
 
5.4  RNA Ligands  
 
To set up a new methodology of affinity cleavage different RNA ligands were 
chosen for conjugation with our catalyst. A short description of these ligands is given 
below.  
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Figure 5.10: Neamine is a derivative of neomycin, less toxic, but still able to bind 
TAR. 
5.4.1  Tat Peptides  
 
 
 
 
 
 
 
 
 
 
The first two ligands (Fig. 5.9) are two peptides derived from Tat, the 86 amino acids 
long transactivator protein of HIV-1. Tat plays a crucial role in the viral life 
increasing the expression of the viral mRNA. For its function, the protein must bind 
the  trans-activating response element TAR, a 59-bases hairpin-stem-bulge RNA 
structure positioned at the 5-end of all nascent HIV-1 transcripts.
[111] The peptide 
sequence Tat49-57 of this protein has been demonstrated to be essential for TAR RNA 
binding in vivo and sufficient for TAR recognition in vitro.
[64a][112] In Fig. 5.9 the 
sequences of the two peptides used in this work are reported. In Tat11 the Tat49-57 
sequence is highlighted in red, in addition there are then an additional cysteine for 
the conjugation and a tyrosin for UV determination. Tat16, similar to Tat 11, has 3 
additional alanines to evaluate the effect of an expanded peptidic spacer.
 [107] 
 
5.4.2 Neamine   
 
Aminoglycosides constitute a large family of natural antibiotics that have as target 
rRNA. Neomycin B also binds to other RNA targets such as TAR, unfortunately this 
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molecule is highly toxic. Studies to improve its properties demonstrated that neamine 
is less toxic and it can serve as minimal structural motif still conserving affinity for 
RNA targets 
[17] (Fig. 5.10).  
This small antibiotic with affinity for TAR was conjugated to 30 (Fig. 5.12) by 
Jérôme Désiré in the group of Jean-Luc Décout (Université Joseph Fourier at 
Grenoble).  
 
5.4.3  Bcr-Abl Binding Peptide 
 
 
The sequence of the last ligands resulted from a collaboration with Jörg Bäumler 
who provided two peptides selected during his Ph.D. by phage display (Fig. 
4.11).
[106c] The target is a fragment of the mRNA of the Bcr-Abl oncoprotein, 
corresponding to the breakpoint sequence where the two fragments of the genes of 
BCR and ABL are fused to form the oncogene BCR-ABL (Fig 5.11). 
The fatal effect of several oncogenes is based on aberrant exchange of genetic 
material, one of the most known is called Philadelphia chromosome. In this case a 
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Figure 5.11: The two enantiomeric Bcr-Abl mRNA substrates. The arrow indicates 
the point of fusion of the two genes Bcr and Abl. Bottom: sequence of the binding 
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translocation of DNA between the chromosome 9 and 22 with molecular 
juxtaposition of the gene BCR and ABL generates a fusion BCR-ABL oncogene. 
Both proteins are involved in the cell cycle. The onconcoprotein Bcr-Abl deregulates 
the cellular cycle and renders the leukaemia cells resistant against the programmed 
cell death (apoptosis). This BCR-ABL translocation is found in 90 % of the patients 
affected by chronic myelogenous leukaemia and in some with acute leukaemia.
[113] 
The fusion of the two mRNAs creates a new RNA with peculiar characteristics that 
may be recognized by new ligands, such as the peptides selected by Jörg Bäumler. 
The two peptides were synthesised in both enantiomeric forms D and L, conjugated 
with the tris(2-aminobenzimidazole), and tested with the normal RNA substrate 176 
and its enatiomeric form 190. 
 
5.5 Conjugation  Strategies. 
 
To obtain the conjugation of different ligands two approaches have been tried (Fig. 
5.12). In the first approach two maleinimide tris(2-aminobenzimidazoles) derivatives 
were synthesized, with a long linker 37, and in collaboration with Kathrin Beier with  
 
 
a shorter linker. These two molecules are suitable for the conjugation with mercapto 
groups present in RNA ligands. In the second approach, two carboxylic acid 
derivatives of the tris(2-aminobenzimidazole) were prepared, 30 without any linker 
and 80 with a GABA linker. These last two compounds are suitable for peptidic 
conjugation, when mercapto groups are not available in the binding domain of the 
ligand. 
N
HN
HN
NH
N
H
N
N
HN
N
N
H
O
N
H
OH
O
N
HN
HN
NH
N
H
N
N
HN
N
N
H
O
NH
HN
O
N
O
O
N
HN
HN
NH
N
H
N
N
HN
N
N
H
O
NH
H
N
O
N
O
O
SH
RNA-ligand
N
HN
HN
NH
N
H
N
N
HN
N
N
H
O
OH
NH2
RNA-ligand
37 30
80
 
Figure 5.12: Conjugation strategies. 5 Applications of the Tris(2-aminobenzimidazole) in Affinity Cleavage                  79 
   
5.6  Synthesis of the Catalysts Suitable for 
Peptidic Conjugation 
 
The synthesis of compound 37 and its analogue with the short linker are described 
below (Sch. 5.1). A diamine with 2 or 6 CH2 was singly protected with BOC-ON. 
The mono protected amines 13 or 47 were then converted in the compounds 35 or 48 
by amide coupling with 30, using DIC and HOBT. The BOC protecting group of 35 
was removed with a diluted solution of HCl, yielding 36, which was coupled with the 
commercial N-succinimidyl 3-maleimidopropionate to give the desired compound 
37. The analogue of 37 with a short linker was prepared by Kathtrin Beier starting 
from the precursor 48. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the conjugation by peptidic bonds the compound 30 is readily obtainable by acid 
induced hydrolysis of 29. To introduce a short linker conserving a carboxylic acid, 
GABA was converted into 76 by protection of the amino group with a Z group using 
benzyl chloroformate. The subsequent esterification with tert-butanol and DCC gave 
77. Removal of the Z group with H2/Pd produced 78, which was coupled to 30 using 
DIC and HOBT to form 79. The final compound 80 was obtained by hydrolysis of 
the tert-butyl ester of its precursor with diluted HCl (Sch. 5.2). 
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5.7 Peptidic  Conjugation 
 
Starting form 37 and the peptides described above, 4 different conjugates were made 
via maleinimide chemistry (Sch. 5.3). In the protocol of this conjugation to a solution 
of 2 mg of peptides in water was added a solution of 37 (2 equivalents) in DMF. The 
reaction between the free thiol and the maleinimide occurred almost instantaneously 
and quantitatively (Sch. 5.3a). The purification was then performed by HPLC.  
 
Jérôme Désiré made the fifth conjugate with neamine, using the compound 30 (Fig. 
5.12) synthesized during my thesis. 
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5.8  Test of Affinity Cleavage 
 
Dr. Ute Scheffer performed the tests for affinity cleavage. The first test was made 
with the Tat11 conjugate named 2001 (Fig. 5.13C). The conjugate was incubated 
with TAR substrate 153 or its enantiomeric form 158 (Fig. 5.13B). In fact it is known 
that Tat11 made of (D)-amino acids conserves binding affinity for TAR.
[114] 
Therefore, the (L) form is expected to bind the enantiomeric form of TAR. The use 
of the enantiomeric RNA substrate as shown above allows to exclude artefacts due to 
RNase contaminations (see 2.7.2). The concentration of the RNA substrate was kept 
constant (150 nM), while the pH was 6 or 7.5. The concentration of the conjugate 
was varied from 1.25 μM to 0.125 μM, the buffer used was 50 mM Tris-HCl, 20 mM 
KCl, 0.01 % Triton x-100, at 37 °C, for 20 h. The results of these preliminary studies 
are reported in Tab. 5.2. From these data a certain selectivity of the cleavage for the 
bulge and the hairpin loop emerged with a major selectivity for the last.  
In Fig. 5.13A is shown the cleavage of the enantiomeric TAR 158 (150 nM) in 
presence of 2001 (0.31 μM), pH 7.5, 37 °C, 20 h. Here it is visible that the cleavage 
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occurred mostly in the hairpin loop. Probably the recognition occurred in the bulge, 
while the catalyst was addressed to the loop. 
 
After these preliminary studies also the Tat16 conjugate 2003 was tested (Fig. 
5.13b). In this second series of experiments the conjugate was incubated with 158,  
the proper substrate, but also with 190 and 202 (Fig. 2.32 and Fig. 5.11), non-related 
RNA substrates, with the aim to characterize the selectivity of these peptides. The 
Table 5.2: Results of cleavage of 2001 when incubated with 153 and 158. Conditions: 50 mM 
Tris-HCl, 20 mM KCl, 0.01 % Triton x-100, 37 °C, 20 h. ALF-file: 150_041.alx 150_041.fmv; RNA cleavage 
150_041.xls 
2001 
conc., µM 
TK buffer, pH 7.5 
% degradation 153 (150 
nM)  
Total 
TK buffer, pH 6.0 
% degradation 153 (150 
nM)  
Total 
TK buffer, pH 7.5 
% degradation 158 (150 
nM)  
Total 
TK buffer, pH 6.0 
% degradation 158 (150 
nM)  
Total 
1.25 27,37 25,51 12,89 26,41 
0.63 35,14 36,84 11,44 27,47 
0.31 contaminated  12,58 17,24 22,07 
0.156 contaminated  14,11 27,67 
2001 
conc., µM 
TK buffer, pH 7.5 
% degradation 153 (150 
nM) 
Loop 
TK buffer, pH 6.0 
% degradation 153 (150 
nM)  
Loop 
TK buffer, pH 7.5 
% degradation 158 (150 
nM)  
Loop 
TK buffer, pH 6.0 
% degradation 158 (150 
nM)  
Loop 
1.25 10,97 10,81 5,07 10,19 
0.63 15,80 10,24 2,98 9,83 
0.31 contaminated  8,03 7,41 7,72 
0.156 contaminated  n.d. 6,95 10,02 
2001 
conc., µM 
TK buffer, pH 7.5 
% degradation 153 (150 
nM) 
Stem 
TK buffer, pH 6.0 
% degradation 153 (150 
nM) 
Stem 
TK buffer, pH 7.5 
% degradation 158 (150 
nM) 
Stem 
TK buffer, pH 6.0 
% degradation 158 (150 
nM) 
Stem 
1.25 16,40 14,70 7,82 16,22 
0.63 19,34 26,59 8,47 17,64 
0.31 contaminated  4,55 9,84 14,34 
0.156 contaminated  n.d. 7,16 17,65 
2001  NH2-YRKKR RQRRR C-Linker-Catalyst
153
TAR
158
Enantio TAR
A)
B)
C)
 
 
Figure 5.13: A) Cleavage of RNA 158 (150 nM) induced by conjugate 2001 at concentrations of 
0.31 µM. Conditions: 50 mM Tris-HCl, 20 mM KCl, 0.01 % Triton x-100, pH 7.5, 37 °C, 20 h. Lane 
b: base ladder of substrate 158 (Na2CO3). B) RNA substrates 158 and 153. C) Tat conjugate 2001. 5 Applications of the Tris(2-aminobenzimidazole) in Affinity Cleavage                  83 
   
buffer used was 50 mM Tris-HCl, 20 mM KCl, pH 7.5, at 37 °C for 20 h. The 
concentration of the RNA substrates was kept constant at 150 nM, while the 
concentration of 2003 was varied from 1000 nM to 63 nM. The influence of MgCl2 
was also tested to see if the Mg
2+ could change the activity or the selectivity. In Fig. 
5.14 is shown that a pattern similar to that of 2001 was produced when 2003 was 
incubated with 158.  
 
 
 
 
 
 
 
 
 
 
 
The summary of the results of these tests are reported in Tab. 5.3 where it is possible 
to see that the highest activity of 2003 is with 190 (mRNA of the Bcr-Abl, see 5.4.3), 
an RNA not related with TAR. Therefore it seems logical to conclude that the 
peptide used must have affinity for TAR but a low selectivity so that it can bind also 
non-related RNA. The action of Mg
2+ seems not to be clear: in some cases it was 
possible to observe an increase of cleavage, in some other an inhibition. 
 
 
Table 5.3:  Cleavage of 2003 incubated with 158 ± Mg
2+,  190 ± Mg
2+,  202 ± Mg
2+. 
Conditions: 50 mM Tris-HCl, 20 mM KCl, ± 1 mM MgCl2, pH 7.5, at 37 °C, 20 h. Substrate 
selectivity Tat conjugate 2003.  ALF-files:  158: 286_041.alx 286_041.fmv, 190: 287_041.alx 287_041.fmv, 202: 
285_041.alx 285_041.fmv; RNA cleavage285_041.xls 
Tat-BnIm3 
conc., µM 
% degr. 158 
-Mg
2+ 
% degr. 158 
+Mg
2+ 
% degr. 190 
-Mg
2+ 
% degr. 190 
+Mg
2+ 
% degr. 202 
-Mg
2+ 
% degr. 202 
+Mg
2+ 
0 (Control 0h)  n.d. n.d. 5,5 5,2 3,3  1,8
0 (Control 20h)  0,6 1,0 2,8 5,3 2,5  2,5
1 1,7 2,5 23,0 12,2 3,1 2,7
0.5 0,9 2,4 6,6 6,5 4,0 2,7
0.25 0,7 2,2 4,4 6,5 3,1 1,4
0.125 0,9 1,8 4,1 6,3 2,2 1,1
0.063 1,1 1,5 4,2 4,4 2,5 0,2
*n.d. = not detectable **n.a. = not analyzed 
 
Figure 5.14: a) Cleavage pattern of 2003 (20 nM), with TAR 158 (150 nM) 
Conditions: 50 mM Tris-HCl, 20 mM KCl, pH 7.5, at 37 °C, 20 h. b) Tat conjugate 
2003. 84                 5 Applications of the Tris(2-aminobenzimidazole) in Affinity Cleavage 
 
Within the series of the peptidic conjugates the last two were 2004 and its D 
enantiomer 2005, selected to have affinity for the Bcr-Abl RNA substrate 176 and its 
enantiomeric form 190 (Fig. 5.11). Both conjugates were incubated with the 
corresponding RNA substrates: 2004 with 176 and 2005 with 190, but also 2004 with 
the mirror image substrate 190, and 2005 with 176. The incubation was done in a 
buffer containing 50 mM Tris-HCl, 20 mM KCl, at pH 6, at 37 °C and for 20 h. As 
comparison the non-conjugate 29 (Fig. 2.22, Tab. 5.4) was also tested with both 
substrates 176 and 190. The concentration of RNA substrates was kept constant (150 
nM), while the concentration of the conjugates was varied from ~ 50 μM to ~ 2 μM. 
In Tab. 5.4 are reported the results of cleavage of these experiments. It is evident that 
no real specificity exists at least under these conditions. Moreover, the cleavage 
patterns for the conjugates are very similar with the pattern of the free catalyst 29.  
 
 
 
A different type of conjugate, but with relevance to these studies of affinity cleavage 
is the 29-neamine conjugate, developed in collaboration with the group of Professor 
Jean-Luc Décout. This compound at concentrations of 630 nM and 320 nM, was 
incubated with 153 (150 nM) in a buffer containing 50 mM Tris-HCl, 20 mM KCl, at 
pH 7.4, at 37 °C and for 20 h. 
The preliminary results of this compound are illustrated in Fig. 5.15. Two slightly 
different patterns were generated when the conjugate was at 630 nM (lane a) or 320 
nM (lane b). The cleavage occurred in both cases mostly in the bulge of TAR where 
neamine presumably should bind. In this case a certain affinity cleavage was 
demonstrated. 
Table 5.4: Results of cleavage of 2004 (42, 10.5, 2.6 mM), 2005 (36, 9, 2.3 mM), and 29 (50, 
12.5, 3.1 mM) with 176 (150 nM) and 190 (150 nM). Conditions: 50 mM Tris-HCl, 20 mM KCl, 
pH 6, 37 °C 20 h. ALF-file: 247_041; 247_041.fmv; RNA cleavage 247_041.xls 
      L-bcrAbl 
2004 
D-BcrAbl 
2005 
BnIm3 
29 
 
% degradation  bckg  42  10.5  2.6  36  9  2.3  50  12.5  3.1 
BcrAbl      176  18,20 90,57  95,74 93,15 98,30 94,74 85,56 92,30 22,08 31,49 
L-BcrAbl  190  14,36 92,47  78,07 54,26 60,44 38,43 42,21 68,96 21,85 22,82 
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5.9 Conclusions 
 
To conclude, tris(2-aminobenzimidazole) was converted in molecules that can be 
easily conjugated to ligands with primary mercaptans by maleinimide chemistry or to 
ligands with amino groups by peptidic linkage. In these preliminary studies of 
affinity cleavage, the RNase activity was always conserved, but due to low 
specificity of the ligands used, a consequent lack of specificity of the conjugates was 
evidenced. Therefore, applications in affinity cleavage for this catalyst should 
possible, but further validations with better ligands are still required. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Cleavage pattern for the neamine conjugate. Lane a: 29-neamine conjugate 
630 nM. Lane b: 29-neamine conjugate 320 nM. Lane c: base ladder of substrate 158 (Na2CO3). 
Conditions: 50 mM Tris-HCl, 20 mM KCl, pH 7.4, 37 °C, 20 h. 86                 5 Applications of the Tris(2-aminobenzimidazole) in Affinity Cleavage 
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6  Gold Nanoparticles Functionalised with 
2-Aminobenzimidazoles 
 
The development of the tris(2-aminobenzimidazole) as a catalyst started with the 
observation that monomeric 2-aminobenzimidazole could better catalyse RNA 
cleavage compared to simple guanidinium groups. When several of these groups 
were combined in the bis(2-aminobenzimidazole) and then in the tris(2-
aminobenzimidazole), the activity increased progressively.
[16] The reason of this 
increase of activity is still not clear, but 2-aminobenzimidazole was identified as a 
building block for construction of artificial RNases. From such observations the idea 
was developed to make gold nanoparticles functionalized with 2-
aminobenzimidazoles that could act in cooperativity on the surface (Fig. 6.1). Using 
then the property of these materials,
[18][19] by place-exchange it should be possible to 
achieve a further fuctionalisation with RNA ligands and to get substrate specificity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1  Gold Nanoparticles in General 
 
Aggregates of gold atoms with a size of several nm can be formed in solution under 
particular conditions.
[115] These aggregates can be covered by a monolayer of thiols. 
The synthesis and characterization of these materials have reached good levels. They 
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Figure 6.1: Conceptual development of gold nanoparticles functionalised 
with 2-aminobenzimidazoles.88                                 6 Amino-benzoimidazoles Assembled on Gold Nanoparticles 
 
have also found technological applications.
[116] A summary of the reactivity and the 
possibility to modify these nanoparticles are reported in Fig. 6.2. 
 
 
The organic layer that covers the surface of the gold aggregates, protects the surface 
of the metal, avoiding the association into bigger insoluble particles. The MPCs 
(monolayer protected clusters) are therefore stable and depending on the nature of 
the organic ligands that cover the metallic surface they are soluble in different 
solvents.  
 
 
Figure 6.2: a) Place-exchange. b) Reaction of p-mercaptophenol with propionic anhydride. c) 
SN2 reaction of ω-bromoalkanethiolated MPCs with primary alkylamines. d) Amide and ester 
coupling reactions. e) Siloxane formation reactions. f) Transition-metal-catalyzed ring opening 
metathesis polymerization.
[115] 6 Amino-benzoimidazoles Assembled on Gold Nanoparticles                                  89 
   
6.1.1  Synthesis of MPCs 
 
The synthesis of MPCs became more easy and reproducible after the work of Brust 
and Schiffrin,
[117] who demonstrated that in presence of an aliphatic thiol the 
reduction of HAuCl4 to Au (0) by NaBH4 led to the formation of gold aggregates 
protected with a monolayer of thiolates with a diameter of 1-3 nm (Sch. 6.1). The 
salts of Au
3+ are not soluble in organic solvents. Therefore, they must be transferred 
in organic phase by a phase transfer reagent such as Oct4NBr. 
 
The MPC obtained with this procedure are stable and soluble in common organic 
solvents, and they can be handled like normal organic compounds. 
This procedure can be also started from thiols carrying some functional group. The 
result will be then gold nanoparticles with a functionalized surface. 
When the thiolic ligand is soluble in water or in alcoholic solvents the synthesis can 
be done directly in this solvents without the use of the phase transfer catalyst.
[118] 
Another important point in this synthesis is that the size of the MPCs can be 
controlled in different ways. For example the ratio Au/RSH is proportional to the 
size, so with a ratio of 6/1 the inorganic core has a size of 6 nm, while using a large 
excess of mercaptan the core has a diameter of 1.5 nm.
[119] Other parameters to 
control the diameter of the core are: the type of reductant, the time of reduction and 
the temperature. 
 
 
 
HAuCl4 (aq) + Oct4NBr (toluene) HBr (aq)+O c t 4NAuCl4 (toluene)
Oct4NAuCl4 + RSH toluene Au
S
R
n 1
1 (toluene) + NaBH4 (aq)
Au S
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S
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H
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Scheme 6.1:  Procedure of Schiffrin for the synthesis of gold MPC.  HAuCl4 is 
transferred in toluene by Oct4NBr and then reduced in presence of thiols with NaBH4. 90                                 6 Amino-benzoimidazoles Assembled on Gold Nanoparticles 
 
6.1.2 Functionalization  of  MPCs 
 
For rendering the gold nanoparticles able of some particular activity, the presence of 
functional groups on their surface are often required. This can be achieved with two 
methods: 
a)  Starting the synthesis from the beginning with a mercaptan carrying the 
required functional group (Fig. 6.3a). 
b)  By exchange. In fact a property of the thiols on the MPC surface is that they 
can exchange with other thiols in solution.
[18][19] As consequence an 
unspecific MPC can be functionalized by a partial exchange with ligands 
carrying a functional group (Fig. 6.3b). 
 
6.2  Gold Nanoparticles as Catalysts 
 
By cooperativity of functional groups, nature is often able to increase the activity of 
single building blocks with poor catalytic activity.
[120] This is well shown in   
RNase A, where two histidines work cooperatively. The viruses take also advantage 
of that. For example, the attachment of the influenza virus to a cell occurs through 
several interactions between hemagglutinin and sialic acid.
[121] The gold 
nanoparticles are ideal to enhance the reactivity of weakly active functional groups 
because, by the self-assembly around the gold core, many identical groups are 
ordered and come into close contact. Pasquato and Scrimin have given two examples 
of this concept. In the first example a gold nanoparticle functionalised with N-
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methylimidazole was able to catalyse in a methanol/water solution the cleavage of 
2,4-dinitrophenyl acetate more than one order of magnitude faster compared to the 
momomeric acetyl-N-methylhistamine, and better then the comicellar analogue (Fig. 
6.4).
[122] 
 
 
 
 
 
 
 
In a second example a gold nanoparticle protected by a monolayer of sulfanyloctane 
was prepared and subsequently subjected to place-exchange with an azacrown-
functionalized thiol (Fig. 6.5). 
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Figure 6.4: MPCs functionalized with N-methylimidazole.
[122] 
 
Figure 6.5: Gold MPCs functionalized with triazacyclononane.
[123] 92                                 6 Amino-benzoimidazoles Assembled on Gold Nanoparticles 
 
The triazacyclononane units are able to bind transition-metal ions such as Cu
II and 
Zn
II. This system was therefore supposed to operate as a metal enzyme mimic. In 
fact, the most active system was the one fully loaded with Zn
II ions. A kinetic 
analysis was done monitoring the cleavage of 2-hydroxypropyl p-nitrophenyl 
phosphate (HPNP). This study showed that the formal second-order rate constant for 
HPNP cleavage is of  4.4 s
-1M
-1, which is more than 600-times faster than the k2 of a 
monomeric  Zn
II “active unit” under the same conditions. Once again the micellar 
analogue showed a lower activity compared to the MPC.
[123]  
 
6.3  Synthesis of 45 as Ligand for Gold 
Nanoparticles 
 
As already illustrated in Fig. 6.1, one aim of this work was to synthesize a MPC 
functionalised with 2-aminobenzimidazole units. To this purpose 45 was synthesized 
as a ligand suitable for the assembling and the functionalising of MPC. This 
molecule was then sent to the group of Professor Scrimin in Padova, for the 
assembling of the gold nanoparticles. 
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As it is illustrated in Sch. 6.2, the thiourea 41 was prepared with a yield of 55 %, by 
reaction of 13 with thiocarbonyl diimidazole, followed by a second substitution with 
1,2-phenylene diamine. The 2-aminobenzimidazole derivative 42 was obtained with 
quantitative yield by closure of 41 in a solution of ethanol in presence of HgO, while 
the free primary amine 44 was got by hydrolysis of the Boc protecting group. In 
parallel the substitution of bromide with thioacetic acid in the 8-bromo-octanoic acid 
gave 8-acetylsulfanyl-octanoic acid 43. Therefore, the hydrochloride amine 44 and 
the carboxylic acid 43 were coupled using DIC and HOBT as condensing agent, 
giving the final compound 45. 
 
6.4  Assembly of the Gold Nanoparticles 
 
The ligand 45 was sent to Padova to the group of professor Scrimin, where Flavio 
Manea assembled the gold nanoparticles. Three different approaches were attempted 
to synthesize these gold nanoparticles. In the first attempt (Fig. 6.6a) the direct 
synthesis of the MPC from the 2-aminobenzimidazole ligand produced aggregates 
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that precipitated and resulted insoluble in most of the common solvents. The second 
attempt (Fig. 6.6b) was a functionalization by place exchange of hydrocarbon-
protected MPCs, but also in this case an insoluble precipitated was formed. In the 
last approach water soluble MPCs were used for a place exchange with the 2-
aminobenzimidazole ligand. The solubility of these MPCs in water is guaranteed by 
a monolayer of ligands with a hydrocarbon chain part anchored to the metal core and 
a water-soluble part of triethylene glycol on the external surface (Fig. 6.6c). This last 
place exchange produced gold nanoparticles soluble in DMF and in water with a 
percentage of the ligand 45 on the protecting ligand of 30 %. These last MPCs were 
finally tested by Kathrin Beier in our laboratory.  
 
6.5  Assay for RNA Cleavage  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this test are reported in Tab. 6.1, where it is possible to see that under 
more basic conditions there was an increase of cleavage. A more careful analysis 
revealed that the cleavage occurred mostly between pyrimidine pyrimidine linkage. 
This kind of selectivity is typical for RNases contaminations. Therefore, these results 
Table 6.1: Results of cleavage test of the MPCs. Conditions: 50 
mM Tris-HCl, 37 °C for 20 h. 
pH Conc. 
Catalyst 
Conc. 
Substrate 
% DMF  %Cleavage 
6  35    μM 150  nM  20  12 
6 17.5  μM 150  nM  10  1.7 
6    8.7 μM 150  nM  5  15 
6    4.4 μM 150  nM  2.5  9 
        
7  35    μM 150  nM  20  2.4 
7 17.5  μM 150  nM  10  12 
7    8.7 μM 150  nM  5  13 
7    4.4 μM 150  nM  2.5  1.5 
        
8  35    μM 150  nM  20  25 
8 17.5  μM 150  nM  10  5 
8    8.7 μM 150  nM  5  3 
8    4.4 μM 150  nM  2.5  1.7 6 Amino-benzoimidazoles Assembled on Gold Nanoparticles                                  95 
   
are not reliable and should be considered preliminary. Other tests could be done with 
enantiomeric RNA. However, the ratios of cleavage were not impressive. A reason 
could be that 30 % of the 2-aminobenzimidazole versus 70 % of triethylene glycol 
ligands, is insufficient to generate significant catalytic activity and to allow the 2-
aminobenzimidazole to work cooperatively.  
 
6.6 Conclusions 
 
Future synthetic efforts to improve the system, should try to increase the percentage 
of catalytic units on the surface of MPC. This could be done for instance by reducing 
the size of the metal core to improve the solubility. 
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7  Non-Enzymatic Oligomerization of 
Ribonucleotides 
 
7.1  Origin of Bioorganic Compounds  
 
How life could have developed on our planet is still an open question that science has 
not been able to solve. Some points seem to be clear. For instance, that life started 
3.8 billion years ago. It is obvious that life depends on the ability to self-replicate, to 
evolve and to self-adapt to different challenging situations. Mechanisms must exist to 
conserve the information acquired in the evolution and to transmit them to successive 
generations. In our days it is known that nature has chosen DNA for information 
storage. A widely accepted hypothesis assumes however, that in the early phases of 
life, RNA has adopted this role and also acted as catalyst. 
From a chemical point of view the question is how these molecules could self-
assemble within the prebiotic soup. 
To explain the origin of life currently three hypotheses are taken in consideration:
[124] 
 
1.  Synthesis in an reducing atmosphere 
2.  Input by meteorites 
3.  Synthesis on metal sulfides in deep-sea vents. 
 
Some indications how organic compounds may be generated from inorganic material 
under conditions similar to those of the primitive atmosphere came from the classical 
experiment by Urey and Miller.
[125] In their experiment they demonstrated how a 
mixture of CH4, NH3, H2O and H2 when subjected to electrical discharges can form 
amino acids. Much earlier it was demostrated that simple sugars can be formed 
readily from formaldehyde in the formose reaction.
[126] However, this reaction is not 
selective, and biologically important sugars like ribose are formed only in trace 
amounts. In contrast, Eschenmoser has recently shown that glycoaldehyde phosphate 
aldomerizes in aqueous NaOH solution. In presence of 0.5 mol-equiv. of 
formaldehyde, sugar phosphates are produced with a yield of 45 %, with pentose  98                                            7 Non-Enzymatic Oligomerization of Ribonucleotides  
 
2,4-diphosphates predominating over hexose 2,4,6-triphosphates and with rac-ribose 
2,4-diphosphates as major component (Fig. 7.1).
[127] 
 
 
 
 
 
 
 
 
Other key elements of life are the purines and pyrimidines. Evidence for a possible 
synthesis of adenine from aqueous solutions of ammonium cyanide at temperatures 
below 100 °C were given by Oro,
[128] while Ferris, Sanchez and Orgel demonstrated 
the formation of pyrimidines from cyanoacetylene and cyanate.
[129] Further 
cyanoacetylene in aqueous or anhydrous ammonia gives β-aminoacrylnitrile that 
leads to formation of imidazole by photolysis.
[129] 
In Fig. 7.2 are summarized some important reactions that could have contributed to 
the origin of life. 
 
 
7.2  The RNA World 
 
In the past the biochemical dogma has been that chemical reactions are catalysed by 
proteins, while nucleic acids merely carry the genetic information. The recent 
discovery that also RNA itself possesses catalytic activity
[20][21][22] has changed this 
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Figure 7.1: Aldomerization of glycoaldehyde phosphate. 
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Figure 7.2: Reactions producing bioorganic compounds.
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view, leading to the hypothesis that life may have been originated from an ‘‘RNA 
world’’, where RNA enzymes were able to catalyse all the necessary biochemical 
reactions. Some examples of living fossils of that world could be the ribosomes, 
nucleotidic cofactors and ribozymes as catalytic active RNA. 
A recent review on the origin of RNA catalysis in ribozymes is given by Lilley.
[130] 
RNA can generate catalysis by general acid-base catalysis, electrostatic effects, 
substrate orientation and proximity. The main players are the RNA nucleobases and 
bound metal ions. Experiments of in vitro selection have then shown that new 
ribozymes with unique abilities can be generated. One example, given by Unrau and 
Bartel
[131] shows that isolated RNA molecules are able to catalyse the synthesis of 
pyrimidine nucleotides (Fig. 7.3). 
 
The ability to form amide-bonds should be necessary to pass from a RNA world to 
the contemporary protein dominated biology. Concerning this step Lohse and 
Szostak isolated ribozymes catalysing amino acid transfer reactions.
[132] 
 
7.2.1  Energetic Source of the RNA world 
 
We know that most of the biological processes and syntheses need ATP or 
occasionally GTP as energetic source, but it seems unlikely that such sources of 
energy played a role in the evolution of biological compounds. Lohrmann and Orgel 
proposed that the primary chemical energy reserve was rather a mixture of inorganic 
and organic polyphosphates. In fact they demonstrated that by heating mixtures 
containing urea, ammonium phosphate, metal ions and nucleosides in various 
proportions at moderate temperature, phosphorylated nucleotide derivatives were 
formed. It was found that ATP or AppA react with imidazole to form ImpA (Fig. 
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7.4). Further studies of template-directed oligomerization showed that these 
phosphoroimidazolide nucleotides can condense on a poly U as template to form di- 
and short poly A oligonucleotides.
[23][133] In this way it was demonstrated a possible 
spontaneous formation of short oligonucleotides. 
 
These first studies started to give some information of how biopolymers could have 
been formed. However, if there was an RNA world that evolved into the current 
biology, it needed as every evolving system to self replicate and to undergo selection, 
by which can originate new proprieties or more complex systems. Of course all this 
must have happened at least in the beginning, without the help of any enzyme or 
ribozyme. Assuming that the monomeric building blocks were available in sufficient 
amounts, the objective of this research became to find how polymers, possibly RNA, 
can self-replicate to undergo selection that led to the RNA world first, and then to the 
modern cellular biology.
[134] 
 
7.3 Non-Enzymatic  Oligomerization 
 
We have seen that to clarify the origin of life it is necessary to find a self replicating 
system. In this context we speak about non-enzymatic oligomerization, meaning a 
system where starting from activated building blocks a sequence-template drives the 
replication of new sequences without any enzyme. To evaluate how a template 
sequence is duplicated, we have to take into consideration
[134]: 
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Figure 7.4: A scheme for the prebiotic activation of nucleotides.
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The efficiency, the amount of complementary copies of the template produced.  
The fidelity, the percentage of wrong bases incorporated during the elongation. 
The regiospecificity, the ratio of natural 3’-5’ linkages to unnatural 2’-5’. 
The non-enzymatic template-directed studies started using as activated building 
blocks phosphoroimidazolide nucleotides (Fig. 7.4). Later it was observed that 
phosphoroimidazolides with a methyl group in position 2 of imidazole gave a more 
efficient oligomerization.
[135] As a consequence this compound became a model for 
non-enzymatic oligomerization (Fig. 7.5).
[24]  
 
 
 
 
 
 
After the first experiments of RNA oligomerization directed by a template, new 
problems and questions started to arise. The obstacles for an efficient RNA primer 
extension are: 
 
1.  Tendency of G-rich templates to form quadruplexes in presence of high 
concentration of Na
+. To bypass this problem a solution may be to work at 
low concentration of Na
+.
[136] 
2.  Weakness of the A-U base pair is the cause for inefficient incorporation of U 
monomers on a polyA template. The oligomerization directed by random 
copolymer of A and C is also less efficient then that by a poly C or a 
copolymers of C and G. A solution of this problem can be the use of 
diaminopurine instead of A (Fig. 7.6).
[137] 
 
3.  Inhibition by enantiomeric monomers. 
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Figure 7.5: 5’-phosphoroimidazolide nucleotide.
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4.  Inhibition by purine-pyrimidine alternation.
[137] 
A solution at the latter problem would perhaps be to avoid the irregularities and the 
pyrimidines. An alternative could be therefore, the use of analogous Watson-Crick 
base pairing, but involving only purines. An example is given by the base pair 
G/isoG (Fig. 7.7). 
 
 
 
 
 
 
5.  Inhibition by single 2',5' connections.
[138]  
6.  By-products due to hydrolysis or incorrect chain extension 
             cause irreversible "poisoning". 
In contrast to the natural RNA, where the connection is of 3’,5’-bond type, studies of 
non-enzymatic oligomerization using the activated phosphoroimidazolides evidenced 
that the regioselectivity is much more in the direction of the 2’,5’-bond, with a ratio 
of 6:1 and if the oligomerization is template directed the ratio became even 18:1.
[138] 
Studies of the polymerisation of adenosine 2’,3’-cyclic phosphate on a poly U 
template catalysed by aqueous ethylenediamine showed the formation of 97 % of 
2’,5’-linkage.
[25]  
Given this evidence, among the researchers of this field rose a new hypothesis, 
according to that before the RNA world could have existed another world. A new 
term was coined: “unnatural selection”.
[134] The idea is that a self-replicating system 
can evolve under selection also without being alive. Hence, not necessarily the 
natural RNA should be at the origin of life, but also something else that then evolved 
into the “RNA world” to arrive finally in the current biology. Consequently, the new 
aim was to find a more general self-replicating system, possibly related to RNA, but 
not necessarily. 
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7.4  Motivation to Synthesize an Oligonucleotide 
G/isoG 
 
We have already seen that during a non-enzymatic polymerisation of RNA the most 
favoured connection results to be 2’,5’. This could turn out to be advantageous. 
Actually during the enzymatic polymerisation there are mechanisms of correction to 
undo the mistakes of incorporation. These mechanisms are obviously not present in a 
non-enzymatic system. Nevertheless, knowing that the formation of 2’,5’ linkages 
are reversible while that of 3’,5’ bonds are not,
[26] a sort of mechanism of correction 
can be introduced by the reversibility of the 2’,5’ linkage formation (Fig. 7.8). 
 
The reason of reversibility of the 2’,5’ linkages is illustrated in Fig. 7.9. The cleavage 
occurs by an in-line mechanism, for instance when the 3’ OH and O in 5’ are both in 
apical positions. In the linkage 3’,5’ the 2’ OH does not adopt the proper position for 
an in-line cleavage (Fig. 7.9a). Therefore, this linkage results to be more resistant. 
On the contrary, in the 2’,5’ linkage (Fig. 7.9b), the 3’ OH has the proper position for 
an in-line cleavage.
[26] 
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We have seen that the 2’-5’ connection should allow the correction of possible 
mistakes of incorporation. However, the formation of double stranded helixes is not 
favoured in nucleic acids connected by 2’,5’ linkages.
[27][139] The reason lies in the 
electrostatic repulsion of the negative charges of the phosphates that get close in this 
kind of linkage. This poses a new problem for a self-replicating nucleic acid. To 
solve this problem, once again the solution could be to use an alternative base pairing 
involving only purines such as the base pair G/isoG. This should space out the 
negative charges of the phosphates (Fig. 7.10), allowing a formation of stable double 
stranded helixes. 
 
 
The stability of G/isoG pairing in a duplex was already observed in pyranosyl-
RNA,
[140] but not in RNA itself. Considering all these problems of oligomerization 
 
 
Figure 7.9: Structural basis of the reversibility of the 2’-5’ 
connection. 
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with the natural bases, a solution may be to use a system consisting only of purines. 
A summary of the problems that could be solved using only purines for base pairing 
is reported in Fig. 7.11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A system capable to self-replicate should therefore fulfil the following requirement: 
1) A reversible 2’, 5’ connection for having the possibility to correct the mistakes. 2) 
An efficient recognition of the template. For this reason three hydrogen bonds are 
better than two. 3) Formation of stable duplexes, this could be improved by stacking 
and spacing out the negative phosphate charges. All these motivations give the 
arguments to investigate the stability of an RNA duplex with purine/purine base 
pairing and with a 2’, 5’ connection. 
Therefore, the synthesis of isoguanosine was started with the aim to investigate the 
palindromic sequences shown in Fig. 7.12c and Fig. 7.12d and to compare their 
duplex stability with the sequences in Fig. 7.12a and 7.12b. This would disclose 
important information about the stability of all-purine RNA duplexes connected by 
2’, 5’ bonds. This could then form the basis for a new set of non-enzymatic 
oligomerization tests. 
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7.4.1  Stability of Nucleic Acid Duplexes  
 
The stability of a nucleic acid duplex is given by the so called melting point Tm. Base 
stacking is accompanied by a reduction of UV absorption (hypochromicity). 
Therefore, a solution of polynucleotides has a lower extinction coefficient compared 
to a solution containing the same amount of mononucleotides. This phenomenon can 
be used as indicator of formation and breakdown of double helices. If the 
temperature of a solution containing a nucleic acid in duplex form is increased, at a 
certain temperature the absorption will increase suddenly. The midpoint of this 
transition is called the “melting temperature” or Tm. This parameter is characteristic 
of a certain nucleic acid sequence, and it shifts to higher temperature with an increase 
of the duplex stability. The factors that can increase the stability of the duplex are: 
stacking, length of the sequence, the ionic strength, the number of hydrogen bonds 
for base pairing, and the proximity of the phosphate anions. The increase of the 
extinction coefficient passing from ordered to disordered form is called 
hyperchromicity hr and is defined in terms of absorbance:  
 
 
% hr =
A(melted species) - A(double strand)
A(double strand)  
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7.5  Synthesis of Isoguanosine 
 
 
 
Guanosine was converted into isoguanosine 86 following the procedure reported in 
literature (Sch. 7.1).
[141] The first step was an esterification of the OH groups of the 
ribose using acetic anhydride in presence of pyridine. After a crystallization in 
propanol 81 was obtained in pure form. The base’s carbonyl C-6 was chlorinated by 
POCl3 giving 82. Subsequently, compound 83 was synthesised heating a solution of 
82 in DMF at 100 °C with toluene-4-thiol and triethylamine. Then, the treatment of 
83 with NaNO2 led to the compound 85. The final isoguanosine 86 was achieved by 
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stirring a solution of 85 in concentrated aqueous NH3 over night in an autoclave at 80 
°C. The isoguanosine 86 was afterwards selectively protected following the scheme 
7.2.
[142] The amino group in position 6 was protected with N,N-dimethylformamide 
dimethyl acetal in DMF producing 89. The primary 5’ OH was protected with DMT-
Cl in pyridine. The remaining OH groups in 2’ and 3’ of 90 were protected using (i-
Pr)3Si-Cl, furnishing a mixture of the two constitutional isomers that were separated 
by RP HPLC, with a yield of 16 % for 91 and of 40 % for 92.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The next step had to be the phosphitylation of the OH groups at 2’ or 3’ using the 
commercial 2-cyanoethoxy-N,N-diisopropylphosphoramidochloride. Surprisingly the 
phosphitylation did not occur at the expected position (Fig. 7.13b). Nevertheless, the 
isolated compound 95 had a proper 
31P NMR spectrum (Fig. 7.14). In a first 
comparison of the 
1H-NMR spectra of 91 and 95 (Fig. 7.15), it was clear that the 
signal of the N-H 3 of guanine had disappeared (arrow a). On the other side a shift of 
the H 8 signal occurred (arrow b) and the signal of the OH at 3’ seemed to be still 
present (arrow c). A further COSY spectrum (see appendix), confirmed the presence 
of 3’ OH and the formation of compound 95 as shown in Fig. 7.13a  
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To avoid this side reaction, a protection of the carbonyl at position 2 was planned. 
According to the procedure published by Pfleiderer,
[143] starting from a mixture of 91 
and  92, the p-nitrophenylethyl group (NPE) was introduced by the Mitsunobu 
reaction (Sch. 7.3). Consequently, a new mixture of the desired compounds 96, 97 
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Figure 7.14: 
31P NMR of 95. 
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Figure 7.15: 
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plus the side products 98, 99, and triphenylphosphine oxide was achieved. A HPLC 
separation was therefore required to isolate the single compounds. 
 
 
7.6 Conclusions 
 
Although a synthetic route to the fully protected isoguanosine has been traced, an 
efficient synthesis of a phosphoramidite of isoguanosine would be improved by 
introducing a new set of protecting groups (Fig. 7.16). 
The polarity of the molecule often complicated the purification during the normal 
silica gel flash chromatography, but also during HPLC purification, because neutral 
conditions were required to preserve all the protecting groups. To increase the 
lipophilicity, the NH2 group in position 2 may be protected with N,N-
dibutylformamide dimethyl acetal instead of N,N-dimethylformamide dimethyl 
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acetal. An alternative would be the 4-isopropyl phenoxy acetyl group. In addition the 
purine carbonyl group could be converted into a diphenylcarbamate,
[144] in place of 
using the NPE as protecting group, which complicated the purification and led to the 
formation of side reactions. 
 
 
 
Concerning the OH groups at 2’ and 3’, they could be protected using tert-
butyldimethylchlorosilyl instead of (i-Pr)3Si-. This to reduce the steric hindrance and 
to make the phosphithylation of the remaining free OH group easier. For time reason 
the project was not finished, but a synthetic way to achieve the final product has been 
explored evidencing a set of synthetic problems, which can be solved as suggested. 
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8  Summary and Outlook 
 
At the beginning of my thesis evidence from previous studies had shown that   
tris(2-aminobenzimidazoles) are excellent catalysts for RNA cleavage. However, due 
to the tendency of these 
molecules to aggregate, the 
activity of the monomeric 
non-aggregated catalyst was 
not exactly known. During 
my work 4 different 5’ DNA 
conjugates were produced 
via disulfide linkage (Fig. 
8.1:  1000,  1001,  1002, 
1006). The cleavage tests of these conjugates proved without any doubt the activity 
of aminobenzimidazole catalysts. Furthermore, a pH activity relation was 
established, evidencing an optimum at pH 8. A high level of site-specific cleavage 
was obtained with these constructs by the use of helper oligonucleotides. A similar 
conjugate of PNA was also synthesised (Fig. 8.1 1011), but interestingly proved 
inactive. The reasons of this failure must still be investigated. Even if applications in 
vivo seem to be still difficult to achieve, in vitro these conjugates could be used as 
sequence specific artificial RNAses. Some questions about the mechanism of the 
catalyst are still open and important indications could come from a crystal of the 
catalyst-substrate complex. Moreover studies to clarify the action of these 
aminobenzimidazole catalysts will be fundamental to design new cleaving agents 
that could allow to reach promising results for applications in vivo.  
 
These 5’-conjugates as expected did not show turnover. Consequently a new class of 
conjugates carrying the catalyst in the middle of the DNA strand was designed to 
allow multiple turnover (Fig. 8.2). Of these new conjugates two were based on 
serinol (1007, 1008) and one on a modified nucleotide (1004). The conjugate 1007 
based on serinol with a short linker resulted to be the most active. These molecules 
successfully achieved site-specific cleavage and, at the same time, multiple 
turnovers. For 1007 an approximated kcat of 0.03 h
-1 was obtained. Concerning this 
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3'-TATGGAACAGTC- - CTTC-
5'-AUACCUUGUCAG    GAAGAGAGGCCGUUA-3'
                                  GA
3'-TATGGAACAG TCCTTC-
5'-AUACCUUGUCAGGAGAAGAGAGGCCGUUA-3'
210
1012
1012
210
Figure 8.3: 5’ Oligonucleotide conjugate 
producing turnover. 
project it still remains to investigate 
the specificity and efficiency 
depending on the bulge-size. This 
problem could be solved without 
particular efforts by custom 
synthesis of new substrates that can 
form bulges of the desired size. 
Based on a work of Häner,
[54b][54c] 
an alternative strategy to allow 
turnover was applied by 
synthesizing  1012  (Fig. 8.3). This 
new DNA conjugate was prepared 
carrying the catalyst at the 5’ end 
via amide bonds. In analogy to the 
work of Häner, conjugate 1012 was 
expected to form a bulge with 
substrate 210. This bulge has been 
the principal cleavage site in the 
study of Häner (Fig. 8.3). 
Unfortunately in our case the 
formation of the bulge seems to be 
not energetically favoured, while an 
alternative bulge-less duplex structure seems to be more preferred. Therefore, the 
cleavage occurred exclusively in single strand region without exhibiting turnover. 
Hence, the key to solve this project will be to understand which factors are important 
in the stabilization of the bulge 
formation. 
 
After these conjugation studies 
with DNA the tris(2-
aminobenzimidazole) catalyst 
appeared suitable for practical 
applications such as affinity 
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Figure 8.2: Oligonucleotide conjugates 
exhibiting turnover. 
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cleavage. To test this application, different derivatives were prepared, suitable for 
conjugation via amide bonds and via maleimide chemistry (Fig. 8.4). Using 37, four 
different peptide conjugates were synthesized (Fig. 8.5). 2001 and 2003 were based 
on the short sequence 49-57 of Tat, 
which is fundamental for the 
recognition of TAR. 2004 and 2005 
were made from a peptide selected by 
Jörg Bäumler to have affinity for the 
mRNA of Bcr-Abl, and Again 
targeting TAR another conjugate with 
neamine was prepared in 
collaboration with the University of Grenoble (Professor Jean-Luc Décout). The tests 
of these 5 conjugates to validate our catalyst for affinity cleavage indicated that the 
cleaving activity was always conserved, but in some case the specificity for the target 
was lacking. Thereby, in this project an optimal system for conjugation via 
maleinimide and peptidic bonds was established, but to finally prove this method in 
affinity cleavage some more tests must be still done with more reliable specific RNA 
ligands.  
 
In collaboration with Professor Paolo 
Scrimin and Flavio Manea, a gold 
nanoparticle functionalised with 2-
aminobenzimidazole was prepared (Fig. 
8.6). This project tried to answer the 
question if several copies of 2-
aminobenzimidazole might cooperate in 
phosphoryl transfer catalysis when 
brought together in a geometrically less defined assembly. Due to reasons of poor 
solubility only the 30 % of the ligands on the metallic core carried the 2-
aminobenzimidazole. The cleavage test could not show significant catalytic activity. 
Therefore, to achieve a positive result it seems necessary to increase the percentage 
of functional groups on the metallic surface. An alternative strategy to coordinate 
these functional groups could be the use of dendrimers. 
2001  NH2-YRKKR RQRRR C-Linker- Catalyst
2003  NH2-AAARKKRRQRRRAAAC-Linker-Catalyst
2004  NH2-KHLHLHKGGGC -Linker-Catalyst (L)
2005  NH2-KHLHLHKGGGC -Linker-Catalyst (D)
Neamine-Linker- Catalyst
 
Figure 8.5: Peptide conjugates, neamine 
coniugate. 
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Figure 8.6: Gold nanoparticle 
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A final project studied in this thesis, was the synthesis of a palindromic sequence of 
2’,5’ guanosine/isoguanosine in order to verify the stability of this duplex expected 
to form Watson-Crick type purine-purine base pairs. This project had to be the basis 
for new experiments of non-enzymatic oligomerization of ribonucleotides. 
Consequently, the synthesis of a phosphoramidite of isoguanosine was started. 
However, due to a lack of time the project was not finished. Nevertheless, a synthetic 
path to this molecule was explored, recognizing series of synthetic problems that 
could be solved in the future with a new set of protecting groups, as illustrated in Fig. 
8.7. 
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9  Experimental Section  
 
9.1  Materials and Methods  
 
General: All reagents were of the highest grades commercially available. Chemicals 
for polyacrylamide gel electrophoresis were purchased from Roth (Karlsruhe, 
Germany), blue dextran 2000 from Amersham Biosciences (Freiburg, Germany). 
The commercial chemical compounds were used without further purification, where 
not specified, and were provided by the following companies: Aldrich, Fluka, Merck, 
Lancaster, Biospring, Proligo, and Roth. 
Solvents: The solvents for chromatography were distilled. Absolute solvents were 
used for reactions. 
Thin Layer Chromatography (TLC): Aluminium sheets with silica gel 60 F254 
(0.25 mm, Merck). The detection was done under UV lamp. 
The oligonucleotides not synthesized in the own laboratory were obtained from 
Biospring (Frankfurt, Germany). 
Inactivation of RNases: All experimental steps were performed under sterile 
conditions. Plasticware, tubes and most solutions were treated with 
diethylpyrocarbonate (DEPC). Solutions that are not compatible with DEPC 
treatment were prepared by mixing up molecular biology grade powdered reagents in 
DEPC-treated ultrapure water. All glassware was baked at 180 °C for six hours. 
Purification of Cy-5-labelled oligonucleotides and conjugates: The 
oligonucleotides were purified by denaturing PAGE (16 % monomer, 7 M urea). The 
bands of interest were excised, the gel fragments transferred to a nuclease-free tube 
and submerged with elution buffer (500 mM NaOAc, 0.1 % SDS, 2 mM EDTA). We 
routinely incubated the gel fragments under vigorous shaking overnight at room 
temperature. Quantum Prep Freeze’N’Squeeze spin columns (BioRad, Munich, 
Germany) were used to remove the gel fragments. After ultrafiltration on Microcon 
YM3, the retentate was diluted to 1 mL with DEPC-treated H2O and desalted on a 
NAP-10 column. The pooled fractions were lyophilized to dryness, and the pellet 
was dissolved in DEPC-treated H2O to give a conc. of approximately 0.5 µg / µL. 118                                                                                            9 Experimental Section 
 
Polyacrylamide gel electrophoresis: The oligonucleotide fragments were separated 
by denaturing PAGE (16 % monomer, 7 M urea) on a DNA sequencing device 
(ALFexpress, Amersham Biosciences). Prior to electrophoresis each sample was 
completed with one volume of loading buffer (5 mg / mL blue dextran in formamide) 
and 10 µL were loaded on the gel. Following running conditions were chosen:   
1500 V (maximum), 60 mA (maximum), 30 W (constant), 55 °C, 2 s sampling 
interval and 350 minutes running time. For analysing the electropherograms the 
AlleleLinks 1.01 software package (Amersham Biosciences, Uppsala, Sweden) was 
used. The peak areas under the curves were added up, and the percentage of 
degraded RNA was calculated. Multiple cleavage reactions were disregarded in this 
system. All data were averaged over a minimum of two experiments. 
RNA cleavage assay: 1.5 pmol Cy5-labelled RNA substrates were incubated in a 
final volume of 10 µL with the indicated conjugate concentration (0.15-1.5µM) in a  
50 mM Tris- HCl buffer at pH 8.0 (if not indicated otherwise) containing 0 or 100 
mM NaCl. All cleavage reactions were performed at 37 °C, time as indicated. 
FCS Measurements: Aggregation studies were carried out with a ConfoCor 2 (Carl 
Zeiss, Jena, Germany). As additional equipment an Axiovert 200 M microscope 
containing a laser adapted Zeiss C-Apochromat 40x /1.2 W corr H2O-immersion 
objective was used. Fluctuation measurements, which are calculated in real time to 
give an autocorrelation curve, and further analysis, like determination of the average 
number and the diffusion time (at 24 °C) of the fluorescent particles in the confocal 
volume, were performed with the Fluorescence Correlation Microscope ConfoCor 2 
Software version 3.2 SP1. Free Cy5 dye was used for calibration of the instrument 
(excitation source: He/Ne laser at 633 nm) and cover slips (24 x 60 mm, Roth, 
Karlsruhe, Germany) served as sample carriers. For comparison reasons similar 
conditions as used for RNA-cleavage experiments were chosen. Conjugates 1000, 
1001, 1002, 1003, and 1006 (1.5 µM) were either assayed with their cognate RNA 
(200nM) or with a mixture of an undegradable Cy5-labeled T20U probe 108 (25 nM) 
and an unlabeled DNA oligonucleotide 109 (175 nM) in 50 mM Tris-HCl buffer  
(pH 8.0). The incubation step (20 h, 37 °C) was omitted and the assay volume was 
increased to 30 µL. Each sample (30 µL droplet) was measured five times for 30 s. 
Determination of oligonucleotide concentrations: To determine the concentration 
of an oligonucleotide an aliquot of 10 μL was diluted in 1 mL, the absorbance at 260 9 Experimental Section                                                                                             119 
   
nm was measured corresponding to the OD
260. The molar extinction coefficient at 
260 nm for the oligo is given by the following formula: a(16.000) + b(12.000) + 
c(7.000) + d(9.600)= ε, where a is the number of A’s, b is the number of G’s, c is the 
number of C’s, d is the number of T’s. 
The molar concentration of the stock solution is given by: 
(OD
260 × dilution factor) / ε = concentration in μM. 
 
 
9.2 Instrumentation   
 
Melting point: Kofler hot plate microscope, uncorrected. 
1H-Nuclear Magnetic Resonance Spectroscopy (
1H-NMR):  Bruker AM 250, 
Bruker Avance 400. 
The chemical shifts (δ) in are indicated in ppm and the coupling constant (J) are 
expressed in Hertz (Hz). 
The chemical shifts are given using the non-deuterated solvent as internal standard. 
The multiplicity of the signals are given according to the following indication:   
s = singlet, d = doublet, t = triplet and m = multiplet, br. = broad  
31P Nuclear Magnetic Resonance Spectroscopy (
31P-NMR): Bruker Avance 400 
(162 MHz). phosphoric acid has been taken as external standard. 
13C Nuclear Magnetic Spectroscopy (
13C-NMR):  Bruker AM 250 (63 MHz) 
Bruker AMX 400 (100 MHz). The signal of the solvent has been taken as internal 
standard. 
Fourier-Transform-Infrared Spectroscopy (FT-IR): Perkin-Elmer 1600. In the 
infrared spectra the position of absorptions bands (ν) are given in cm
-1. The intensity 
is indicated with s = strong, m = medium and w = weak. 
Ultraviolet Spectroscopy: Varian Cary 1E UV-Visible Spectrophotometer.  
Mass Spectroscopy (MS): ESI: Fisons VG Platform II. MALDI: Fisons Instruments 
(VG Topspec / MALDI; N2 – Laser 337 μm; Pulse frequency 4 nsec). MALDI-
MATRIX: 2,5-Dihydroxy-benzoic acid. 
Elementary Analysis: Hereaus CHN-Rapid. 
Flash Chromatography: silica gel 60 (40-63 μm, 230-400 mesh) Merck.  120                                                                                            9 Experimental Section 
 
Preparative High Performance Liquid Chromatography (HPLC): Merck 
sepTech, with Merck/Hitachi L4000A UV-Detector, column 700 x 50 mm und 250 x 
50 mm internal diameter, packed with Macherey and Nagel Nucleoprep 20 μm.  
Centrifuges: Eppendorf Centrifuge 5417R. 
Lyophilisator: Christ Alpha 2-4. 
Thermal Block: Biometra TB1 Thermoblock. 
DNA-/RNA-Synthesizer: Applied Biosystems ABI 381A. 
SpeedVac: vacuum pump Savant UVS400A, Savant SpeedVac Plus SC 110A. 
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9.3  Synthetic Methods  
 
 
9.3.1  Methyl 3,4-diaminobenzoate (2)  
 
NH2
NH2
O
O
NH2
NH2
HO
O
2
2
 
 
3,4-Diaminobenzoic acid (10.0 g, 65.7 mmol) was suspended in 200 mL of MeOH 
and cooled to 0 °C. Within 30 min 5 ml of SOCl2 were added drop wise. The 
reaction was warmed up to room temperature, and then heated to reflux. After 15 h 
the reaction was complete. The solvent was evaporated ant the residue was adjusted 
to pH 9 adding a solution of saturated NaHCO3. Ethyl acetate (300 mL) was added, 
the mixture was shaken in a separation funnel and the aqueous layer was further 
extracted with ethyl acetate (3×100 mL). The combined organic layers were washed 
with 5 % sodium bicarbonate (3×100 mL) and water (3×100 mL) and then dried over 
Na2SO4. The solvent was removed in vacuo. The crude material was purified by 
recrystallization from 30 mL chloroform adding 200 mL of hexane to provide 7.3 g 
(67 %) of the compound 2 as a pale yellow solid. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 3.71 (s, 3H, CH3); 4.64 (s, 2H, NH2); 5.26 (s, 
2H, NH2); 6.50 (d, J=8.3, 1H, Ar-H); 7.09 (dd, J=8.3, J=2.3, 1H, Ar-H); 7.15 (d, 
J=2.3, 1H, Ar-H). 
 
IR (KBr): 3437s, 3365s, 3199m, 1692s, 1671s, 1630m, 1591s, 1514m, 1453s, 
1428m, 1318s, 1296m, 1238s, 1189w, 1162w, 1112w, 1065w, 992w, 893w, 832w, 
808w, 767m, 719w, 671w, 638w cm
-1. 
 
MALDI-MS m/z: calcd for C8H11N2O2
+ (M+H
+) 167.1. Found 166.9 (M+H
+). 122                                                                                            9 Experimental Section 
 
 
Analysis:   C8H10N2O2   (166.18)  calculated: C 57.82  H 6.07  N 16.86. 
                                                              found: C 57.77  H 6.06  N 16.99. 
 
M.p.: 103-105 °C. Let: 103-105 °C. 
 
 
9.3.2 Bis-[2-(tert-butoxycarbonylamino)ethyl]-(2-aminoethyl)amine 
(5). 
 
N
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Tris(2-aminoethyl)amine 4 (1.49 mL, 9.50 mmol) was dissolved in 40 mL of dry 
THF and cooled to 0 °C. A solution of Boc-ON (4.95 g, 20.1 mmol) in 50 mL dry 
THF was added dropwise during 1 h. The mixture was stirred at room temperature 
for 48 h. After removal of the solvent under reduced pressure, the remaining yellow 
oil was dissolved in ethyl acetate and washed twice with 0.5 N NaOH. The aqueous 
phase was diluted with brine and reextracted with ethyl acetate. The combined 
organic phases were dried over MgSO4 and the solvent was removed under reduced 
pressure. Chromatographic purification of the crude product (CH2Cl2/MeOH 45/4/1 
% ammonia ) yielded 2.07 g (63 %) of the compound 5 as a pale yellow oil. 
  
1H-NMR (DMSO-d6) δ: 1.37 (s, 18H, CH3); 2.38-2.44 (m, 6H, CH2); 2.56 (m, 2H, 
CH2); 2.95 (m, 4H, CH2); 6.72 (br. t, 2H, NHC=O). 
 
IR (KBr): 3356m, 2976m, 2818m, 1695s, 1521s, 1456m, 1391m, 1365s, 1276s, 
1251s, 1172s, 1067w, 969w, 864w, 780w, 758w cm
-1. 9 Experimental Section                                                                                             123 
   
 
ESI-MS m/z: calcd for C16H35N4O4
+ (M+H
+) 347.2. Found 347.1 (M+H
+). 
 
9.3.3 4-Amino-3-(3-{2-[bis-(2-{tert butoxycarbonylamino} ethyl) 
amino]ethyl} thioureido) benzoic acid methyl ester (6). 
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A solution of amine 5 (1.97 g, 5.68 mmol) in 20 mL acetonitrile was added dropwise 
at 0 °C to a mixture of thiocarbonyl diimidazole (1.52 g, 8.55 mmol) and imidazole 
(0.116 g, 1.71 mmol) in 30 mL acetonitrile. The reaction mixture was stirred at room 
temperature for 1 h. 3,4-diaminobenzoic acid methyl ester 2 (1.42 g, 8.55 mmol) was 
dissolved in 10 mL acetonitrile and added dropwise to the reaction mixture. The 
solution was stirred at 50 °C for 4 h and at room temperature over night. After the 
removal of the solvent the chromatographic purification (ethyl acetate/hexane 1/1 → 
ethyl acetate) yielded 2.80 g (88 %) of 6 as mixture with its constitutional isomer. 
 
1H-NMR (DMSO-d6) δ: 1.38 (s, 18H, CH3); 2.45-2.54 (m, 4H, CH2, overlap with 
DMSO); 2.59 (t,  J=5.6, 2H, CH2); 2.94 (m, 4H, CH2NC=O); 3.47 (m, 2H, 
CH2NC=S); 3.76 (s, 3H, OCH3); 5.68 (br. s, 2H, NH2); 6.65 (t, J=5.2, 2H, NHC=O); 
6.77 (d, J=9, 1H, Ar-H); 7.32 (br. s, 2H, NHC=S) 7.58-7.61 (m, 2H, Ar-H); 8.87 (s, 
1H, NH-Ar).  
 
IR (KBr): 3330s, 2977s, 2949m, 2839w, 1694s, 1625s, 1519s, 1438m, 1392m, 
1366s, 1292s, 1251s, 1168s, 1103m, 1062w, 995w, 859w, 769m cm
-1. 
 
ESI-MS m/z: calcd for C25H43N6O6S
+ (M+H
+) 555.3. Found 555.2 (M+H
+). 124                                                                                            9 Experimental Section 
 
 
9.3.4 2-{2-[Bis-(2-{tert-
butoxycarbonylamino}ethyl)amino]ethylamino}-1H-
benzimidazole-5-carboxylic acid methyl ester (7). 
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To a refluxing solution of thiourea 6 (1.50 g, 2.70 mmol) in 60 mL abs. EtOH 
containing a catalytic amount of sulfur, yellow HgO (2.34 g, 10.8 mmol) was added 
in several portions over 5 h. After filtration through celite
®, the solvent was 
evaporated under reduced pressure. The residue was chromatographed (ethyl 
acetate/MeOH 5/1) yielding 1.36 g (97 %) of 7 as white solid. 
 
1H-NMR (DMSO-d6) δ: 1.37 (s, 18H, CH3); 2.49-2.54 (m, 4H, CH2, overlap with 
DMSO); 2.67 (t,  J=6.1, 2H, CH2); 2.95-3.02 (m, 4H, CH2NC=O); 3.33 (m, 2H, 
CH2N-Ar, overlap wit H2O); 3.82 (s, 3H, O-CH3); 6.78 (t, J=4.6, 2H, NHC=O); 6.87 
(br. s, 1H, NH-Ar); 7.18 (d, J=8.3, 1H, Ar-H); 7.59-7.62 (m, 1H, Ar-H); 7.74 (d, 
J=1.6, 1H, Ar-H) 10.96 (br. s, 1H, Ring-NH). 
 
IR (KBr): 3358s, 2977s, 2826m, 1690s, 1636s, 1602s, 1578s, 1522s, 1458m, 1436s, 
1392m, 1366s, 1290s, 1252s, 1170s, 1088m, 987w, 859w, 776m, 752w cm
-1. 
ESI-MS m/z: calcd for C25H41N6O6
+ (M+H
+) 521.3. Found 521.4 (M+H
+). 
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9.3.5 2-[2-(Bis-{2-[3-(2-
nitrophenyl)thioureido]ethyl}amino)ethylamino]-1H-
benzimidazole-5-carboxylic acid methyl ester (24). 
 
N
H
N
HN
H
N
O
O
O
O
7
N
N
H
O
O
7
N
H
N
HN
N
H
S
HN
S
N
H
N
N
H
O
O O2N
NO2
23 24
24
 
 
A solution of compound 7 (1.27 g, 2.44 mmol) in 30 mL abs. MeOH was cooled to  
 0 °C and SOCl2 (1.77 mL, 24.4 mmol) was added dropwise. The mixture was stirred 
at room temperature for 3 h. The solvent was removed under reduced pressure 
yielding the hydrochloride of 23 quantitatively. NMR confirmed the removal of Boc 
and the crude product 23 was used in the next step without further purification. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 3.17 (br. s, 10H, CH2); 3.87 (m, 5H, CH2 CH3); 
7.51 (d, J=8.4, 1H, Ar-H); 7.87 (dd, J=1.5, J=8.4, 1H, Ar-H); 7.96 (d, J=1.5, 1H, Ar-
H); 8.40 (br. s, 4H, NH); 9.64 (br. t, 1H, NH); 13.54 (br. s, 2H, NH). 
 
A solution of 2-nitrophenylisothiocyanate (967 mg, 5.37 mmol) in 30 mL abs. EtOH 
was diluted with 10 mL TEA. The compound 23 was dissolved in 20 mL abs. EtOH 
with 10 mL TEA and added to the isothiocyanate solution at 0 °C. The mixture was 
stirred at room temperature over night. After removal of the solvent under reduced 
pressure, the crude product was chromatographed (ethyl acetate → ethyl 
acetate/MeOH 5/1) yielding 1.54 g (92 %) of 24 as a yellow solid: 
 
1H-NMR (250 MHz, DMSO-d6)  δ:   2.67-2.89 (m, 6H, CH2); 3.40-3.53 (m, 2H 
CH2); 3.54-3.71 (m, 4H, CH2); 3.81 (s, 3H, CH3); 6.86 (br. t, 1H, NH-Ar); 7.16 (d, 
J=8.3, 1H, Ar-H); 7.37 (m, 2H, Ar-H); 7.55-7.82 (m, 6H, Ar-H); 7.98 (dd, J= 8.2, 
J=1.3, 2H, Ar-H); 8.44 (br. t, 2H, NHC=S); 9.81 (s, 2H, C=S-NH-Ar); 11.0 (s, 1H, 
Ring-NH). 126                                                                                            9 Experimental Section 
 
 
IR (KBr): 3300m, 3040w, 2947m, 2841w, 1701m, 1686m, 1635m, 1605s, 1578m, 
1508s, 1458m, 1439m, 1341s, 1286s, 1206m, 1160m, 1088m, 1044w, 863w, 776m, 
724m cm
-1. 
 
MALDI-MS m/z: calcd. for C29H33N10O6S2
+ (M+H
+) 681.2. Found 681.8 (M+H
+). 
 
M.p.: 104 °C. 
 
9.3.6 2-[2-(Bis-{2-[3-(2-aminophenyl) thioureido] ethyl}amino) 
ethylamino]-1H-benzimidazole-5-carboxylic acid methyl ester 
(25). 
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Nitro compound 24 (1.00 g, 1.47 mmol) was dissolved in MeOH (50 mL) saturated 
with ammonia. 20 % Pd on activated charcoal (200 mg) was added and the mixture 
was stirred in an autoclave (purged with Ar) at 50 bar hydrogen pressure and 60 °C 
for 5 h. The catalyst was removed by centrifugation at 6000 min
-1 for 15 min and the 
clear solution was decanted from the charcoal. The solvent was evaporated under 
reduced pressure and the residue chromatographed (ethyl acetate/MeOH 9/1) to give 
635 mg (70 %) of compound 25 as pale compound. 
 
1H-NMR (250 MHz, DMSO-d6)   δ:   2.59-2.76 (m, 6H, CH2); 3.26-3.57 (m, 6H, 
CH2); 3.82 (s, 3H, CH3); 4.85 (s, 4H, NH2); 6.52-6.51 (dt, J=7.5, 1.3, 2H, Ar-H); 
6.75 (dd, J=8.3, J=1.3, 2H, Ar-H); 6.93-7.00 (m, 4H, Ar-H); 7.17 (d, J=8.3, 1H, Ar-9 Experimental Section                                                                                             127 
   
H); 7.58 (dd, J=8.40, J=1.2, 1H, Ar-H); 7.73 (d, J=1.3, 1H, Ar-H); 8.95 (s, 2H, NH-
Ar); 10.97 (br. s, 1H, Ring-NH). 
 
IR (KBr): 3364s, 3055m, 2948m, 1694s, 1634s, 1602s, 1575s, 1464s, 1404w, 
1362w, 1290s, 1271s, 1237m, 1210m, 1163w, 1117w, 1089w, 1059w, 1013w, 742m 
cm
-1. 
 
MALDI-MS m/z: calcd for C29H37N10O2S2
+ (M+H
+) 621.3. Found 623.0 (M+H
+).  
 
M.p.: 120 °C 
 
9.3.7 2-(2-{Bis-[2-(1H-benzimidazol-2-
ylamino)ethyl]amino}ethylamino)-1H-benzimidazole-5-
carboxylic acid methyl ester (29) 
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To a refluxing solution of thiourea 25 (582 mg, 0.94 mmol) in 50 mL abs. EtOH 
containing a catalytic amount of sulphur, yellow HgO (609 mg, 2.81 mmol) was 
added over 8 h in several portions. The mixture was filtered through celite
® and the 
solvent removed at reduced pressure. Chromatography (CH2Cl2/MeOH 44/5/1 % 
NH3) yielded 218 mg (58 %) of the trisbenzimidazole ester 29 as pink compound. 
 
1H-NMR (250 MHz, DMSO-d6): δ 2.73-2.83 (m, 6H, CH2); 3.34-3.51 (m, 6H, CH2 
overlap with water); 3.81 (s, 3H, CH3); 6.52 (s, 2H, Ar-H); 6.87-6.92 (m, 4H, Ar-H); 128                                                                                            9 Experimental Section 
 
7.00 (s, 1H, NH-Ar); 7.11-7.19 (m, 5H, Ar-H); 7.59 (dd, J=8.3, J=1.7, 1H, Ar-H); 
7.72 (d, J=1.6, 3H, Ar-H); 9.62 (br.s, 3H, NHAr). 
 
IR (KBr): 3312s, 2947s, 1686s, 1633s, 1603s, 1579s, 1464s, 1435m, 1401m, 1362m, 
1289s, 1210s, 1162m, 1117m, 1089m, 1058w, 1013w, 896w, 742s cm
-1. 
 
ESI-MS m/z: calcd for C29H33N10O2
+ (M+H
+) 553.3. Found 553.5 (M+H
+). 
 
Analysis:   C29H32N10O2   (552.64)   calculated: C 63.03  H 5.84  N  25.35. 
                                                                  found: C 62.25  H 6.03  N  24.69. 
                     0.4 H2O        (559.85)   calculated: C 62.22  H 5.91  N  25.02. 
 
M.p.: 155-158 °C. 
 
9.3.8 (6-Amino-hexyl)-carbamic  acid  tert-butyl ester (13) 
 
H2N
NH2 H2N
H
N
O
O
13
13
 
 
1,6-Diaminohexane (10.78 g, 92.8 mmol) was dissolved in 80 mL of dry THF and 
cooled to 0 °C. A solution of Boc-ON (5.71 g, 23.2 mmol) in 50 mL of dry THF was 
added dropwise during 1 h, the mixture was stirred for 48 h at room temperature. 
After filtration the solvent was removed under reduced pressure and the crude 
product was purified by silica gel chromatography (CH2Cl2/MeOH/aqueous NH3 
45/4/1) yielding 5.06 g (25 %) of 13 as colourless oil. 
 
1H-NMR (250 MHz, DMSO-d6) δ:  1.25-1.56 (m, 17H, 4CH2, 3CH3); 2.51 (m, 2H, 
CH2N overlap with DMSO); 2.89 (m, 2H, CH2NC=O); 6.77 (m, 1H, NHC=O). 
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IR (KBr): 3369s, 2973m, 2935s, 2862m, 1686s, 1627w, 1522s, 1480m, 1465m, 
1390w, 1365m, 1350w, 1278m, 1251m, 1173s, 1051w, 1016w, 995w, 869w, 821w, 
782w, 730w, 606w cm
-1. 
 
ESI-MS m/z: calcd for C11H25N2O2
+ (M+H
+) 217.2. Found 217.0 (M+H
+). 
 
Analysis:   C11H24N2O2   (216.3)   calculated: C 61.07  H 11.18  N 12.95. 
                                                               found: C 59.93  H 11.13  N 12.93. 
                    0.2 H2O        (219.9)   calculated: C 60.07  H 11.18  N 12.74. 
 
9.3.9 (6-{[2-(2-{Bis-[2-(1H-benzoimidazol-2-ylamino)-ethyl]-amino}-
ethylamino)-1H-benzoimidazole-5-carbonyl]-amino}-hexyl)-
carbamic acid tert-butyl ester (35) 
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Methyl ester 29 (200 mg, 0.36 mmol) was refluxed in 25 mL of 6 M HCl for 2 h, the 
solvent was removed under reduced pressure. NMR and ESI spectrometry confirmed 
the ester hydrolysis. The crude product was used for the next step. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 3.90 (m, 6H, CH2N); 4.19 (m, 6H, CH2N); 7.28 
(m, 4H, Ar-H); 7.38 (m, 4H, Ar-H); 7.44 (m, 1H, Ar-H); 7.97 (m, 1H, Ar-H); 7.99 
(m, 1H, Ar-H). 
 
ESI-MS m/z: calcd for C28H31N10O2
+ (M+H
+) 539.3. Found 539.2 (M+H
+). 
 
To a solution of 30 (0.36 mmol) in anhydrous DMF (10 mL), Et3N (500 μL), DIC 
(68 mg, 0.54 mmol), HOBt (73 mg, 0.54 mmol) and 13 (102 mg, 0.47 mmol) were 
added. The reaction was stirred at room temperature for 18 h. The solvent was 
evaporated by kugelrohr distillation, and the solid residue was purified by silica gel 
chromatography (CH2Cl2/MeOH/aqueous NH3 55/4/1), giving 133 mg (50 %) of 35 
as pink amorphous solid. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 1.35-1.68 (m, 17H, 4CH2, 3CH3); 2.88 (t, J=6.3, 
6H, CH2); 3.04 (t, J=6.8, 2H, CH2); 3.37 (t, J=7.0, 2H, CH2); 3.47 (m, 6H, CH2); 
6.96 (m, 4H, Ar-H); 7.12-7.19 (m, 5H, Ar-H); 7.47 (dd, J=8.3, J=1.7, 1H, Ar-H); 
7.61 (d, J=1.7, 1H, Ar-H). 
 
IR (KBr): 3299m, 3058w, 2974w, 2932s, 1684s, 1633s, 1602s, 1581s, 1523m, 
1461s, 1398w, 1361w, 1267s, 1168m, 1105w, 1052w, 1010w, 738s cm
-1. 
 
ESI-MS m/z: calcd for C39H53N12O3
+ (M+H
+) 737.4. Found 737.7 (M+H
+). 
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9.3.10 2-(2-{Bis-[2-(1H-benzoimidazol-2-ylamino)-ethyl]-amino}-
ethylamino)-1H-benzoimidazole-5-carboxylic acid {6-[3-(2,5-
dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]-hexyl}-amide 
(37) 
35 36 37
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To 35 (200 mg, 0.27 mmol) in MeOH (20 ml) was added 2 mL of HCl (1 M), the 
reaction was stirred at room temperature for 2 h and the solvent was removed under 
reduced pressure. NMR and ESI spectrometry confirmed the Boc hydrolysis and the 
formation of 36. The crude product was used for the next step. 
 
1H-NMR (250 MHz, MeOD-d4 ) δ: 1.50 (m, 4H, CH2); 1.71 (m, 4H, CH2); 2.96 (t, J 
= 7.5, 2H, CH2); 3.03 (m, 6H, CH2); 3.44 (t, J=7.0, 2H, CH2); 3.62 (m, 6H, CH2); 
7.21-7.35 (m, 9H, Ar-H); 7.71 (dd, J=8.3, J=1.7, 1H, Ar-H); 7.74 (m, 1H, Ar-H). 
 
ESI-MS m/z: calcd for C34H45N12O
+ (M+H
+) 637.4. Found 637.2 (M+H
+). 
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To 36 dissolved in DMF (8 mL), were added TEA (2 mL) and O-succinimidyl 3-
maleimidopropionate (100 mg, 0.38 mmol). The reaction was followed by TLC (n-
Butanol/AcOH/H2O 5/2/3, rf 0.3). After 2 h at room temperature the solvent was 
removed, and the crude material was purified on RP HPLC performed on Maisch 
Reprosil-AQ column (250×20) using isocratic elution with 0.1 % TFA (aq.) 68 %, 
CH3CN 32 %, flow: 7 ml/min, yielding 83.1 mg (19 %) of pure 37 compound in 
form of trifluoroacetate. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 1.28-1.69 (m, 8H, CH2); 2.43 (t, J=6.8, 2H, 
CH2C=O); 3.02 (m, 6H, CH2N); 3.12 (t, J=6.0, 2H, CH2NC=O); 3.39 (t, J=7.3, 2H, 
CH2NC=O); 3.60 (m, 6H, CH2N); 3.74 (t, J=6.8, 2H, CH2N(C=O)2); 6.79 (s, 2H, 
=CH); 7.17-7.30 (m, 9H, Ar-H); 7.65 (m, 1H, Ar-H); 7.70 (m, 1H, Ar-H). 
 
MALDI-MS m/z: calcd for C41H50N13O4
+ (M+H
+) 788.4. Found 788.5 (M+H
+). 
 
Analytical HPLC was performed on a Variant Polaris column (50×4.6) using 5 min. 
isocratic elution with 0.1 % TFA (aq.), then a linear gradient to the same buffer 
containing 70 % CH3CN in 20 min. 
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9.3.11 Peptide  conjugates (2001, 2003, 2004, 2005). 
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2005  NH2-KHLHLHKGGGC -Linker-Catalyst (D)
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This general protocol was used for each of the 4 different peptides. 
To a solution of peptide (2 mg) in 0.5 mL of 50 mM Tris-HCl pH 7 buffer, NaBH4  
(2.7 mg) was added, the disulfide reduction was followed by HPLC, and after 2 h, 
the reaction was quenched adding 100 μL of acetone, the pH adjusted to 7 and 4.6 
mg of 37 trifluoroacetate in 200 μL of DMF were added. The reaction was followed 
by HPLC, was completed after 1 h. The reaction mixture was stored at   
–80 °C, and the crude material of 2001, 2004, 2005, was purified on RP HPLC 
performed on Phenomex
® Gemini column (250×10) using isocratic elution with 0.1 
% TFA (aq.) 75 %, CH3CN 25 %, flow: 2 mL/min. The crude material of 2003 was 
purified on RP HPLC performed on Nucleodur 100-7 C 18 ec (250×21) column 
using 30 min. isocratic elution with 0.1 % TFA (aq.), followed by a stepwise 
gradient 0.1 % TFA (aq.), 70 %, CH3CN 30 %, flow 10 mL/min. 134                                                                                            9 Experimental Section 
 
2001 
MALDI-MS m/z: calcd for C106H171N46O175 2001 (M+H
+) 2391.3. Found 2462.0, 
2501.0 
 
2003 
MALDI-MS m/z: calcd for 2003 C115H192N51O21S (M+H
+) 2655.2. Found 2696.6. 
 
Analytical HPLC was performed on Variant Polaris column (50×4.6) using 5 min. 
isocratic elution with 0.1 % TFA (aq.), then a linear gradient to the same buffer 
containing 70 % CH3CN in 20 min. 
 
 
 
 
 
 
 
 
 
 
Analytical HPLC was performed on Phenomex
® Gemini column (150×4.6) using 
isocratic elution with 0.1 % TFA (aq.) 75 %, CH3CN 25 %, flow: 0.8 mL/min. 
 
 
 
 
 
 
 
 
 
 
 
 
Starting peptide 
 
Peptide after treatment 
with NaBH4 
Peptide after treatment 
with 37 
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2004 
MALDI-MS m/z: calcd for C92H134N33O15S 2004 (M+H
+) 1974.3.0. Found: 2059.7. 
 
Analytical HPLC was performed on Variant Polaris column (50×4.6) using 5 min. 
isocratic elution with 0.1 % TFA (aq.), then a linear gradient to the same buffer 
containing 70 % CH3CN in 20 min. 
 
 
 
 
 
 
 
 
 
 
Analytical HPLC was performed on Phenomex
® Gemini column (150×4.6) using 
isocratic elution with 0.1 % TFA (aq.) 75 %, CH3CN 25 %, flow: 0.8 mL/min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide after treatment 
with NaBH4 
Peptide after treatment 
with 37 
Starting peptide 
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2005 
MALDI-MS m/z: calcd for C92H134N33O15S 2005 (M+H
+) 1974.3. Found 2057.4. 
 
Analytical HPLC was performed on Variant Polaris column (50×4.6) using 5 min. 
isocratic elution with 0.1 % TFA (aq.), then a linear gradient to the same buffer 
containing 70 % CH3CN in 20 min. 
 
 
 
 
 
 
 
 
 
Analytical HPLC was performed on Phenomex
® Gemini column (150×4.6) using 
isocratic elution with 0.1 % TFA (aq.) 75 %, CH3CN 25 %, flow: 0.8 mL/min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide after treatment 
with NaBH4 
Peptide after treatment 
with 37 
Starting peptide 
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9.3.12 (2-Amino-ethyl)-carbamic  acid  tert-butyl ester (47) 
 
H2N
NH2 H2N
H
N
O
O
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1,2-Diaminoethane (3 g, 49.9 mmol) was dissolved in 80 mL of dry THF and cooled 
to 0 °C. A solution of Boc-ON (6.15 g, 25.0 mmol) in dry THF (50 mL) was added 
dropwise during 1h, the mixture was stirred at room temperature 16 h. After filtration 
the solvent was removed under reduced pressure and the crude product was purified 
by silica gel chromatography (CH2Cl2/MeOH/aqueous NH3 45/4/1 %) yielding 2.8 g 
(35 %) of 47 as colourless oil. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.38 (s, 9H, CH3); 2.53 (t, J=6.5, 2H, CH2N); 
2.91 (m, 2H, CH2NC=O); 6.76 (br. t, 1H, NHC=O). 
 
ESI-MS m/z: calcd. for C7H17N2O2
+ (M+H
+) 161.1. Found 160.7 (M+H
+). 
 
IR (KBr): 3364s, 2986w, 2937w, 1686s, 1639w, 1596m, 1534s, 1466m, 1390w, 
1368m, 1278s, 1252m, 1223w, 1177s, 1039w, 974w, 870w, 818w, 792w, 767w, 632m 
cm
-1. 
 
Analysis:    C7H16N2O2   (160.7)   calculated: C 52.48  H 10.07  N 17.48. 
                                                              found: C 48.79  H   9.77  N 16.39. 
                    0.65 H2O     (171.9)   calculated: C 48.90  H 10.14  N 16.29. 
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9.3.13  (2- {[2 -(2 -{Bis-[2 -(1H-benzoimidazol-2-ylamino) -ethyl] 
amino} -ethylamino) -1H-benzoimidazole-5-carbonyl] -amino} -
ethyl)-carbamic acid tert-butyl ester (48) 
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Methyl ester 29 (230 mg, 0.42 mmol) was refluxed in 25 ml of 6 M HCl for 2 h, the 
solvent was removed under reduced pressure. NMR and ESI spectrometry confirmed 
the complete formation of 30. The crude was used for the next step. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 3.90 (m, 6H, CH2N); 4.19 (m, 6H, CH2N); 7.28 
(m, 4H, Ar-H); 7.38 (m, 4H, Ar-H); 7.44 (m, 1H, Ar-H); 7.97 (m, 1H, Ar-H); 7.99 
(m, 1H, Ar-H). 
 
ESI-MS m/z: calcd for C28H31N10O2 (M+H
+) 538.3. Found 539.2 (M+H
+). 
 
To a solution of the carboxylic acid 30 (0.42 mmol) in anhydrous DMF (10 mL), 
Et3N (500 μl), DIC (80 mg, 0.63 mmol), HOBT (85 mg, 0.63 mmol) and 47   
(101 mg, 0.63 mmol) were added. The reaction was stirred at room temperature for 9 Experimental Section                                                                                             139 
   
18 h. The solvent was evaporated by distillation in the kugelrohr, and the solid 
residue was purified by silica gel column chromatography (CH2Cl2/MeOH/aqueous 
NH3 55/4/1 %), giving 180 mg (63 %) of 48 as pink amorphous solid.  
 
1H-NMR (250 MHz, MeOD-d4) δ: 1.46 (s, 9H, CH3); 2.85 (m, 6H, CH2); 3.22 (t, 
J=6.3, 2H, CH2); 3.31 (m, 2H, CH2); 3.46 (m, 6H, CH2); 6.95 (m, 4H, Ar-H); 7.14 
(m, 5H, Ar-H); 7.49 (dd, J=8.3, J=1.3, 1H, Ar-H); 7.63 (m, 1H, Ar-H). 
 
IR (KBr): 3328m, 2975w, 1686m, 1636s, 1603s, 1578s, 1534m, 1465s, 1390w, 
1365m, 1272s, 1165m, 1056w, 742s, cm
-1. 
 
ESI-MS m/z: calcd for C35H45N12O3 (M+H
+) 681.4. Found 681.3 (M+H
+). 
 
 
9.3.14 {6-[3-(2-Amino-phenyl)-thioureido]-hexyl}-carbamic acid tert-
butyl ester (41) 
 
H2N
H
N O
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A solution of amine 13 (3.00 g, 13.89 mmol) in 20 mL acetonitrile was added 
dropwise to a mixture of 1,1’-thiocarbonyldiimidazole (3.21 g, 18.1 mmol) and 
imidazole (0.200 g, 2.94 mmol) in acetonitrile (30 mL) at 0 °C. The reaction mixture 
was stirred at room temperature for 1 h. 1,2-Phenylenediamine (2.16 g, 20.0 mmol) 
was dissolved in 10 mL acetonitrile and was added dropwise to the reaction mixture. 
The reaction solution was stirred at 50 °C for 4 h and at room temperature over night. 
The solvent was removed and the crude material purified by silica gel 
chromatography (ethyl acetate/hexane 1/3) yielding 2.80 g (55 %) of 41 as pale 
amorphous solid. 
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1H-NMR (250 MHz, DMSO-d6)  δ: 1.12−1.50 (m, 17H, 4CH2, 3CH3); 2.89 (m, 2H, 
CH2NC=O); 3.40 (m, 2H, CH2NC=S); 4.79 (s, 2H, NH2); 6.56 (dt, J=7.5, J=1.4, 1H, 
Ar-H); 6.75 (m, 2H, NHC=O and Ar-H); 6.97 (m, 2H, Ar-H); 7.22 (s, 1H, NHC=S); 
8.73 (s, 1H, Ar-NH). 
 
IR (KBr): 3407m, 3283s, 3144s, 2974m, 2934s, 2855w, 1707s, 1690s, 1618w, 
1540s, 1509s, 1495s, 1453w, 1390w, 1365m, 1302w, 1251s, 1170s, 1040w, 854w, 
752m, 707w, 644w, 607w cm
-1. 
 
ESI-MS m/z: calcd for C18H31N4O2S (M+H
+) 367.2. Found 367.2 (M+H
+). 
 
Anallysis: C18H30N4O2S (366.5) calculated: C 58.98  H 8.25  N 15.29. 
                                                            found: C 59.02  H 8.24  N 15.36. 
 
M.p.: 115-116 °C. 
 
9.3.15 [6-(1H-Benzoimidazol-2-ylamino)-hexyl]-carbamic acid tert-
butyl ester (42) 
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To a refluxing solution of thiourea 41 (2.00 g, 5.46 mmol) in abs. EtOH (50 mL) 
containing a catalytic amount of sulphur, yellow HgO (3 g, 13.9 mmol) was added 
over 1 h in several portions. The mixture was filtered through celite
® and the solvent 
removed under reduced pressure. The crude material was purified by silica gel 
chromatography (Hexane/EtOAc/Et3N 3/1/1 %) yielding 1.7 g (95 %) of 42 as white 
solid. 
100 mg of product were crystallized from CH2Cl2 for full characterization. 
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1H-NMR (250 MHz, DMSO-d6)  δ: 1.20−1.62 (m, 17H, 4CH2, 3CH3); 2.90 (m, 2H, 
CH2NC=O); 3.24 (m, 2H, CH2N-Ar); 6.49 (t, J=5.7, 1H, NHC=O); 6.76 (br. t, 1H, 
NH-Ar); 6.84 (m, 2H, Ar-H); 7.09 (m, 2H, Ar-H); 10.64 (s, 1H, NHAr). 
 
IR (KBr): 3438w, 3371m, 2929m, 2857w, 1685s, 1637w, 1626w, 1584s, 1519s, 
1465w, 1365w, 1277m, 1256w, 1209w, 1179w, 969w, 916w, 850w, 760w, 750w, 
670w cm
-1. 
 
ESI-MS m/z: calcd for C18H29N4O2 (M+H
+) 333.2. Found 333.0 (M+H
+). 
 
Analysis: C18H28N4O2 (332.4) calculated: C 65.03  H 8.49  N 16.85.  
                                                         found: C 64.78  H 8.34  N 17.00. 
 
M.p.: 159-160 °C. 
 
 
9.3.16   8-Acetylsulfanyl-octanoic acid (43) 
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To 160 mL of MeOH 850 mg of Na (36.9 mmol) were added. After the development 
of H2 had terminated, it was added in the follwing order: thioacetic acid (2.90 g, 38.1 
mmol), 8-bromooctanoic acid (4.00 g, 17.9 mmol). The reaction was stirred under 
argon, at 80 °C for 15 h. The mixture was diluted with 15 g of ice, treated with HCl 6 
M until pH 3 and extracted with CH2Cl2 (3×40 mL). The collected organic phases 
were washed with brine (3×40 mL) and a saturated solution of NaHCO3 (3×40 mL). 
The organic layer was dried over Na2SO4, filtrated and evaporated. The oil obtained 
was purified on silica gel column chromatography (Hexane/EtOAc 1/1), giving 3.2 g  
(82 %) of 43 as yellow viscous product.  142                                                                                            9 Experimental Section 
 
 
Rf (Hexane/AcOEt 3/2) = 0.73. 
 
1H-NMR (250 MHz, CDCl3) δ: 1.30 (m, 6H, 3CH2); 1.56 (m, 4H, 2CH2); 2.28 (s, 
3H, CH3); 2.30 (t, J=7.3, 2H, CH2C=O); 2.82 (t, J=7.3, 2H, CH2-S), 9.50 (br. s, 1H, 
COOH). 
 
IR (KBr): 2932m, 2857w, 1707s, 1693s, 1413w, 1354w, 1280w, 1135m, 954m, 
671m, 628m cm
-1. 
 
ESI-MS m/z: calcd for C10H18O3S (M+H
+) 219.1. Found 218.7 (M+H
+). 
 
Analysis:    C10H18O3S   (218.3)   calculated: C 55.02  H 8.31. 
                                                              found: C 54.83  H 8.29. 
 
9.3.17 Thioacetic  acid  S-{7-[6-(1H-benzoimidazol-2-ylamino)-
hexylcarbamoyl]-heptyl} ester (45) 
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To a solution of 42 (1.00 g, 3.01 mmol) in MeOH (20 mL) were added 2 mL of 1 M 
HCl, the reaction was stirred at room temperature for 2 h and the solvent was 
removed under reduced pressure. The Boc hydrolysis and the formation of 44 was 9 Experimental Section                                                                                             143 
   
confirmed by NMR and ESI spectrometry, and the crude product was used for the 
next step.  
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.37 (m, 4H, 2CH2); 1.59 (m, 4H, 2CH2); 2.76 
(m, 2H, CH2 Ν); 3.43 (m, 2H, CH2N-Ar); 7.20 (m, 2H, Ar-H); 7.39 (m, 2H, Ar-H) 
8.00 (br. s, 3H, NH3); 9.21 (t, J=5.7, 1H, NH-Ar); 12.90 (br. s, 2H, 1NHAr
+). 
 
ESI-MS m/z: calcd for C13H21N4
+ (M+H
+) 233.2. Found: 232.9 (M+H
+). 
 
To a solution of 43 (1 g, 4.58 mmol) in anhydrous DMF (10 mL), were added Et3N 
(1 mL), DIC (578 mg, 4.58 mmol), HOBT (619 mg, 4.58 mmol) and the amine 
hydrochloride  44  (3.01 mmol). The reaction was stirred at room temperature for   
18 h. The solvent was evaporated by kugelrohr distillation, and the solid residue was 
purified on silica gel column chromatography (CH2Cl2/MeOH/aqueous NH3 
45/4/0.15), giving 683 mg (52 %) of 45 as pale solid. 
 
Rf (CH2Cl2/MeOH/aqueous NH3 45/4/0.15) = 0.62. 
 
1H-NMR (250 MHz, CDCl3)  δ:  1.17-1.69  (m, 18H, 9CH2); 2.19 (t,  J=5.7, 2H, 
CH2=O); 2.31 (s, 3H, CH3); 2.84 (t, J=7.3, 2H, CH2-S); 3.17 (m, 2H, CH2NC=O); 
3.39 (t, J=6.7, 2H, CH2N); 5.42 (br. s, 1H, NH-Ar); 5.96 (br. t, J=5.9, 1H, NHC=O); 
7.02 (m, 2H, Ar-H); 7.27 (m, 2H, Ar-H); 8.45 (br. s, 1H, NHAr). 
 
IR (KBr): 3417m, 3299m, 3054w, 2933s, 2858m, 1692s, 1638s, 1601s, 1586s, 
1542s, 1478m, 1462s, 1420w, 1353w, 1253m, 1207w, 1132w, 1051w, 1015w, 953w, 
753m, 728w, 629w cm
-1. 
 
ESI-MS m/z: calcd for C23H37N4O2S (M+H
+) 433.3. Found 433.2 (M+H
+). 
 
Analysis:     C23H36N4O2S (432.6)  calculated:  C 63.85  H 8.39  N 12.95. 
                                                                found:  C 63.59  H 8.36  N 13.05. 
 
M.p.: 119-120 °C. 144                                                                                            9 Experimental Section 
 
9.3.18 1-(2-Amino-phenyl)-3-(2-dimethylamino-ethyl)-thiourea (52). 
 
NH2
N
H
N
H
S
N
H2N
N
52
52
 
 
A solution of 2-dimethylaminoethylamine (1 g, 11.3 mmol) in 20 mL acetonitrile 
was added dropwise to a mixture of 1,1’-thiocarbonyldiimidazole (3.03 g, 17.0 
mmol) and imidazole (0.200 g, 2.94 mmol) in acetonitrile (30 mL) at 0 °C. The 
reaction mixture was stirred at room temperature for 1 h. 1,2-P  henylenediamine 
(1.84 g, 17.0 mmol) was dissolved in 10 mL acetonitrile and added dropwise to the 
reaction mixture. The solution was stirred at 50 °C for 4 h and at room temperature 
over night. After removal of the solvent the solid residue was purified on silica gel 
column chromatography (EtOAc/MeOH/Et3N 84/16/1), giving 1.86 g (69 %) of 52 
as pale solid. 
 
Rf (EtOAc/MeOH/Et3N 84/16/1) = 0.2. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.18 (s, 6H, 2CH3); 2.42 (t, J=6.5, 2H, CH2); 
3.53 (m, 2H, CH2NC=S); 4.83 (s, 2H, NH2); 6.55 (dt, J=7.6, J=1.4, 1H, Ar-H); 6.74 
(dd, J=7.8, J=1.0, 1H, Ar-H); 6.93-6.99 (m, 2H, Ar-H); 7.22 (s, 1H, NH); 9.00 (s, 
1H, NH-Ar). 
 
IR (KBr): 3403m, 3282m, 3250m, 3150s, 2931m, 2947m, 2823w, 2780w, 1618m, 
1543s, 1508s, 1494s, 1456m, 1317w, 1299w, 1264s, 1236s, 1172w, 1158m, 1114w, 
1063m, 1044m, 1022s, 868w, 857w, 790w, 749s, 707w, 646m, 613m, 572w cm
-1. 
 
ESI-MS m/z: calcd for C11H19N4S (M+H
+) 239.13. Found 238.7 (M+H
+). 
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Analysis:    C11H18N4S   (238.4)   calculated:  C 55.43  H 7.61  N 23.51. 
                                                              found:  C 53.83  H 7.49  N 23.02. 
                    0.4 H2O       (245.6)   calculated:  C 53.80  H 7.72  N 22.82. 
 
 
9.3.19  N'-(1H-Benzoimidazol-2-yl)-N,N-dimethyl-ethane-1,2-diamine 
(54) 
 
NH2
N
H
N
H
S
N
N
H
N H
N
N
54 52
52 54
 
 
To a refluxing solution of thiourea 52 (1.8 g, 7.55 mmol) in abs. EtOH   
(50 mL) containing a catalytic amount of sulphur, yellow HgO (3.0 g, 13.9 mmol) 
was added over 1 h in several portions. The mixture was filtered through celite and 
the solvent removed at reduced pressure. The crude material was purified by silica 
gel chromatography (CH2Cl2/MeOH/aqueous NH3 45/4/0.15). The compound was 
further crystallized from EtOAc yielding 1.4 g (91 %) of 54 as white solid. 
 
Rf (CH2Cl2/MeOH/ aqueous NH3 45/4/1 %) = 0.39. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.18 (s, 6H, 2CH3); 2.45 (t, J=6.5, 2H, CH2); 
3.38 (m, 2H, CH2); 6.34 (br. t, 1H, NH-Ar); 6.85 (m, 2H, Ar-H); 7.12 (m, 2H, Ar-H); 
10.72 (s, 1H, HNAr). 
 
13C-NMR (75 MHz, CDCl3) δ: 41.08, 45.19, 59.72, 112.19, 120.16, 138.51, 156.81. 
 
IR (KBr): 3401s, 3191m, 2940s, 2819s, 1637s, 1602s, 1465s, 1465s, 1409m, 1362m, 
1333w, 1309w, 1265s, 1186m, 1159m, 1118m, 1079w, 1059m, 1046s, 1013s, 997w, 
959w, 914w, 858m, 788w, 760m, 745s, 723m, 668w, 616w cm
-1. 146                                                                                            9 Experimental Section 
 
ESI-MS m/z: calcd for C11H17N4 (M+H
+) 205.1. Found 204.9 (M+H
+). 
 
M.p.: 147-149 °C. 
 
9.3.20  S-(2-Pyridylthio) cysteamine Dihydrochloride (58) 
 
N S
S N HS
NH2HCl
N S
S
NH2 2 HCl
58
58
 
 
Aldrithiol-2
TM (2.21 g, 10.0 mmol) was dissolved in 20 ml of methanol and 0.8 mL 
of acetic acid. Into this mixture a solution of 2-amino-ethanethiol hydrochloride (570 
mg, 5.0 mmol) in 10 ml of methanol was added over a period of 30 min. The reaction 
was stirred for 24 h at room temperature under argon. After the evaporation of the 
solvent, the oil obtained was washed twice with 20 ml of diethyl ether, the crude was 
dissolved in 5 mL of methanol, and the product precipitated twice, with 25 ml of 
diethyl ether each time, giving 868 mg (67 %) of 58 as white crystals. 
 
1H-NMR (250 MHz, MeOD-d6) δ: 3.15 (t, J=6.5, 2H, CH2); 3.30 (m, overlap with 
solvent signal, 2H, CH2) 7.34 (m, 1H, Py-H); 7.68 (m, 1H, Py-H); 7.82 (m, 1H, Py-
H); 8.56 (m, 1H, Py-H).  
 
IR (KBr): 2953s, 2911s, 1608m, 1575m, 1558m, 1449s, 1417m, 1328m, 1245w, 
1113m, 1040m, 948w, 870m, 811m, 765s, 713w cm
-1. 
 
ESI-MS m/z: calcd for C7H11N2S2 
+ (M+H
+) 187.0. Found 186.7 (M+H
+). 
 
Analysis:   C7H12Cl2N2S2   (259.2)   calculated:  C 32.43  H 4.67  N 10.81. 
                                                                  found:  C 31.35  H 4.76  N 10.47. 
                    0.5 H2O          (268.2)    calculated:  C 31.35  H 4.89  N 10.44. 9 Experimental Section                                                                                             147 
   
 
9.3.21 6-S-Trityl-6-mercapto-1-hexanol (61) 
 
61
HO
Br
HO
S HS
61
 
 
Triphenylmethyl mercaptan (2 g, 7.2 mmol) was added to a mixture of NaH (637 mg, 
60 % in mineral oil 15.9 mmol) in DMF (40 mL) at 0 °C in 30 min. It was then 
added 6-bromo-1-hexanol (1.4 g, 7.7 mmol) and the reaction was stirred at room 
temperature for 16 h. To the mixture were added 50 mL of water, and 50 mL of 
CHCl3; the extracted organic phase was washed with 3×50 mL of brine. The organic 
layer was evaporated, and the crude product purified by silica gel chromatography 
(hexane/ethyl acetate 5/1), affording 2.1 g (78 %) of 61 as colourless solid. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.09-1.37 (m, 8H, CH2); 2.09 (t, J=7.1, 2H, 
CH2-S); 3.32 (m, 2H, CH2-O); 4.29 (s, 1H, OH); 7.21-7.38 (m, 15H, Ar-H). 
 
IR (KBr): 3318m, 2931s, 2853m, 1593w, 1487m, 1440s, 1180w, 1051w, 1033w, 
753m, 742s, 699s, 625m, 506w cm
-1.  
 
Analysis: C25H28OS  (376.6)   calculated:  C 79.74  H, 7.49  O, 4.25  S, 8.52. 
                                                        found:  C 79.51  H, 7.69. 
 
M.p.: 73-75 °C. 
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9.3.22 Diisopropyl-phosphoramidous acid 2-cyano-ethyl ester 6-
tritylsulfanyl-hexyl ester (62) 
 
62
HO
S
61
Cl P
N
O
N O
S
62
P
N
O
N
61
 
 
61 (1 g, 2.7 mmol) was dissolved in 10 mL of anhydrous CH2Cl2. To this solution 
were added in the following order: diisopropylethylamine (855 μL, 5 mmol) and 2-
cyanoethoxy diisopropylchlorophosphoramidite (753 mg, 3.2 mmol). The reaction 
was stirred at room temperature under argon for 2 h. The crude material was poured 
onto 50 mL of ethyl acetate and the organic phase was washed twice with 40 mL of 
saturated NaHCO3 solution. The extracted organic layer was dried with MgSO4, the 
solvent removed under reduced pressure, and the phosphoramide was purified by 
silica gel chromatography (hexane/ethyl acetate/Et3N 5/1/1 %), giving 1.3 g (83 %) 
of 62 as colourless oil.  
 
1H-NMR (400 MHz, CD2Cl2)  δ: 1.19-1.36 (m, 16H, CH2, CH3); 1.44 (m, 2H, 
CH2βS); 1.57 (m, 2H, CH2βO); 2.19 (t, J=7, 2H, CH2S); 2.64 (t, J=6.5, 2H, CH2CN); 
3.51-3.74 (m, 4H, CH2O, CH); 3.76-3.90 (m, 2H, CH2βCN); 7.23-7.48 (m, 15H, Ar-
H). 
 
31P NMR (161.98 MHz, DMSO-d6) δ: 147.64. 
 
IR (KBr): 2965s, 2253m, 1594m, 1444s, 1363s, 1183s, 975s, 892m, 699s, 621m   
cm
-1. 
 
Analysis: C34H45N2O2PS   (576.8)  calculated:  C  70.80  H  7.86  N  4.86  O  5.55  
                                                                             P  5.37  S  5.56.  
                                                                 found: C  70.59  H  7.88  N  4.79.  9 Experimental Section                                                                                             149 
   
ESI-MS m/z: calcd for C34H46N2O2PS (M+H
+) 577.3. Found 577.4 (M+H
+), 599.3  
(M+Na
+), 615.1 (M+K
+). 
 
 
9.3.23 2-(2-{Bis-[2-(1H-benzoimidazol-2-ylamino)-ethyl]-amino}-
ethylamino)-3H-benzoimidazole-5-carboxylic acid [2-(pyridin-
2-yldisulfanyl)-ethyl]-amide (63) 
 
N
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29 (200 mg, 0.36 mmol) was refluxed in 25 mL of  HCl 6 M for 2 h, the solvent was 
removed under reduced pressure. The complete formation of 30 was confirmed by 
NMR and ESI spectrometry. The crude was used for the next step. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 3.90 (m, 6H, CH2N); 4.19 (m, 6H, CH2N); 7.28 
(m, 4H, Ar-H); 7.38 (m, 4H, Ar-H); 7.44 (m, 1H, Ar-H); 7.97 (m, 1H, Ar-H); 7.99 
(m, 1H, Ar-H). 
 
ESI-MS m/z: calcd for C28H31N10O2
+ (M+H
+) 539.3. Found 539.2 (M+H
+). 
 
To a solution of the carboxylic acid 30 (0.36 mmol) in anhydrous DMF (10 mL), 
were added Et3N (500 μL), DIC (68 mg, 0.54 mmol), HOBT (73 mg, 0.54 mmol) 150                                                                                            9 Experimental Section 
 
and 58 (104 mg, 0.47 mmol). The reaction was stirred at room temperature for 18 h. 
The solvent was evaporated by kugelrohr distillation, and the solid residue was 
purified on silica gel column chromatography (CH2Cl2/MeOH/aqueous NH3 55/4/1 
%), giving 80 mg (31 %) of 63 as pink amorphous solid. 
 
1H-NMR (250 MHz, MeOD-d6) δ: 2.87 (t, J=6, 6H, CH2N); 3.06 (t, J=6.5, 2H, 
CH2S); 3.46 (t, J=6, 6H, CH2N); 3.67 (t, J=6.5, 2H, CH2N-C=O); 6.93-7.19 (m, 9H, 
Ar-H, 1H, Py-H); 7.47 (m, 1H, Py-H); 7.59-7.83 (m, 3H, Ar-H, 1H, Py-H); 8.36 (m, 
1H, Py-H).  
 
IR (KBr): 3280s, 2965m, 1633s, 1602s, 1578s, 1464s, 1417w, 1355w, 1270m, 
1162w, 1115w, 1049w, 878w, 827w, 740m cm
-1. 
 
ESI-MS m/z: calcd for C35H39N12OS2
+ (M+H
+) 707.3. Found 707.4 (M+H
+). 
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9.3.24  Synthesis of conjugates 1000, 1001, 1002 and 1006 via 
disulfide linkage linker chemistry 
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DNA
catalyst-linker-5'GATCGGCAGTCGGCTAG3'
catalyst-linker-5'CGAGATCGGCAGTCGGCTAG3'
catalyst-linker-5'TCGGCAGTCGGCTAG3'
catalyst-linker-5'CTCCTGACAAGGTAT3'
Oligo1000
Oligo1001
Oligo1002
Oligo1006
63
 
 
The oligonucleotides were assembled on an Applied Biosystems Model 381A DNA 
synthesizer with 2-cyanoethyl phosphoramidites (Proligo) and the thio linker 
building block 62 (1 µmol scale). All subsequent steps were done manually with the 
cartridge removed from the synthesizer. To detritylate the thio linker, the support 
carrying the fully protected DNA was treated for 10 min with 1 mL of 0.1 M aqueous 
AgNO3 solution, followed by washing steps with 10 mL of H2O and finally with  
10 mL of CH3CN. Disulfide bonds were then reduced by treatment with 1 mL of 0.1 
M aqueous tris(2-carboxyethyl)phosphine (TCEP) over 10 min. Two washing steps 
with 10 mL of H2O and with 10 mL of CH3CN followed. The cartridge was now 
agitated for 12 h at room temperature with a solution of compound 63 (23.5 mg, 
0.033 mmol in 300 μL DMF), followed by washing steps with 10 mL of DMF and 
10 mL of CH3CN. Afterwards the solid phase was collected in an Eppendorf tube, 152                                                                                            9 Experimental Section 
 
treated with 1.5 mL 25 % aqueous ammonia and agitated at room temperature for  
24 h. The solution obtained was filtrated through a syringe filter (rotilabo
® PVDF 
0.22 μm), and evaporated in a Speed Vac. The crude material was dissolved in 1 mL 
of H2O, and the solution was desalted on a NAP
TM-10 column (Amersham 
Biosciences). The oligonucleotide conjugates were purified by denaturing PAGE and 
characterized by MALDI mass spectrometry. 
 
Oligo 1000 
MALDI-MS m/z: calcd. for 1000 (M+H
+) 5402. Found 5403 (M+H
+). 
 
 
 
Oligo 1001 
MALDI-MS m/z: calcd. for 1001 (M+H
+) 6044. Found 6042 (M+H
+). 
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Oligo 1002 
MALDI-MS m/z: calcd for 1002 (M+H
+) 6976. Found 6973. 
 
 
 
Oligo 1006 
MALDI-MS m/z: calcd for 1006 (M+H
+) 5345. Found 5351. 
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9.3.25  Synthesis of PNA conjugate 1011 via amino linker chemistry 
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The PNA 10mer on solid phase was purchased in a 1 µmol scale by Eurogentec with 
the C6 amino linker already deprotected. The trisbenzimidazole carboxylic acid 30 
was obtained from methyl ester 29 (25 mg, 0.045 mmol) as already reported. 
Conjugate 1012 was prepared manually in the following way: All solutions were 
pumped through the cartridge by tightly fitting two 1 mL syringes (Luer fittings) to 
each side of the column and moving the pistons alternatingly.   
(45 μmol) of carboxylic acid 30, 7.5 mg (49 μmol) N-hydroxybenztriazole mono 
hydrate and 6.2 mg (49 μmol) diisopropyl carbodiimide were dissolved in 1 mL 
DMF alkalized with three drops of NEt3. The coupling solution was thoroughly 
agitated through the cartridge with the C6-aminolinker-PNA over 5 h. The cartridge 
was then rinsed onece with DMF (10 mL) and once with CH3CN (10 mL). The 
conjugate was cleaved from the solid support by agitating a mixture of 95%TFA/m-
cresol 4:1 (200 µL, 90 min.) through the column.  9 Experimental Section                                                                                             155 
   
To the mixture collected from the resin, was added diethyl ether (5 mL) and under 
vortexing the PNA precipitated. The precipitate was washed two more times with 
diethyl ether, and dried. The mass confirmed the successful conjugation.  
 
MALDI-MS m/z: calcd for 1011 (M+H
+) 3375.41. Found 3374.65 (M+H
+). 
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9.3.26  Synthesis of conjugate 1012 via amino linker chemistry 
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The oligonucleotide was assembled in a 1 µmol scale using an Applied Biosystems 
Model 381A DNA synthesizer with 2-cyanoethyl phosphoramidites (Proligo). The 
monomethoxytrityl protected C6 amino linker (TriLink) was coupled to the 5' end of 
the DNA sequence and detritylated by the synthesizer. The trisbenzimidazole 
carboxylic acid 30 was obtained from methyl ester 29 (50 mg, 0.090 mmol) as 
already reported. Conjugate 1012 was prepared manually in the following way: All 
solutions were pumped through the CPG-cartridge by tightly fitting two 1 mL 
syringes (Luer fittings) to each side of the column and moving the pistons 
alternating. (90 μmol) of carboxylic acid 30, 13 mg (96 μmol)  N-
hydroxybenztriazole and 12 mg (95 μmol) diisopropyl carbodiimide were dissolved 
in 1 mL DMF alkalized with three drops of NEt3. The coupling solution was 
thoroughly agitated through the cartridge with the C6-aminolinker-DNA over 5 h. 
The cartridge was then rinsed once with DMF (10 mL) and once with CH3CN  
(10 mL). Afterwards the solid phase was collected in an Eppendorf tube, treated with 
1.5 mL 25 % aqueous ammonia and agitated at room temperature for 24 h. The 
solution obtained was filtrated through a syringe filter (rotilabo® PVDF 0.22 μm), 
and evaporated in a Speed Vac. The crude material was dissolved in 1 mL of H2O. 9 Experimental Section                                                                                             157 
   
After evaporation the conjugate was desalted using a NAP-10 column. The conjugate 
1012 was then purified by preparative PAGE. 
 
MALDI-MS m/z: calcd for 1012 (M+H
+) 5556.9. Found 5558.87 (M+H
+). 
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9.3.27 8-Tritylsulfanyl-octanoic acid (66) 
 
HO
O
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O
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Triphenylmethyl mercaptan (1.24 g, 4.49 mmol) was added stepwise to a mixture of 
NaH (358 mg, 60% in mineral oil 8.95 mmol) in DMF (50 mL) at 0 °C. After 30 
min. 8-bromo-octanoic acid (1.0 g, 4.48 mmol) was added. The reaction was stirred 
at room temperature for 16 h. To the mixture were added 50 mL of water and the pH 
was adjusted to 3 by treatment with HCl 6 M. 50 mL of CHCl3 were added and the 
extracted organic phase was washed with 3×50 mL of HCl (pH 2). The organic layer 
was evaporated, and the crude product purified by silica gel chromatography 
(hexane/ethyl acetate 3/1), affording 1.37 g (73 %) of 66 as colourless oil.  
 
Rf (hexane/ethyl acetate 3/2) = 0.68. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.15-1.69 (m, 10H, 5CH2); 2.16 (t, J=7.2, 2H, 
CH2); 2.34 (t, J=7.5, 2H, CH2), 7.20-7.48 (m, 15H, Ar-H). 
 
IR (KBr): 2929m, 1708s, 1595w, 1490m, 1444m, 1280w, 1082w, 1034w, 938w, 
743s, 700s, 621m cm
-1. 
 
ESI-MS m/z: calcd for C27H29O2S
- (M
-) 417.2. Found 417.2 (M
-). 
 
Analysis:    C27H30O2S   (418.6)   calculated: C 77.47  H 7.22.  
                                                              found: C 75.70  H 7.26.  
                    0.5 H2O       (427.6)   calculated: C 75.84  H 7.31.  
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9.3.28  8-Tritylsulfanyl-octanoic acid (2-hydroxy-1-hydroxymethyl-
ethyl)-amide (67) 
 
 
N
H
O
S
67
67
HO
O
S
HO
HO
66
66
 
 
To a solution of 66 (2.9 g, 6.93 mmol) in anhydrous DMF (20 mL), Et3N (2 mL ), 
DIC (1.3 g, 10.30 mmol), HOBT (1.41 g, 10.41 mmol) and 2-amino-propane-1,3-diol 
(948 mg, 10.44 mmol) were added. The reaction was stirred at room temperature for 
18 h. The solvent was removed by kugelrohr distillation, and the solid residue was 
purified on silica gel column chromatography, eluting with a gradient ethylacetate → 
ethylacetate / MeOH 95/5. To remove traces of DMF, the material was dissolved in 
CH2Cl2 (100 mL) and washed with brine (100 mL). The organic layer was dried over 
MgSO4 and the solvent removed under reduced pressure yielding 2.05 g (60 %) of 67 
as a white solid compound. 
 
Rf (AcOEt / MeOH 95/5) = 0.48. 
 
1H-NMR (400 MHz, CD3CN) δ: 1.09-1.24 (m, 6H, 3CH2); 1.33 (m, 2H, CH2); 1.49 
(m, 2H, CH2); 2.08-2.13 (m, 4H, CH2-C=O, CH2-S); 3.08 (br. s, 2H, OH); 3.53 (m, 
4H, CH2-O); 3.79 (m, 1H, CH); 6.34 (d, J=5.76, 1H, NH); 7.21-7.43 (m, 15H, Ar-H). 
 
13C-NMR (63 MHz, CDCl3) δ: 25.97, 28.89, 29.25, 29.36, 32.23, 36.92, 62.93, 
66.70, 126.89, 127.28, 128.17, 129.95, 130.48, 145.50, 174.64. 
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IR (KBr): 3405s, 3057w, 2927m, 2854w, 1638s, 1543m, 1490m, 1444m, 1364w, 
1036m, 973w, 743s, 700s, 676s, 622s cm
-1. 
 
ESI-MS m/z: calcd for C30H37NO3S-Na
+ (M+Na
+) 514.2. Found 514.5 (M+Na
+). 
 
Analysis:     C30H37NO3S  (491.68)   calculated: C 73.28  H 7.58  O 2.85. 
                                                                   found: C 63.34  H 6.99  O 2.31. 
                      1.2 CH2Cl2    (593.61)   calculated: C 63.13  H 6.69  O 2.36. 
 
 
9.3.29 (R,S)-8-Tritylsulfanyl-octanoic acid {1-[bis-(4-methoxy-
phenyl)-phenyl  methoxymethyl]-2-hydroxy-ethyl}-amide (rac-
68) 
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67  (1.38 g, 2.81 mmol) was dried by three co-evaporations with pyridine and 
dissolved in anhydrous pyridine (15 ml). Dimethoxytritylchloride (952 mg, 2.81 
mmol) was added under argon atmosphere and stirred at room temperature for 2 h. 
The mixture was poured on water and extracted twice with dichloromethane, dried 
over MgSO4 and evaporated. The crude material was purified by silica gel column 
chromatography (hexane/ethyl acetate 3/2), yielding 914 mg (41 %) of rac-68 as a 
white solid compound. 
 
Rf (hexane/ethyl acetate, 1/1) = 0.36. 9 Experimental Section                                                                                             161 
   
 
1H-NMR (400 MHz, DMSO-d6) δ: 1.02-1.16 (m, 6H, CH2); 1.24 (m, 2H, CH2); 1.42 
(m, 2H, CH2); 2.04 (m, 4H, CH2-S, CH2-C=O); 2.95 (m, 2H, CH2OC); 3.43 (m, 2H, 
CH2O); 3.71 (s, 6H, 2CH3); 3.99 (m, 1H, CH); 4.58 (t, J=5.4, 1H, OH); 6.83-6.86 (m, 
4H, Ar-H); 7.07-7.38 (m, 24H, Ar-H); 7.56 (d, J=8.6, 1H, NH). 
 
IR (KBr): 3422m, 3056w, 2928m, 2854w, 1654s, 1608m, 1508s, 1461w, 1444m, 
1302w, 1250s, 1176m, 1155w, 1115w, 1082w, 1033m, 828m, 744w, 727w, 700m, 
617w, 584w cm
-1. 
 
Analysis:    C51H55NO5S   (794.1)   calculated: C 77.14  H 6.98  N 1.76. 
                                                                 found: C 76.95  H 6.98  N 1.59. 
 
M.p.: 44-45 °C. 
 
9.3.30 Diisopropyl-phosphoramidous acid 3-[bis-(4-methoxy-
phenyl)-phenyl-methoxy]-2-(8-tritylsulfanyl-octanoylamino)-
propyl ester 2-cyano-ethyl ester (71) (mixture of 
stereoisomers) 
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68  (914 mg, 1.15 mmol) was dried by three co-evaporations with pyridine and 
dissolved in 20 mL of anhydrous CH3CN. To this solution were then added: 
diisopropylethylamine (600 μL, 3.47 mmol) and then 2-cyanoethoxy-N,N-
diisopropylphosphoramidochloride (330 mg, 1.4 mmol). The reaction was stirred at 162                                                                                            9 Experimental Section 
 
room temperature under argon for 2 h. The crude material was poured onto ethyl 
acetate and the organic phase was washed twice with saturated NaHCO3 solution. 
The organic layer was dried over MgSO4, the solvent removed at reduced pressure, 
and the phosphoramidite was purified by silica gel chromatography (hexane/ethyl 
acetate/Et3N 3/1/1%), giving 537 mg (47 %) of 71 as a white solid. 
 
Rf (hexane/ethyl acetate/Et3N 1/1/1%) = 0.83. 
 
1H-NMR (400 MHz, CD3CN) δ: 1.06-1.20 (m, 18H, dCH3, kCH2, lCH2, mCH2,); 
1.30 (m, 2H, jCH2); 1.46 (m, 2H, 2-nCH2); 2.04-2.10 (m, 4H, iCH2, oCH2); 2.54-2.58 
(m, 2H, gCH2); 3.07-3.16 (m, 2H, aCH2); 3.48-3.60 (m, 2H, eCH); 3.63-3.73 (m, 4H, 
cCH2, fCH2); 3.75 (s, 6H, OCH3); 4.12-4.24 (m, 1H, bCH); 6.23-6.29 (2d, J=8.8, 1H, 
hNH); 6.78-6.86 (m, 4H, Ar-H); 7.12-7.44 (m, 24H, Ar-H). 
 
31P NMR (162 MHz, DMSO-d6) δ: 146.71, 147.04. 
 
IR (KBr): 3422m, 3056w, 2928s, 2252w, 1654s, 1608m, 1578w, 1508s, 1459w, 
1444w, 1364w, 1301w, 1250s, 1178s, 1126w, 1081m, 1033s, 976m, 899w, 828m, 
790w, 743m, 700s, 616w, 583w cm
-1. 
  
Analysis:    C60H72N3O6PS   (994.3)   calculated: C 72.48  H 7.30  N 4.23.  
                                                                    found: C 72.31  H 7.48  N 3.96. 
 
9.3.31 3-Tritylsulfanyl-propionic acid (69) 
 
 69
HO Br
O
HO S
O
 69
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Triphenylmethyl mercaptan (3.63 g, 13.1 mmol) was added stepwise to a mixture of 
NaH (1.21 g, 60% in mineral oil, 30.3 mmol) in DMF (50 mL) at 0 °C. After 30 min 
3-bromo-propionic acid (2 g, 13.1 mmol) was added and  the reaction was stirred at 
room temperature for 16 h. To the mixture were added 50 mL of water and the pH 
was adjusted to pH 3 with 6 M HCl. 50 mL of CHCl3 were added and the extracted 
organic phase was washed with 3×50 mL of HCl (pH 2). The organic layer was 
evaporated, the crude product dissolved in 150 mL of CHCl3 and 200 mL of hexane 
were added. The precipitate formed was collected by filtration yielding 3.86 g (85 %) 
of 69 as a white powder. 
 
Rf (ethyl acetate) = 0.65. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.13-2.32 (m, 4H, CH2C=O, CH2S); 7.02-7.66 
(m, 15H, Ar-H); 12.23 (br. s, 1H COOH). 
 
IR (KBr): 3031w, 2912w, 1705s, 1592w, 1488m, 1448m, 1431m, 1408w, 1342w, 
1253s, 1032w, 958m, 747s, 702s, 620w cm
-1. 
 
ESI-MS m/z: calcd for C22H19O2S
- (M
-) 347.1. Found 347.1 (M
-). 
 
Analysis:    C22H20O2S   (348.5)   calculated: C 75.83  H 5.79. 
                                                              found: C 75.63  H 5.82. 
 
M.p.: 203-204 C. 
 
 
9.3.32  N-(2-Hydroxy-1-hydroxymethyl-ethyl)-3-tritylsulfanyl-
propionamide (73) 
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To a solution of 69 (2 g, 5.7 mmol) in anhydrous DMF (20 mL), Et3N (2 mL ), DIC 
(869 mg, 6.9 mmol), HOBT×H2O (1.06 mg, 6.9 mmol) and 2-amino-propane-1,3-
diol (628 mg, 6.9 mmol) were added. The mixture was stirred at room temperature 
for 18 h. The solvent was removed by kugelrohr distillation, and the solid residue 
was purified on silica gel column chromatography (gradient ethylacetate → 
ethylacetate / MeOH 95/5), yielding 1.53 g (63 %) of 73 as a white solid compound. 
 
Rf (ethyl acetate/MeOH 95/5) = 0.53. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.20 (m, 4H, CH2S, CH2C=O); 3.35 (m, 4H, 
CH2O); 3.59-3.71 (m, 1H, CH); 4.57 (t, J=5.5, 2H, OH); 7.21-7.38 (m, 15H, Ar-H); 
7.52 (d, J=8.1,1H, NH). 
 
13C-NMR (63 MHz, DMSO-d6) δ: 169.90, 144.44, 129.04, 127.99, 126.67, 65.88, 
60.04, 52.85, 33.86, 27.43. 
 
IR (KBr): 3382s, 3310s, 3064w, 2937w, 1654s, 1560m, 1490w, 1441w, 1279m, 
1069w, 1030w, 1001w, 754m, 744m, 701s, 676w, 625m cm
-1. 
 
MALDI-MS m/z: calcd for C25H27NNaO3S
+ (M+Na
+) 444.2. Found 445.9 (M+Na
+). 
 
Analysis:     C25H27NO3S  (421.55)   calculated: C 71.23  H 6.46  N 3.32. 
                                                                  found: C 68.87  H 6.48  N 3.02. 
                         0.8 H2O    (435.97)   calculated: C 68.87  H 6.61  N 3.21. 
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9.3.33 (R,S)-N-{1-[Bis -(4-methoxy-phenyl) -phenyl-methoxymethyl] 
2-hydroxy-ethyl} -3-tritylsulfanyl-propionamide (rac-74) 
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73 (1 g, 2.37 mmol) was dried by three co-evaporations with pyridine and dissolved 
in anhydrous pyridine (15 mL). Dimethoxytritylchloride (883 mg, 2.61 mmol) was 
added under argon atmosphere and stirred at room temperature for 2 h. The mixture 
was poured on water and the organic phase was extracted twice with 
dichloromethane, dried over MgSO4 and concentrated. The crude material was 
purified by silica gel column chromatography (hexane/ethyl acetate 3/2), yielding 
739 mg (43 %) of 74 as white solid compound. 
 
Rf (hexane/ethyl acetate 3/2) = 0.46. 
 
1H-NMR (400 MHz, CDCl3) δ: 1.96 (t, J=7.3, 2H, CH2C=O); 2.51 (t, J=7.3, 2H, 
CH2S); 2.70 (m, 1H, OH); 3.28 (m, 2H, CH2OC); 3.59-3.81 (m, 2H, CH2O); 3.77 (s, 
6H, OCH3); 4.02 (m, 1H, CH); 5.83 (d, J=7.6, 1H, NH); 6.80-6.83 (m, 4H, Ar-H); 
7.17-7.44 (m, 24H, Ar-H). 
 
13C-NMR (63 MHz, DMSO-d6) δ: 27.44, 34.02, 50.92, 54.96, 60.69, 62.49, 65.90, 
85.06, 113.03, 126.48, 126.64, 127.68, 127.96, 129.04, 129.67, 135.35, 135.80, 
144.44, 145.07, 157.94, 169.80. 
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IR (KBr): 3406m, 3056w, 2931w, 2834w, 1654s, 1607m, 1508s, 1444m, 1301w, 
1250s, 1176s, 1081m, 1033s, 829s, 744m, 701s, 617w, 584w cm
-1. 
 
ESI-MS m/z: calcd for C46H45NNaO5S
+ (M+Na
+) 746.3. Found 746.2 (M+Na
+). 
 
Analysis:     C46H45NO5S  (723.9)   calculated: C 76.32  H 6.27  N 1.93.  
                                                                 found: C 76.04  H 6.34  N 1.75. 
 
9.3.34 Diisopropyl-phosphoramidous acid 3-[bis-(4-methoxy-
phenyl)-phenyl-methoxy]-2-(3-tritylsulfanyl-propionylamino)-
propyl ester 2-cyano-ethyl ester (75) (mixture of 
stereoisomers) 
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74  (700 mg, 0.97 mmol) was dried by three co-evaporations with pydidine and 
dissolved in 20 mL of anhydrous CH3CN. To this solution were added: 
diisopropylethylamine (600 μL, 3.47 mmol) and then 2-cyanoethoxy-N,N-
diisopropylphosphoramidochloride (274 mg, 1.16 mmol). The reaction was stirred at 
room temperature under argon for 2 h. The crude material was poured onto ethyl 
acetate and the organic phase was washed twice with saturated NaHCO3 solution. 
The organic layer was dried over MgSO4, the solvent removed by reduced pressure. 
The purification by silica gel chromatography (hexane/ethyl acetate/Et3N 2/1/1 %), 
yielded 537 mg (60 %) of 75 as white solid. 
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Rf (hexane/ethyl acetate/Et3N 2/1/1%) = 0.55. 
 
1H-NMR (400 MHz, DMSO-d6) δ: 1.00-1.16 (m, 12H, CH3); 2.16-2.28 (m, 4H, 
CH2S, CH2C=O); 2.60-2.68 (m, 2H, CH2CN); 2.92-3.03 (m, 2H, CH2OC); 3.42-3.55 
(m, 2H, CH-Isoprop); 3.60 (m, 2H, CH2βCN); 3.71 (s, 6H, OCH3); 4.03-4.14 (m, 1H, 
CH-NC=O); 6.80-6.88 (m, 4H, Ar-H); 7.17-7.37 (m, 24H, Ar-H); 7.78-7.82 (2d, 
J=5.2, 1H, NH). 
 
31P NMR (162 MHz, DMSO-d6) δ: 149.30, 149.52. 
 
IR (KBr): 3423m, 3057w, 2965s, 2252w, 1676m, 1654m, 1608m, 1560w, 1508s, 
1459w, 1444m, 1364w, 1301m, 1301m, 1250s, 1178s, 1155w, 1126w, 1081m, 1033s, 
977m, 878w, 829m, 790w, 744m, 701s, 617w, 583w cm
-1. 
 
ESI-MS m/z: calcd for C55H63N3O6PS
+ (M+H
+) 924.4, C55H62N3NaO6PS
+ (M+Na
+) 
946.4. Found 924.2 (M+H
+), 946.4 (M+Na
+). 
 
Analysis:     C55H62N3O6PS  (924.14)   calculated: C 71.48  H 6.76  N 4.55. 
                                                                      found: C 71.20  H 6.85  N 4.32. 
 
9.3.35  N-[3-(1-{5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-
hydroxy-tetrahydro-furan-2-yl}-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidin-5-yl)-prop-2-ynyl]-3-tritylsulfanyl-propionamide (70) 
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To a solution of 69 (522 mg, 1.50 mmol) in anhydrous DMF (20 mL), Et3N  
(0.5 mL), (DIC 189.3 mg, 1.5 mmol), HOBT (202.7 mg, 1.50 mmol) and amino 
derivative (800 mg, 1.37 mmol) were added. The reaction was stirred at room 
temperature for 18 h. The solvent was removed by kugelrohr distillation, and the 
solid residue was purified by silica gel column chromatography (ethyl acetate), 
yielding 639 mg (51 %) of 70 as white foam. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.27. 
 
1H-NMR (400 MHz, CD3CN) δ: 2.01 (t, J=7.3, 2H, CH2-C-S); 2.25-2.34 (m, 4H, 
CH2S, 2’-H); 3.16-3.34 (m, 2H, 5’-H); 3.48 (d, J=4.3, 1H, OH); 3.74 (s, 3H, OCH3); 
3.75 (s, 3H, OCH3); 3.78 (dd, J=5.3, J=2.4, 2H, CH2C≡C); 3.98 (m, 1H, 4’-H); 4.46-
4.52 (m, 1H, 3’-H); 6.11 (m, 1H, 1’-H); 6.20 (br. t, 1H, NHC=O); 6.85-6.89 (m, 4H, 
Ar-H); 7.19-7.46 (m, 24H, Ar-H); 7.94 (s,1H, 6-H); 9.25 (s, 1H, 3-NH). 
 
IR (KBr): 3412m, 3058w, 2932w, 1686s, 1608m, 1560w, 1508s, 1458m, 1444m, 
1281m, 1250s, 1177m, 1090w, 1033m, 829w, 744w, 701s, 618w, 585w cm
-1. 
 
ESI-MS m/z: calcd. for C55H50N3O8S- (M
-) 912.3, C55H55N4O8S
+ (M+NH4
+) 931.4, 
C55H51N3NaO8S
+ (M+Na
+) 936.3. Found 912.4 (M
-), 931.4 (M+NH4
+), 936.3 
(M+Na
+). 
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Analysis:  C55H51N3O8  (914.07)   calculated: C 72.27  H 5.62  N 4.60. 
                                                               found: C 71.19  H 5.78  N 4.18. 
    0.7 ethyl acetate        (975.77)   calculated: C 71.15  H 5.85  N 4.31. 
 
9.3.36 Diisopropyl-phosphoramidous acid 2-[bis-(4-methoxy-
phenyl)-phenyl-methoxymethyl]-5-{2,4-dioxo-5-[3-(3-
tritylsulfanyl-propionylamino)-prop-1-ynyl]-3,4-dihydro-2H-
pyrimidin-1-yl}-tetrahydro-furan-3-yl ester 2-cyano-ethyl ester 
(72) (Mixture of diastereoisomers) 
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70 (447 mg, 0.49 mmol) was dissolved in 10 mL of anhydrous CH2Cl2. To this 
solution were then added: diisopropylethylamine (500 μL, 2.9 mmol) and then   
2-cyano-N,N-diisopropylphosphoramidochloride (174 mg, 0.74 mmol). The reaction 
was stirred at room temperature under argon for 2 h. The crude material was poured 
onto ethyl acetate (150 mL) and the organic phase was washed twice with saturated 
NaHCO3 solution and the organic layer was dried over MgSO4. The solvent was 
removed under reduced pressure, and the phosphoramidite was purified by silica gel 
chromatography (hexane/ethyl acetate 4/1), giving 323 mg (59 %) of 72 as white 
foam. 
 
1H-NMR (400 MHz,CD3CN) δ: 1.05-1.18 (m, 12H, CH3
iprop); 1.99 (m, 2H, CH2-
C-S); 2.29 (m, 2H, CH2S); 2.33-2.51 (m, 2H, 2’-H); 2.59 (m, 2H, CH2CN); 3.23-3.37 
(m, 2H, 5’-H); 3.52-3.79 (m, 12H, 2CH 
iprop, CH2OP, 2OCH3, CH2C≡C); 4.10-4.15 
(m, 1H, 4’-H); 4.58-4.67 (m, 1H, 3’-H); 6.07 (br. m, 1H, NHC=O); 6.09-6.15 (m, 1H, 170                                                                                            9 Experimental Section 
 
1’-H); 6.85-6.89 (m, 4H, Ar-H); 7.10-7.46 (m, 24H, Ar-H); 7.95 (2s, 1H, 6-H); 9.00 
(br. s, 1H, 3-NH). 
 
31P-NMR (161.98 MHz, CD3CN) δ: 148.176, 149.184. 
 
9.3.37  Synthesis of conjugates 1004, 1007 and 1008 via thio linker 
chemistry 
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5'AGATCGGC-Linker-Catalyst-CGGCTAG3'
5'GAGATCGG-Linker-Catalyst-TCGGCTAG3'
5'GAGATCGG-Linker-Catalyst-TCGGCTAG3'
 
 
The oligonucleotides were assembled on an Applied Biosystems Model 381A DNA 
synthesizer with 2-cyanoethyl phosphoramidites (Proligo) and the thio linker 9 Experimental Section                                                                                             171 
   
building blocks 71,  72 or 75 (1 µmol scale). All subsequent steps were done 
manually with the cartridge removed from the synthesizer. To detritylate the thio 
linker, the support carrying the fully protected DNA was treated for 10 min. with 1 
mL of 0.1 M aqueous AgNO3 solution, followed by washing steps, first with 10 mL 
of H2O and then with 10 mL of CH3CN. Disulfide bonds were then reduced by 
treatment with 1 mL of 0.1 M aqueous tris(2-carboxyethyl)phosphine (TCEP) over 
10 min. Two washing steps, first with 10 mL of H2O and then with 10 mL of CH3CN 
followed. The cartridge was now agitated for 12 h at room temperature with a 
solution of compound 63 (23.5 mg, 0.033 mmol, in 300 μL DMF), followed by 
washing steps with 10 mL of DMF and 10 mL of CH3CN. Afterwards the solid phase 
was collected in an Eppendorf tube, treated with 1.5 mL 25 % aqueous ammonia and 
agitated at room temperature for 24 h. The solution obtained was filtrated through a 
syringe filter (rotilabo® PVDF 0.22 μm), and evaporated in a Speed Vac. The crude 
material was dissolved in 1 mL of H2O, and the solution was desalted on a NAP
TM-
10 column (Amersham Biosciences). The oligonucleotide conjugates were purified 
by denaturing PAGE and characterized by MALDI mass spectrometry. 
 
MALDI-MS m/z: calcd for oligo 1004 (M+H
+) 5646. Found 5645.22 (M+H
+). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2825.14
2894.99
5499.68
5561.39
5645.22
5715.45
5785.21
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MALDI-MS m/z: calcd for oligo 1007 (M+H
+) 5784.1. Found 5782.6 (M+H
+). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MALDI-MS m/z: calcd for oligo 1008 (M+H
+) 5854.3. Found 5866.7. 
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9.3.38 4-Benzyloxycarbonylamino-butyric acid (76) 
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To a solution of 4-amino-butyric acid (2 g, 19.4 mmol) dissolved in 40 mL of 3 N 
NaOH at 0 °C, 2.73 mL (19.4 mmol) of benzyl chloroformate were added. The 
reaction mixture was stirred at room temperature for 2 h, then neutralized by adding 
6 M aqueous HCl solution until pH 2. The protected amino acid was extracted with a 
1:1 mixture of ether and ethyl acetate. The organic layer was dried over MgSO4, 
filtered and evaporated to give 4.05 g (88 %) of 76 as a white solid product. 
 
Rf (ethyl acetate) = 0.68. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.63 (m, 2H, CH2β); 2.22 (t, J=7.4, 2H, CH2α); 
3.01 (m, 2H, CH2γ); 5.01 (s, 2H, OCH2); 7.26-7.38 (m, 6H, NH, Ar-H); 12.05 (s, 1H, 
COOH). 
 
IR (KBr): 3332m, 3061w, 2922w, 1689s, 1547s, 1499w, 1453m, 1427w, 1414w, 
1364w, 1316w, 1272s, 1211m, 1185w, 1144w, 1103w, 1077w, 1019m, 908w, 868w, 
780w, 749m, 722m, 698m, 620w, 574w cm
-1. 
 
MALDI-MS m/z: calcd for C12H15NNaO4
+ (M+Na
+)  260.09. Found 260.04 
(M+Na
+). 
 
Analysis:     C12H15NO4  (237.25)   calculated: C 60.75  H 6.37  N 5.90. 
                                                                found: C 60.86  H 6.61  N 6.09. 174                                                                                            9 Experimental Section 
 
 
M.p.: 58-59 °C. 
 
9.3.39 4-Benzyloxycarbonylamino-butyric acid tert-butyl ester (77) 
 
N
H
OH
O
O
O
76 77
N
H
O
O
O
O
77 76
 
 
To a solution of 76 (1 g, 4.22 mmol) in DCM (50 mL), were added in the following 
order: t-butanol (938 mg, 12.7 mmol), DMAP (51 mg, 0.42 mmol) and DCC (1 g, 
4.85 mmol). The reaction was stirred at room temperature for 18 h. The mixture was 
filtrated and the solution washed with 2×50 mL of H2O, 2×50 mL of 1N HCl, 2×50 
mL of 5 % NaHCO3 solution. The organic phase was dried over Na2SO4, the solvent 
was evaporated in vacuo, and the residue product was purified by silica gel 
chromatography (hexane/ethyl acetate 4/1), giving 800 mg (65 %) of 77 as colourless 
oil. 
 
Rf (hexane/ethyl acetate 5/1) = 0.30. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 1.39 (s, 9H, CH3); 1.63 (m, 2H, CH2β); 2.20 (t, 
J=7.4, 2H, CH2α); 3.01 (m, 2H, CH2γ); 5.02 (s, 2H, OCH2); 7.27 (br. t, 1H, NH); 
7.29-7.38 (m, 5H, Ar-H). 
 
13C-NMR (63 MHz, CDCl3) δ: 25.19, 28.36, 32.78, 40.47, 66.56, 80.45, 128.04, 
128.28, 128.47, 136.61, 156.45, 172.58. 
 
IR (film): 3345m, 2977m, 2935m, 1726s, 1702s, 1534m, 1456m, 1367m, 1253s, 
1154s, 1090w, 1025w, 845w, 777w, 752w, 697m cm
-1. 
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Analysis:     C16H23NO4  (293.36)   calculated: C 65.51  H 7.90  N 4.77. 
                                                                found: C 65.32  H 7.77  N 4.64. 
 
 
9.3.40 4-Amino-butyric  acid  tert-butyl ester (78)
[145] 
 
77 78
H2N
O
O
78
N
H
O
O
O
O
77
HCl
 
 
To a solution of 77 (543.6 mg, 1.85 mmol) in 10 mL of MeOH and 1 mL of 
CH3COOH, 15% w/w of Pd/C (150 mg) was added. The reaction mixture was 
hydrogenated at normal pressure for 4 h at room temperature. The catalyst was 
removed by filtration, and the clear solution was evaporated. 50 mL of 0.5 M HCl 
were added to the residue and the solution washed with a mixture of hexan:ether 1:1 
(2×50 mL). The pH was then adjusted to 10 with aqueous ammonia. The product was 
then extracted with a mixture of 2-propanol:chloroform 1:3 (3×50 mL), the organic 
layer was dried over Na2SO4, and evaporated. The crude product was used for the 
further step.  
 
1H-NMR (250 MHz, MeOD) δ: 1.42 (s, 9H, CH3); 1.86 (m, CH2β); 2.34 (t, J=7.2, 
2H, CH2α); 2.91 (m, 2H, CH2γ). 
 
MALDI-MS m/z: calcd for C8H18NO2
+ (M+H
+) 160.1. Found 159.8 (M+H
+). 
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9.3.41 4-{[2-(2-{Bis-[2-(1H-benzoimidazol-2-ylamino)-ethyl]-amino}-
ethylamino)-1H-benzoimidazole-5-carbonyl]-amino}-butyric 
acid tert-butyl ester (79) 
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Methyl ester 29 (270 mg, 0.49 mmol) was refluxed in 25 mL of  HCl 6 M for 2 h, the 
solvent was removed under reduced pressure. The ester hydrolysis was confirmed by 
NMR and ESI spectrometry, and the crude product was used for the next step. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 3.90 (m, 6H, CH2N); 4.19 (m, 6H, CH2N); 7.28 
(m, 4H, Ar-H); 7.38 (m, 4H, Ar-H); 7.44 (m, 1H, Ar-H); 7.97 (m, 1H, Ar-H); 7.99 
(m, 1H, Ar-H). 
 
ESI-MS m/z: calcd for C28H31N10O2
+ (M+H
+) 539.3. Found 539.2 (M+H
+). 
 
To a solution of 30 (0.49 mmol) in anhydrous DMF (10 mL), were added Et3N  
(500 μL), DIC (125 mg, 0.99 mmol), HOBT×H2O (150 mg, 0.98 mmol) and 78 (194 
mg, 0.99 mmol). The reaction was stirred at room temperature for 18 h. The solvent 
was evaporated by kugelrohr distillation, and the solid residue was purified on silica 9 Experimental Section                                                                                             177 
   
gel column chromatography (CH2Cl2/MeOH/aqueous NH3 55/4/1), giving 183 mg 
(55 %) of 79 as a pink amorphous solid. 
 
Rf (CH2Cl2/MeOH/NH3 55/4/1%) = 0.23. 
 
1H-NMR (250 MHz, MeOD-d4) δ: 1.43 (s, 9H, CH3); 1.87 (m, 2H, CH2β); 2.32 (t, 
J=7.3, 2H, CH2α); 2.86 (m, 6H, CH2-N-Ar); 3.39 (m, 2H, CH2γ); 3.45 (m, 6H, CH2-
C-N-Ar); 6.91 (m, 4H, Ar-H); 7.10 (m, 5H, Ar-H); 7.43 (dd, J=8.3, J=1.4, 1H, Ar-
H); 7.58 (d, J=1.4, 1H, Ar-H). 
 
IR (KBr): 3384m, 3058w, 2974w, 2922w, 1636s, 1628s, 1603s, 1578s, 1465m, 
1364w, 1271m, 1157m, 741m cm
-1. 
 
ESI-MS m/z: calcd for C36H46N11O3
+ (M+H
+) 680.4. Found 680.4 (M+H
+). 
 
9.3.42 4-{[2-(2-{Bis-[2-(1H-benzoimidazol-2-ylamino)-ethyl]-amino}-
ethylamino)-1H-benzoimidazole-5-carbonyl]-amino}-butyric 
acid (80) 
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To a solution of 79 (100 mg, 0.147 mmol) in THF (4 mL) was added 0.5 M HCl (20 
mL). The mixture was stirred at 70 °C for 3 h. The solvent was removed under 
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ESI spectrometry confirmed the ester hydrolysis and the crude product was used for 
the next step (expected to be done by a cooperation partner). 
 
1H-NMR (250 MHz, MeOD-d4) δ: 1.90 (m, 2H, CH2β); 2.40 (t, J=7.5, 2H, CH2α); 
3.40 (t, J=6.4, 2H, CH2γ); 3.80 (br. m, 6H, CH2-N-Ar); 4.11 (br. m, 6H, CH2-C-N-
Ar); 7.21-7.34 (m, 8H, Ar-H); 7.37 (br. d, J=8.2, 1H, Ar-H); 7.71 (br. dd, J=8.2, 
J=1.4, 1H, Ar-H); 7.79 (br. d, 1H, Ar-H). 
 
ESI-MS m/z: calcd. for C32H38N11O3
+ (M+H
+) 624.3. Found 624.3 (M+H
+). 
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9.3.43 9-(2’,3’,5’-tri-O-acetyl-  β-D-ribofuranosil)-2-amino-6-oxopurine 
(81) 
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To a mixture of pyridine (37 mL) and acetic anhydride (47 mL, 497.7 mmol), in abs. 
DMF (60 mL), guanosine (20 g, 70.6 mmol) was added under an atmosphere of 
argon. The mixture was stirred for 5 h at 75 °C. The solvent was evaporated under 
reduced pressure, and the solid residue was purified by crystallization from 200 mL 
of isopropanol, giving 22.9 g (79 %) of 81 as a white solid. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.25. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.03 (s, 3H, CH3); 2.04 (s, 3H, CH3); 2.11 (s, 
3H, CH3); 4.22-4.40 (m, 3H, 4’-H, 5’-H); 5.49 (m, 1H, 3’-H); 5.79 (t, J=6.1, 1H, 2’-
H); 5.98 (d, J=6.0, 1H, 1’-H); 6.53 (br. s, 2H, NH2); 7.93 (s, 1H, 8-H); 10.72 (s, 1H, 
N-H). 
 
IR (KBr): 3464m, 3312m, 3196s, 3033w, 2936m, 2852w, 2734m, 2288w, 1747s, 
1700s, 1633s, 1597m, 1538m, 1485s, 1418m, 1373s, 1227s, 1171m, 1092w, 1050m, 
10189w, 958w, 910m, 859w, 809w, 783m, 736w, 678m, 638w, 603w cm
-1. 
 
ESI-MS m/z: calcd for C16H20N5O8
+ (M+H
+) 410.1. Found 409.9 (M+H
+). 180                                                                                            9 Experimental Section 
 
 
Analysis:    C16H19N5O8   (409.35)   calculated: C 46.95  H 4.68  N 17.11. 
                                                                  found: C 46.87  H 4.77  N 16.99. 
 
M.p.: 229-230 °C. Lit. [146]: 230-233 °C. 
 
 
9.3.44 9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosil)-2-amino-6-
chloropurine (82) 
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To a suspension of 81 (14.9 g, 36.4 mmol) in dry CH3CN (200 mL), were added in 
the following order: anhydrous Et4NCl (12.1 g, 73.0 mmol), N,N-Dimethylaniline 
(4.41 g, 36.4 mmol) and POCl3 (16.5 g, 107.6 mmol). The mixture was stirred at 100 
°C (at reflux) for 20 minutes. The solvent was evaporated under reduced pressure. 
The solid residue was dissolved in 200 mL of CH2Cl2, poured on water and the 
organic phase was extracted with dichloromethane (2×50 mL). The collected organic 
phases were washed with a saturated solution of NaHCO3 (3×100 mL), dried over 
MgSO4 and evaporated. The solid residue was purified by crystallization from 200 
mL of i-PrOH, giving 11.7 g (75 %) of 82 as a white solid. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.50. 9 Experimental Section                                                                                             181 
   
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.04-2.05 (2s, 6H, 2’+3’ CH3); 2.12 (s, 3H, 5’ 
CH3); 4.26–4.43 (m, 3H, 4’-H, 5’-H); 5.53 (m, 1H, 3’-H); 5.87 (t, J=5.9, 1H, 2’-H); 
6.10 (d, J=5.9, 1H, 1’-H); 7.06 (s, 2H, NH2); 8.36 (s, 1H, 8-H). 
 
IR (KBr): 3444s, 3312s, 3209s, 2922w, 1732s, 1635s, 1613s, 1557s, 1521m, 1484s, 
1409s, 1377s, 1323m, 1249s, 1215s, 1144m, 1103w, 1047s, 997m, 939w, 907s, 805s, 
784s, 740s, 729m, 643m, 597m, 572w cm
-1. 
 
ESI-MS m/z: calcd for C16H19ClN5O7
+ (M+H
+) 428.1. Found 427.9 (M+H
+). 
 
Analysis:    C16H18ClN5O7   (427.80)   calculated: C 44.92  H 4.24  N 16.37. 
                                                                      found: C 44.88  H 4.37  N 16.23. 
 
M.p.: 152-153 °C. Lit. [146]: 152-153 °C. 
 
9.3.45 2-Amino-6-[(4-methylphenyl)thio]-9-(2,3,5-tri-O-acetyl-β-D-
ribofuranosyl)purine (83) 
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To a solution of 82 (3 g, 6.98 mmol) in DMF (30 mL) were added toluene-4-thiol 
(1.75 g, 14.1 mmol) and Et3N (2.1 mL, 15 mmol). The mixture was heated at 100 °C 
and stirred for 1 h. The solvent was evaporated under reduced pressure, and the solid 
residue was purified by crystallization from 30 mL of EtOH giving 3.15 g (88 %) of 
the compound 83 as white crystals. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.80. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.03 (s, 6H, 2 CH3); 2.12 (s, 3H, CH3); 2.35 (s, 
3H, Ar-CH3); 4.25-4.45 (m, 3H, 4’-H, 5’-CH2); 5.55 (dd, J=3.7, J=5.8, 1H, 3’H); 
5.87 (t, J=5.9, 1H, 2’-H); 6.09 (d, J=6.0, 1H, 1’-H); 6.45 (s, 2H, NH2); 7.27 (d, 
J=8.3, 2H, o-Phenyl-H); 7.48 (d, J=8.1, 2H, m-Phenyl-H); 8.22 (s, 1H, 8-H). 
 
IR (KBr): 3451s, 3325s, 3206s, 2885m, 1910w, 1753s, 1619s, 1592s, 1556s, 1506s, 
1466s, 1402s, 1370s, 1318m, 1259s, 1025s, 990s, 910m, 799m cm
-1. 
 
ESI-MS m/z: calcd for C23H26N5O7S
+ (M+H
+) 516.2. Found 515.9 (M+H
+). 
 
Analysis:    C23H25N5O7S   (515.54)   calculated: C 53.58  H 4.89  N 13.58. 
                                                                    found: C 53.23  H 4.91  N 13.75. 
 
M.p.: 176 °C. Lit. [141]: 175-176 °C. 
 
 
9.3.46 6-[(4-Methylphenyl)-thio]-2-oxo-9(2’,3’,5’-tri-O-acetyl-β-D-
ribofuranosyl)-purine (85) 
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To a mixture of 83 (18 g, 34.9 mmol) in 180 mL of CH3COOH/H2O (1:1 v/v) at 50 
°C, NaNO2 (6.9 g, 100 mmol) was added in 1 h. The reaction was followed by TLC 
and after 2 h the deamination process was completed. The products were 
concentrated under reduced pressure, the solid residue dissolved in DCM (150 mL) 
and the resulting solution was washed with satured NaHCO3 solution (2×150 mL), 
dried over MgSO4 and evaporated. The solid residue was purified by silica gel 
chromatography (ethyl acetate/hexane 3/1), giving the 16.7 g (93 %) of the 
compound 84 as a white solid compound. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.75. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 2.04 (s, 6H, 2CH3); 2.12 (s, 3H, CH3); 2.37 (s, 
3H, Ar-CH3); 4.25-4.45 (m, 3H, 4’-H, 5’-CH2); 5.56 (m, 1H, 3’H); 5.91 (t, J=5.9, 1H, 
2’-H); 6.15 (d, 1H, J=5.7, 1’-H); 7.29 (d, 2H, J=7.7, o-Phenyl); 7.50 (d, J=8.0, 2H, 
m-Phenyl); 8.41 (s, 1H, 8-H); 11.74 (s, 1H, N-H). 
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IR (KBr): 3470w, 3108w, 2954m, 1751s, 1623m, 1563s, 1507m, 1445m, 1375s, 
1318w, 1231s, 1135w, 1094m, 1047m, 1006w, 908m, 808m, 790w, 737w cm
-1. 
 
ESI-MS m/z: calcd for C23H25N4O8S
+ (M+H
+) 517.1. Found 516.9 (M+H
+). 
 
Analysis:    C23H24N4O8S   (516.52)   calculated: C 53.48  H 4.68  N 10.85. 
                                                                    found: C 53.34  H 4.90  N 10.67. 
 
M.p.: 109 °C. 
 
9.3.47 Isoguanosine  (86) 
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To a mixture of 85 (3 g, 5.81 mmol) in EtOH (15 mL) stirred in the glass inset of a 
steel autoclave, was added aqueous ammonia (32 %, 45 mL). The autoclave was 
closed and the mixture stirred at 80 °C for 18 h. The resulting mixture was 
evaporated and the solid residue was purified by crystallization from absolute ethanol 
(15 mL), giving 1.17 g (71 %) of the compound 86 a white powder. 
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Rf (Butanol/HOAc/H2O 5/2/3 = 0.6 
 
1H-NMR (250 MHz, DMSO-d6/D2O) δ: 3.53 (dd, J=2.6, J=12.3, 1H, 5’-CH2); 3.61 
(dd, J=2.6, J=12.3, 1H, 5’H); 3.93 (m, 1H, 4’H); 4.08 (m, 1H, 3’H); 4.53 (m, 1H, 
2’H); 5.64 (d, J=6.5, 1H, 1’H); 7.95 (s, 1H, 8-H). 
 
IR (KBr): 3246s, 3108s, 2931s, 1672s, 1614s, 1529m, 1400s, 1319m, 1216m, 
1122m, 1083m, 1053m, 902w, 865w, 803w, 770m, 694m, 672w, 629m cm
-1. 
 
ESI-MS m/z: calcd for C10H12N5O5
- (M
-) 282.1. Found 281.9 (M
-). 
 
Analysis:    C10H13N5O5   (283.24)  calculated: C 42.40  H 4.63  N 24.73. 
                                                                Found: C 39.75  H 4.90  N 22.53 
                        1  H2O       (301.26)  calculated: C 39.87  H 5.02  N 23.25 
 
 
9.3.48 6-N-[(Dimethylamino)methylene]-isoguanosine (89). 
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To a mixture of 86 (2 g, 7.06 mmol) in abs. DMF (30 mL), was added N,N-
dimethylformamide dimethyl acetal (3 g, 25.2 mmol). The mixture was stirred at 186                                                                                            9 Experimental Section 
 
room temperature for 24 h. The solvent was removed under reduced pressure and the 
crude material crystallized from MeOH (15 mL), giving 2.1 g (88 %) of the 
compound 89 as a white powder. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 3.10 (br. d, 3H, CH3); 3.21 (s, 3H, CH3); 3.47-
3.67 (m, 2H, 5’H); 3.92 (m, 1H, 4’H); 4.09 (br. m, 1H, 3’H); 4.55 (br. m, 1H, 2’H); 
5.12 (br. s, 1H, 3’OH); 5.40 (br. s, 1H, 2’OH); 5.60 (br. s, 1H, 5’OH); 5.66 (d, J=6.3, 
1H, 1’H); 8.06 (s, 1H, 8-H); 9.18 (s, 1H, N=CH-N); 11.11 (br. s, 1H, NH). 
 
IR (KBr): 3385m, 2926w, 1654m, 1604s, 1560s, 1425m, 1370s, 1314w, 1124m, 
1086w, 1044w, 981w, 874w, 827w, 781w, 713w, 630w cm
-1. 
 
ESI-MS m/z: calcd for C13H19N6O5
+ (M+H
+) 339.1. Found 338.9 (M+H
+). 
 
Analysis:    C13H18N6O5   (338.32)  calculated: C 46.15  H 5.36  N 24.84. 
                                                                 found: C 44.44  H 5.55  N 24.83. 
                        0.6 H2O     (349.13)  calculated: C 44.72  H 5.54  N 24.07. 
 
9.3.49 5’-O-(4,4’-Dimethoxytrityl)-6-N-[(dimethylamino)methylene]-
isoguanosine (90) 
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Compound  89  (5 g, 14.8 mmol) was co-evaporated three times with anhydrous 
pyridine, and dissolved in anhydrous pyridine (200 mL). Dimethoxytritylchloride (10 
g, 29.5 mmol) was added under argon atmosphere at 60 °C in 6 h (this uncommon 
temperature was required due to the low solubility of the starting material 89 in all 
solvents tested). After the mixture was stirred over night at room temperature the 
mixture was treated with 5% aq. NaHCO3 solution (90 mL) and extracted with DCM 
(2×150 mL). The combined organic layers were dried over MgSO4 and evaporated. 
The crude material was purified by silica gel column chromatography (DCM/MeOH 
9/1) yielding 5.97 g (63 %) of 90 as a white solid compound. 
 
Rf (CH2Cl2/MeOH 9/1) = 0.51. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 3.10 (s, 3H, N-CH3); 3.15-3.23 (m, 5H, N-CH3, 
5’H); 3.73 (s, 6H, O-CH3); 4.00 (m, 1H, 4’H); 4.20 (m, 1H, 3’H); 4.49 (m, 1H, 2’H); 
5.15 (d, J=6.1, 1H, 3’OH); 5.55 (d, J=5.4, 1H, 2’OH); 5.74 (d, J=4.2, 1H, 1’H); 6.82-
6.87 (m, 4H, Ar-H); 7.17-7.38 (m, 9H, Ar-H); 7.97 (s, 1H, 8-H); 9.15 (s, 1H, N=CH-
N); 10.90 (s, 1H, NH). 
 
IR (KBr): 3126w, 2931m, 2835w, 1608s, 1558s, 1508s, 1423m, 1368s, 1302w, 
1250m, 1177m, 1120m, 1063w, 1032m, 903w, 828m, 780w, 756w, 728w, 704w, 
662w, 635w, 585w cm
-1. 
 
ESI-MS m/z: calcd for C34H37N6O7
+ (M+H
+) 641.27, C34H35N6O7
- (M
-) 639.26. 
Found 641.2 (M+H
+), 639.5 (M
-). 
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9.3.50 5’-O-(4,4’-Dimethoxytrity)-6-N-[(dimethylamino)methylene]-2’-
O-(triisopropisilyl)isoguanosine (91) and 5’-O-(4,4’-
Dimethoxytrity)-6-N-[(dimethylamino)methylene]-3’-O-
(triisopropisilyl)isoguanosine (92) 
 
91
91: R = H, R' = TIPS 90
90
N
N
H
N
N
N
O
O O
H H
H H
O
O
N
O
O
N
N
H
N
N
N
O
OH OH
H H
H H
O
O
N
O
O
R R'
92: R = TIPS, R' = H
92
 
 
Compound 90 (5.6 g, 8.74 mmol) was co-evaporated three times with anhydrous 
pyridine, dryed in vacuo over night and dissolved in anhydrous DMF (50 mL). To 
this solution under argon, were added imidazole (1.53 g, 22.5 mmol) and dropwise in 
10 minutes triisopropylsilyl chloride (3.54 g, 18.4 mmol). The mixture was stirred at 
room temperature for 24 h. The reaction was quenched with 5% aqueous NaHCO3 
(20 mL) and concentrated in vacuo. The solid residue was redissolved in CH2Cl2 
(150 mL), washed with satured NaHCO3 solution (2×150 mL), dried over MgSO4 
and concentrated. The solid residue was purified by silica gel column 
chromatography (DCM/MeOH 9/0.1) yielding 3.9 g (56%) of a mixture of 91 and 92 
as a white solid compound, the mixture of the two stereoisomers was purified by 
HPLC performed on Macherey-Nagel Nucleoprep (250×50 mm, 20 μm) column, 
using isocratic elution with dioxane, flow: 1 ml/min, giving the coumpond 91 (1.09 
g, 16 %) and 92 (2.81 g, 40 %). 
 
Rf (DCM/MeOH 9/0.1) = 0.34 9 Experimental Section                                                                                             189 
   
 
91: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.87-1.00 (m, 21H, 3CH, 6CH3, 
iProp); 3.10 (s, 
3H, CH3) 3.15-3.27 (m, 2H, 5’H); 3.20 (s, 3H, CH3); 3.72 (s, 6H, CH3O); 4.03 (m, 
1H, 4’H); 4.21 (m, 1H, 3’H); 4.79 (m, 1H, 2’H); 5.05 (d, J=6.7, 1H, 3’OH); 5.81 (d, 
J=4.90, 1H, 1’H); 6.83-6.87 (m, 4H, Ar-H); 7.19-7.38 (m, 9H, Ar-H); 8.01 (s, 1H, 8-
H); 9.13 (s, 1H, N=CH-N); 11.06 (s, 1H, NH).  
 
IR (KBr): 3404w, 2942m, 2865m, 1654m, 1610s, 1553s, 1508m, 1458w, 1423w, 
1367m, 1301w, 1251m, 1176m, 1177m, 1120m, 1032m, 874w, 830w, 782w, 704w, 
687w cm
-1. 
 
ESI-MS m/z: calcd for C43H57N6O7Si
+ (M+H
+) 797.4. Found 797.5 (M+H
+). 
 
92: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.94-1.01 (m, 21H, 3CH, 6CH3, 
iProp); 3.10 (s, 
3H, CH3); 3.11-3.15 (m, 2H, 5’H); 3.19 (s, 3H, CH3); 3.71 (s, 6H, CH3O); 4.01 (m, 
1H, 4’H); 4.36 (m, 1H, 3’H); 4.62 (m, 1H, 2’H); 5.45 (d, J=6.3, 1H, 2’OH); 5.73 (d, 
J=5.7, 1H, 1’H); 6.83-6.86 (m, 4H, Ar-H); 7.18-7.36 (m, 9H, Ar-H); 7.98 (s, 1H, 8-
H); 9.15 (s, 1H, N=CH-N); 11.06 (s, 1H, NH).  
 
IR (KBr): 3230w, 2940m, 2865m, 1654m, 1609s, 1560s, 1508m, 1459w, 1424w, 
1368s, 1301w, 1251s, 1177w, 1120w, 1068w, 1032w, 996w, 915w, 880w, 829m, 
781w, 755w, 727w, 684w cm
-1. 
 
ESI-MS m/z: calcd for C43H57N6O7Si
+ (M+H
+) 797.4. Found 797.6 (M+H
+). 
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9.3.51 5’-O-(4,4’-Dimethoxytrityl)-6-N-[(dimethylamino)methylene]-2’-
O (triisopropylsilyl) isoguanosine 2-N,N’-
Diisopropyl(cyanoethoxy)phosphoramidite (95). 
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91 (600 mg, 0.753 mmol) was dried by three co-evaporations with anhydrous THF 
and dissolved in 20 mL of anhydrous THF. To this solution were added: 
diisopropylethylamine (600 μL, 3.51 mmol) and then 2-cyanoethoxy-N,N-
diisopropylphosphoramidochloride (213.8 mg, 0.903 mmol). The reaction was stirred 
at room temperature under argon for 2 h. The crude material was poured onto ethyl 
acetate, the organic phase was washed twice with saturated NaHCO3 solution and the 
organic layer was let over Na2SO4 for 20 min. After filtration the solvent was 
removed by reduced pressure, and the crude material purified by silica gel 
chromatography (CH2Cl2/ethyl acetate/Et3N 1/1/1 %), giving 340 mg (45 %) of 95. 
 
1H-NMR (250 MHz, DMSO-d6) δ: 0.86-1.00 (m, 21H, 3CH, 6CH3, 
iProp); 1.12-
1.20 (m, 12H, CH3
iProp); 2.76 (t, J=5.82, 2H, CH2CN) 3.10-3.27 (m, 8H, 2CH3, 
5’H); 3.66-3.76 (m, 8H, CH
iProp, CH3O); 3.92 (m, 2H, CH2βCN); 4.08 (m, 1H, 4’H); 
4.21 (m, 1H, 3’H); 4.83 and 4.89 (2t, J=4.9, 1H, 2’H); 5.10 (2d, J=2.9, 1H, 3’OH); 
5.95 (2d, J=3.9 1H, 1’H); 6.82-6.87 (m, 4H, Ar-H); 7.20-7.38 (m, 9H, Ar-H); 8.19-
8.20 (2s, 1H, 8-H); 8.81 (s, 1H, N=CH-N). 
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31P-NMR (161.98 MHz, C6D6) δ: 157.06, 157.08. 
 
 
 
9.3.52  Synthesis of 96-99 
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To the mixture of 91 and 92 (3.65 g, 4.58 mmol) in 200 mL of abs. dioxan, were 
added triphenylphosphine (1.44 g, 5.50 mmol), diethyl azodicarboxylate (958 mg, 
5.50) and p-nitrophenylethanol (919 mg, 5.50 mmol). The reaction was stirred for 24 
h at room temperature. After evaporation to a smaller volume and dilution in 500 mL 
of CHCl3, the solution was washed with water (2 × 100 mL). The organic layer was 
separated, dried over Na2SO4 and evaporated. After a prepurification by silica gel 
column chromatography (EtOAc), a mixture of 96-99 plus triphenylphosphineoxide 192                                                                                            9 Experimental Section 
 
was obtained. A part of the mixture was purified by HPLC performed on a 
Macherey-Nagel Nucleoprep (250×50 mm, 20 μm) column, using isocratic elution 
with ethyl acetate 90 %, dioxane 10 %, flow: 2 ml/min. 4 different fractions were 
isolated and analysed. 
 
Rf (Ethyl acetate) = 0.16, 0.28, 0.38, 0.48. 
 
96: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.97-1.02 (m, 21H, 3CH, 6CH3, 
iProp); 3.04 (t, 
J=7.2, 2H, CH2-Ar); 3.10 (s, 3H, CH3); 3.12-3.37 (m, 2H, 5’H); 3.16 (s, 3H, CH3); 
3.72 (2s, 6H, CH3O); 4.03 (m, 1H, 4’H); 4.39-4.44 (m, 3H, CH2-O, 3’H); 4.66 (m, 
1H, 2’H); 5.43 (d, J=6.3, 1H, 2’OH); 5.74 (d, J=5.5, 1H, 1’H); 6.82-6.87 (m, 4H, Ar-
H); 7.14-7.36 (m, 9H, Ar-H); 7.41 (m, 2H, Ar-NO2); 7.99 (s, 1H, 8-H); 8.10 (m, 2H, 
Ar-NO2); 8.87 (s, 1H, N=CH-N). 
 
ESI-MS m/z: calcd for C51H64N7O9Si
+ (M+H
+) 946.5. Found 946.9 (M+H
+). 
 
97: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.90-0.98 (m, 21H, 3CH, 6CH3, 
iProp); 3.05 (t, 
J=7.1, 2H, CH2-Ar); 3.09 (s, 3H, CH3); 3.16 (s, 3H, CH3); 3.17-3.28 (m, 2H, 5’H); 
3.72 (2s, 6H, CH3O); 4.04 (m, 1H, 4’H); 4.21 (m, 1H, 3’H); 4.43 (m, 2H, CH2-O); 
4.80 (m, 1H, 2’H); 5.06 (d, J=6.7, 1H, 3’OH); 5.80 (d, J=4.9, 1H, 1’H); 6.83-6.87 
(m, 4H, Ar-H); 7.16-7.38 (m, 11H, Ar-H); 8.08 (m, 2H, Ar-NO2); 8.00 (s, 1H, 8-H); 
8.83 (s, 1H, N=CH-N).  
 
ESI-MS m/z: calcd for C51H64N7O9Si
+ (M+H
+) 946.5. Found 946.6 (M+H
+). 
 
98: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.82-0.93 (m, 21H, 3CH, 6CH3, 
iProp); 3.08 (t, 
J=7.1, 2H, CH2-Ar); 3.11 (s, 3H, CH3); 3.19 (s, 3H, CH3); 3.24 (m, 2H, 5’H); 3.71 
(2s, 6H, CH3O); 4.08 (m, 1H, 4’H); 4.29 (m, 1H, 3’H); 4.33-4.48 (m, 2H, CH2-O); 
4.97 (m, 1H, 2’H); 5.16 (d, J=6.2, 1H, 3’OH); 5.94 (d, J=5.2, 1H, 1’H); 6.78-6.83 9 Experimental Section                                                                                             193 
   
(m, 4H, Ar-H); 7.18-7.38 (m, 9H, Ar-H); 7.50 (m, 2H, Ar-NO2); 8.14 (m, 2H, Ar-
NO2); 8.19 (s, 1H, 8-H); 8.82 (s, 1H, N=CH-N).  
 
ESI-MS m/z: calcd for C51H64N7O9Si
+ (M+H
+) 946.5. Found 946.5 (M+H
+). 
 
99: 
1H-NMR (250 MHz, DMSO-d6) δ: 0.94-1.00 (m, 21H, 3CH, 6CH3, 
iProp); 3.09-
3.40, (m+2s, 10H, CH2-Ar, 2CH3, 5’H); 3.70 (2s, 6H, CH3O); 4.03 (m, 1H, 4’H); 
4.39-4.50 (m, 3H, CH2-O, 3’H); 4.82 (m, 1H, 2’H); 5.40 (d, J=6.4, 1H, 2’OH); 5.88 
(d, J=5.4, 1H, 1’H); 6.75-6.81 (m, 4H, Ar-H); 7.16-7.34 (m, 9H, Ar-H); 7.52 (m, 2H, 
Ar-NO2); 8.15 (m, 2H, Ar-NO2); 8.20 (s, 1H, 8-H); 8.84 (s, 1H, N=CH-N).  
 
ESI-MS m/z: calcd for C51H64N7O9Si
+ (M+H
+) 946.5. Found 946.8 (M+H
+). 
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10.2  List of Abbreviations  
 
 
 
Abs.     :  Absolute 
AppA     :  Diadenosine  5',5'-pyrophosphate 
ApA     :  Adenosyl(3'-5')adenosine 
ApUp     :  Adenosyl(3’-5’)-uridine  phosphate 
Ar     :  Aromatic  ring 
Arg     :  Arginine 
ATP     :  Adenosine  5'-triphosphate 
B     :  Base 
BABE     :  (S)-1-[p-(bromoacetamido)benzyl]-EDTA 
B o c      :   T ert-butyloxycarbonyl 
Boc-ON    :  [2-(Boc-oxyimino)-2-phenylaceonitrile,  2-(tert- 
                                                  Butoxycarbonyloxyimino)-2-phenyl-acetonitrile 
BP     :  Binding  Protein 
cDNA     :  Complementary  DNA 
CNCH3   :  Acetonitrile 
COSY     :  COrrelated  SpectroscopY 
CPG        : Controlled Pore Glass    
Cy5     :  Cyanine  5 
DCC     :  N,N’-Dicyclohexyl-Carbodiimide 
DCM     :  Dichloromethane 
Degr.     :  Degradation 
DIEA     :  Diisopropylethylamine 
DEPC     :  Diethylpyrocarbonate 
DIC     :  Diisopropylcarbodiimide 
DMAP     :  4-Dimethylaminopyridine 
DMF     :  N,N’-Dimethylformamide 
DMSO     :  Dimethyl  sulfoxide 
DMT     :  Dimethoxy  trityl 
DMTCl    :  Dimethoxytrityl  chloride 206                                                                                                            10 Appendix 
 
DNA     :  Desoxyribonucleic  Acid 
DTT     :  Dithiothreitol 
E     :  Enzyme   
EtOH     :  Ethanol 
Equiv     :  Equivalent 
EDTA     :  EthyleneDiAmineTetraAcetic  acid   
ESI-MS    :  ElectroSpray  Ionization Mass Spectrometry 
EtOAc     :  Ethyl  Acetate 
FCS     :  Fluorescence  Correlation  Spectroscopy 
FRET        : Fluorescence Resonance Energy Transfer 
FT-IR     :  Fourier  Transform Infrared spectroscopy 
GABA     :  4-Amino-butyric  acid 
Glu     :  Glutamic  Acid   
GTP     :  Guanosine-5'-Triphosphate 
H      :   H o u r s  
Hex     :  Hexane 
His     :  Histidine 
HIV     :  Human  Immunodeficiency  Virus 
HOBT     :  Hydroxybenzotriazole 
HPLC       : High performance liquid chromatography 
HPNP     :  2-Hydroxypropyl  p-nitrophenyl phosphate  
HpPNP   :  2-Hydroxylpropyl-p-nitrophenyl phosphate (2- 
    hydroxylpropyl-4-nitrophenyl  phosphate) 
ImpA     :  5'-Phosphorimidazolide  of  adenosine 
IR     :  Infrared 
Lys     :  Lysine 
MALDI    :  Matrix-Assisted  Laser  Desorption/ionization 
Me     :  Methyl 
MeOH     :  Methanol 
M.p.     :  Melting  point 
MPC     :  Monolayer  Protected  Clusters 
mRNA     :  Messenger  RNA 
N P E      :   p-NitroPhenylEthyl 10 Appendix                                                                                                           207 
   
NMR     :  Nuclear  Magnetic  Resonance 
ODN     :  OligoDeoxyriboNucleotides 
OP     :  1,10-o-Phenanthroline  
P     :  Product 
PAGE     :  PolyAcrylamide  Gel  Electrophoresis; 
Phe     :  Phenylalanine 
pRpp     :  Phospho-Ribosyl-pyrophosphat 
PNA     :  Peptide  Nucleic  Acid 
Py     :  Pyridine 
RNA     :  RiboNucleic  Acid 
RNase     :  Ribonuclease 
RP     :  Reverse  Phase 
rRNA     :  Ribosomal  RNA 
S     :  Substrat 
SDS     :  Sodium  Dodecyl  Sulfate 
SiRNAs      : Small interfiring RNAs 
T A R      :   Trans-Activation Responsive 
tRNA     :  Transporter  RNA 
Tat     :  Transactivator 
TCA     :  Trichloroacetic  acid 
TCEP     :  Tris(2-carboxyethyl)phosphine hydrochloride 
TEA     :  Triethylamine 
TFA     :  Trifluoroacetic  acid. 
THF     :  Tetrahydrofuran 
TIPS-Cl    :  Tri-(Iso-Propyl)Silyl  Chloride 
TLC     :  Thin  layer  Chromatography 
Tm     :  Melting  Temperature   
TREN     :  Tris(2-aminoethyl)amine 
Tris     :  Trishydroxymethylaminomethane 
Triton     :  Octyl  phenol  ethoxylate 
UpNP     :  Uridine 3’-p-nitrophenyl phosphate (uridine 3’-4- 
                                                    nitrophenyl phosphate 
UV-vis     :  Ultraviolet-visible  spectroscopy 208                                                                                                            10 Appendix 
 
Vmax     : Maximal Velocity  
Z     :  Benzyloxycarbonyl 
 
 
 
 
 
 
 
 
 
10.3  Supplementary NMR – COSY Spectra 
 
 
10.3.1  NMR – COSY   (62) 
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10.3.2  NMR – COSY   (71) 
 
10.3.3  NMR – COSY   (75) 
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10.3.4  NMR – COSY   (72) 
 
10.3.5   NMR – COSY   (91) 
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10.3.6  NMR – COSY   (92) 
 
10.3.7  NMR – COSY   (95) 
 212                                                                                                            10 Appendix 
 
10.3.8  NMR – COSY   (96) 
 
10.3.9  NMR – COSY   (97) 
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10.3.10  NMR – COSY   (98) 
 
10.3.11  NMR – COSY   (99) 
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